date generated: 2022-08-23
Mitch performs unidimensional and multidimensional gene set enrichment analysis. The concept behind this dates to work by Cox and Mann (https://doi.org/10.1186/1471-2105-13-S16-S12). This implementation is suited to R based workflows of multi-omics datasets. This software was developed by Antony Kaspi and Mark Ziemann. Learn more about Mitch at the website: https://github.com/markziemann/Mitch
Here is the first few lines of the input profile.
## KO drug
## 5_8S_rRNA -0.4520464 13.3741078
## 7SK -2.2982399 8.2273400
## A1BG -3.3008939 6.5685508
## A1BG-AS1 0.3211569 2.0363758
## A1CF -0.7352419 -0.3352928
## A2M 30.2687300 -19.6839168
Here are some metrics about the input data profile:
Profile metrics | |
---|---|
num_genes_in_profile | 24473 |
duplicated_genes_present | 0 |
num_profile_genes_in_sets | 8850 |
num_profile_genes_not_in_sets | 15623 |
profile_pearson_correl | 0.06908 |
profile_spearman_correl | 0.09129 |
Here is a plot of the input profiles. Note the dynamic ranges.
Here is the contour plot of the profile including all detected genes.
Gene sets metrics | |
---|---|
num_genesets | 2512 |
num_genesets_excluded | 1047 |
num_genesets_included | 1465 |
Number of significant gene sets (FDR<0.05)= 928
All sets with FDR<0.05. Try hovering over the points.
Top N sets irrespective of FDR. Try hovering over the points.
Significance is the -log2(p.adjustMANOVA) and effect size is the s.dist which is the hypotenuse of the s scores.
set | setSize | pMANOVA | p.adjustMANOVA | s.dist | s.KO | s.drug | p.KO | p.drug |
---|---|---|---|---|---|---|---|---|
Peptide chain elongation | 87 | 2.79e-43 | 3.40e-41 | 0.830 | -0.422 | 0.715 | 9.35e-12 | 8.26e-31 |
Viral mRNA Translation | 87 | 3.07e-43 | 3.46e-41 | 0.830 | -0.420 | 0.715 | 1.17e-11 | 7.10e-31 |
Formation of a pool of free 40S subunits | 99 | 1.26e-44 | 1.68e-42 | 0.789 | -0.444 | 0.652 | 2.03e-14 | 3.21e-29 |
Eukaryotic Translation Termination | 91 | 2.19e-41 | 1.89e-39 | 0.794 | -0.402 | 0.684 | 3.27e-11 | 1.32e-29 |
Eukaryotic Translation Elongation | 92 | 1.82e-41 | 1.67e-39 | 0.790 | -0.412 | 0.674 | 8.16e-12 | 4.97e-29 |
Defective EXT1 causes exostoses 1, TRPS2 and CHDS | 13 | 1.43e-06 | 5.93e-06 | 0.799 | 0.358 | -0.714 | 2.55e-02 | 8.23e-06 |
Defective EXT2 causes exostoses 2 | 13 | 1.43e-06 | 5.93e-06 | 0.799 | 0.358 | -0.714 | 2.55e-02 | 8.23e-06 |
Laminin interactions | 23 | 1.23e-11 | 1.39e-10 | 0.827 | 0.269 | -0.782 | 2.58e-02 | 8.23e-11 |
Response of EIF2AK4 (GCN2) to amino acid deficiency | 99 | 6.60e-41 | 5.37e-39 | 0.755 | -0.423 | 0.625 | 3.36e-13 | 5.07e-27 |
Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC) | 93 | 6.86e-38 | 4.02e-36 | 0.749 | -0.424 | 0.617 | 1.55e-12 | 6.83e-25 |
Selenocysteine synthesis | 91 | 1.38e-38 | 8.77e-37 | 0.768 | -0.355 | 0.681 | 4.60e-09 | 2.66e-29 |
Formation of the ternary complex, and subsequently, the 43S complex | 50 | 7.28e-20 | 1.67e-18 | 0.731 | -0.501 | 0.532 | 8.83e-10 | 7.23e-11 |
Syndecan interactions | 19 | 5.07e-10 | 4.45e-09 | 0.844 | 0.216 | -0.816 | 1.04e-01 | 7.21e-10 |
Mucopolysaccharidoses | 11 | 1.36e-05 | 4.58e-05 | 0.799 | 0.756 | -0.258 | 1.41e-05 | 1.38e-01 |
Defective B4GALT7 causes EDS, progeroid type | 18 | 1.10e-07 | 5.83e-07 | 0.739 | 0.371 | -0.639 | 6.44e-03 | 2.71e-06 |
L13a-mediated translational silencing of Ceruloplasmin expression | 109 | 3.24e-39 | 2.26e-37 | 0.702 | -0.466 | 0.525 | 3.94e-17 | 2.32e-21 |
GTP hydrolysis and joining of the 60S ribosomal subunit | 110 | 3.32e-38 | 2.03e-36 | 0.690 | -0.442 | 0.530 | 1.11e-15 | 6.60e-22 |
Defective B3GAT3 causes JDSSDHD | 18 | 9.01e-07 | 3.96e-06 | 0.687 | 0.376 | -0.575 | 5.69e-03 | 2.43e-05 |
Other semaphorin interactions | 15 | 8.68e-06 | 3.06e-05 | 0.689 | 0.359 | -0.588 | 1.59e-02 | 7.98e-05 |
Defective B3GALT6 causes EDSP2 and SEMDJL1 | 18 | 1.31e-06 | 5.63e-06 | 0.677 | 0.375 | -0.564 | 5.92e-03 | 3.38e-05 |
Cap-dependent Translation Initiation | 117 | 2.43e-37 | 1.32e-35 | 0.662 | -0.423 | 0.509 | 2.56e-15 | 1.77e-21 |
Eukaryotic Translation Initiation | 117 | 2.43e-37 | 1.32e-35 | 0.662 | -0.423 | 0.509 | 2.56e-15 | 1.77e-21 |
SRP-dependent cotranslational protein targeting to membrane | 110 | 3.90e-35 | 1.97e-33 | 0.662 | -0.393 | 0.533 | 9.93e-13 | 4.19e-22 |
Reduction of cytosolic Ca++ levels | 12 | 1.99e-04 | 5.13e-04 | 0.656 | 0.423 | -0.502 | 1.12e-02 | 2.59e-03 |
Non-integrin membrane-ECM interactions | 41 | 1.27e-16 | 2.25e-15 | 0.751 | 0.200 | -0.724 | 2.68e-02 | 1.00e-15 |
MET activates PTK2 signaling | 18 | 6.80e-08 | 3.72e-07 | 0.765 | 0.155 | -0.749 | 2.56e-01 | 3.71e-08 |
Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S | 58 | 5.49e-18 | 1.13e-16 | 0.646 | -0.521 | 0.382 | 6.74e-12 | 4.78e-07 |
Mitochondrial iron-sulfur cluster biogenesis | 13 | 1.73e-04 | 4.50e-04 | 0.635 | -0.437 | 0.462 | 6.39e-03 | 3.96e-03 |
Translation initiation complex formation | 57 | 4.76e-17 | 8.61e-16 | 0.634 | -0.512 | 0.373 | 2.15e-11 | 1.12e-06 |
The activation of arylsulfatases | 10 | 1.91e-03 | 3.91e-03 | 0.616 | 0.417 | -0.454 | 2.25e-02 | 1.29e-02 |
HS-GAG degradation | 19 | 7.84e-06 | 2.77e-05 | 0.612 | 0.424 | -0.441 | 1.36e-03 | 8.62e-04 |
Ribosomal scanning and start codon recognition | 57 | 4.22e-16 | 7.19e-15 | 0.615 | -0.488 | 0.374 | 1.87e-10 | 1.03e-06 |
Major pathway of rRNA processing in the nucleolus and cytosol | 180 | 4.38e-48 | 7.14e-46 | 0.607 | -0.442 | 0.415 | 1.15e-24 | 6.33e-22 |
rRNA processing in the nucleus and cytosol | 190 | 1.23e-50 | 2.57e-48 | 0.606 | -0.452 | 0.404 | 4.72e-27 | 6.93e-22 |
Selenoamino acid metabolism | 115 | 5.95e-32 | 2.64e-30 | 0.618 | -0.336 | 0.519 | 4.63e-10 | 6.31e-22 |
Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC) | 113 | 2.07e-30 | 8.41e-29 | 0.606 | -0.392 | 0.462 | 5.64e-13 | 1.93e-17 |
Nonsense-Mediated Decay (NMD) | 113 | 2.07e-30 | 8.41e-29 | 0.606 | -0.392 | 0.462 | 5.64e-13 | 1.93e-17 |
Complex I biogenesis | 57 | 8.21e-22 | 2.23e-20 | 0.740 | -0.123 | 0.729 | 1.09e-01 | 1.49e-21 |
Biotin transport and metabolism | 11 | 8.11e-04 | 1.83e-03 | 0.631 | 0.561 | -0.290 | 1.28e-03 | 9.61e-02 |
rRNA processing | 214 | 9.34e-54 | 2.74e-51 | 0.589 | -0.397 | 0.435 | 1.09e-23 | 4.38e-28 |
ATF4 activates genes in response to endoplasmic reticulum stress | 26 | 4.79e-07 | 2.26e-06 | 0.583 | -0.453 | 0.367 | 6.33e-05 | 1.20e-03 |
SLBP Dependent Processing of Replication-Dependent Histone Pre-mRNAs | 11 | 1.38e-03 | 2.94e-03 | 0.607 | -0.543 | 0.273 | 1.83e-03 | 1.18e-01 |
SLBP independent Processing of Histone Pre-mRNAs | 10 | 3.65e-03 | 6.97e-03 | 0.586 | -0.502 | 0.303 | 6.02e-03 | 9.69e-02 |
Regulation of expression of SLITs and ROBOs | 166 | 3.50e-39 | 2.33e-37 | 0.570 | -0.356 | 0.445 | 2.19e-15 | 4.05e-23 |
CREB1 phosphorylation through the activation of Adenylate Cyclase | 10 | 1.71e-03 | 3.56e-03 | 0.632 | 0.195 | -0.602 | 2.86e-01 | 9.85e-04 |
A tetrasaccharide linker sequence is required for GAG synthesis | 24 | 3.10e-06 | 1.21e-05 | 0.567 | 0.325 | -0.465 | 5.89e-03 | 7.89e-05 |
Influenza Viral RNA Transcription and Replication | 134 | 3.21e-30 | 1.27e-28 | 0.555 | -0.386 | 0.398 | 1.09e-14 | 1.59e-15 |
Chondroitin sulfate biosynthesis | 19 | 7.00e-05 | 1.98e-04 | 0.553 | 0.350 | -0.428 | 8.18e-03 | 1.25e-03 |
PKA activation | 16 | 2.75e-05 | 8.39e-05 | 0.646 | 0.145 | -0.630 | 3.17e-01 | 1.29e-05 |
Diseases associated with glycosaminoglycan metabolism | 35 | 2.97e-08 | 1.79e-07 | 0.551 | 0.273 | -0.479 | 5.21e-03 | 9.35e-07 |
Respiratory electron transport | 103 | 4.70e-27 | 1.64e-25 | 0.610 | -0.160 | 0.589 | 4.90e-03 | 4.56e-25 |
Regulation of localization of FOXO transcription factors | 12 | 1.54e-03 | 3.24e-03 | 0.580 | 0.206 | -0.542 | 2.16e-01 | 1.15e-03 |
set | setSize | pMANOVA | p.adjustMANOVA | s.dist | s.KO | s.drug | p.KO | p.drug |
---|---|---|---|---|---|---|---|---|
Peptide chain elongation | 87 | 2.79e-43 | 3.40e-41 | 0.8300 | -4.22e-01 | 0.715000 | 9.35e-12 | 8.26e-31 |
Viral mRNA Translation | 87 | 3.07e-43 | 3.46e-41 | 0.8300 | -4.20e-01 | 0.715000 | 1.17e-11 | 7.10e-31 |
Formation of a pool of free 40S subunits | 99 | 1.26e-44 | 1.68e-42 | 0.7890 | -4.44e-01 | 0.652000 | 2.03e-14 | 3.21e-29 |
Eukaryotic Translation Termination | 91 | 2.19e-41 | 1.89e-39 | 0.7940 | -4.02e-01 | 0.684000 | 3.27e-11 | 1.32e-29 |
Eukaryotic Translation Elongation | 92 | 1.82e-41 | 1.67e-39 | 0.7900 | -4.12e-01 | 0.674000 | 8.16e-12 | 4.97e-29 |
Defective EXT1 causes exostoses 1, TRPS2 and CHDS | 13 | 1.43e-06 | 5.93e-06 | 0.7990 | 3.58e-01 | -0.714000 | 2.55e-02 | 8.23e-06 |
Defective EXT2 causes exostoses 2 | 13 | 1.43e-06 | 5.93e-06 | 0.7990 | 3.58e-01 | -0.714000 | 2.55e-02 | 8.23e-06 |
Laminin interactions | 23 | 1.23e-11 | 1.39e-10 | 0.8270 | 2.69e-01 | -0.782000 | 2.58e-02 | 8.23e-11 |
Response of EIF2AK4 (GCN2) to amino acid deficiency | 99 | 6.60e-41 | 5.37e-39 | 0.7550 | -4.23e-01 | 0.625000 | 3.36e-13 | 5.07e-27 |
Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC) | 93 | 6.86e-38 | 4.02e-36 | 0.7490 | -4.24e-01 | 0.617000 | 1.55e-12 | 6.83e-25 |
Selenocysteine synthesis | 91 | 1.38e-38 | 8.77e-37 | 0.7680 | -3.55e-01 | 0.681000 | 4.60e-09 | 2.66e-29 |
Formation of the ternary complex, and subsequently, the 43S complex | 50 | 7.28e-20 | 1.67e-18 | 0.7310 | -5.01e-01 | 0.532000 | 8.83e-10 | 7.23e-11 |
Syndecan interactions | 19 | 5.07e-10 | 4.45e-09 | 0.8440 | 2.16e-01 | -0.816000 | 1.04e-01 | 7.21e-10 |
Mucopolysaccharidoses | 11 | 1.36e-05 | 4.58e-05 | 0.7990 | 7.56e-01 | -0.258000 | 1.41e-05 | 1.38e-01 |
Defective B4GALT7 causes EDS, progeroid type | 18 | 1.10e-07 | 5.83e-07 | 0.7390 | 3.71e-01 | -0.639000 | 6.44e-03 | 2.71e-06 |
L13a-mediated translational silencing of Ceruloplasmin expression | 109 | 3.24e-39 | 2.26e-37 | 0.7020 | -4.66e-01 | 0.525000 | 3.94e-17 | 2.32e-21 |
GTP hydrolysis and joining of the 60S ribosomal subunit | 110 | 3.32e-38 | 2.03e-36 | 0.6900 | -4.42e-01 | 0.530000 | 1.11e-15 | 6.60e-22 |
Defective B3GAT3 causes JDSSDHD | 18 | 9.01e-07 | 3.96e-06 | 0.6870 | 3.76e-01 | -0.575000 | 5.69e-03 | 2.43e-05 |
Other semaphorin interactions | 15 | 8.68e-06 | 3.06e-05 | 0.6890 | 3.59e-01 | -0.588000 | 1.59e-02 | 7.98e-05 |
Defective B3GALT6 causes EDSP2 and SEMDJL1 | 18 | 1.31e-06 | 5.63e-06 | 0.6770 | 3.75e-01 | -0.564000 | 5.92e-03 | 3.38e-05 |
Cap-dependent Translation Initiation | 117 | 2.43e-37 | 1.32e-35 | 0.6620 | -4.23e-01 | 0.509000 | 2.56e-15 | 1.77e-21 |
Eukaryotic Translation Initiation | 117 | 2.43e-37 | 1.32e-35 | 0.6620 | -4.23e-01 | 0.509000 | 2.56e-15 | 1.77e-21 |
SRP-dependent cotranslational protein targeting to membrane | 110 | 3.90e-35 | 1.97e-33 | 0.6620 | -3.93e-01 | 0.533000 | 9.93e-13 | 4.19e-22 |
Reduction of cytosolic Ca++ levels | 12 | 1.99e-04 | 5.13e-04 | 0.6560 | 4.23e-01 | -0.502000 | 1.12e-02 | 2.59e-03 |
Non-integrin membrane-ECM interactions | 41 | 1.27e-16 | 2.25e-15 | 0.7510 | 2.00e-01 | -0.724000 | 2.68e-02 | 1.00e-15 |
MET activates PTK2 signaling | 18 | 6.80e-08 | 3.72e-07 | 0.7650 | 1.55e-01 | -0.749000 | 2.56e-01 | 3.71e-08 |
Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S | 58 | 5.49e-18 | 1.13e-16 | 0.6460 | -5.21e-01 | 0.382000 | 6.74e-12 | 4.78e-07 |
Mitochondrial iron-sulfur cluster biogenesis | 13 | 1.73e-04 | 4.50e-04 | 0.6350 | -4.37e-01 | 0.462000 | 6.39e-03 | 3.96e-03 |
Translation initiation complex formation | 57 | 4.76e-17 | 8.61e-16 | 0.6340 | -5.12e-01 | 0.373000 | 2.15e-11 | 1.12e-06 |
The activation of arylsulfatases | 10 | 1.91e-03 | 3.91e-03 | 0.6160 | 4.17e-01 | -0.454000 | 2.25e-02 | 1.29e-02 |
HS-GAG degradation | 19 | 7.84e-06 | 2.77e-05 | 0.6120 | 4.24e-01 | -0.441000 | 1.36e-03 | 8.62e-04 |
Ribosomal scanning and start codon recognition | 57 | 4.22e-16 | 7.19e-15 | 0.6150 | -4.88e-01 | 0.374000 | 1.87e-10 | 1.03e-06 |
Major pathway of rRNA processing in the nucleolus and cytosol | 180 | 4.38e-48 | 7.14e-46 | 0.6070 | -4.42e-01 | 0.415000 | 1.15e-24 | 6.33e-22 |
rRNA processing in the nucleus and cytosol | 190 | 1.23e-50 | 2.57e-48 | 0.6060 | -4.52e-01 | 0.404000 | 4.72e-27 | 6.93e-22 |
Selenoamino acid metabolism | 115 | 5.95e-32 | 2.64e-30 | 0.6180 | -3.36e-01 | 0.519000 | 4.63e-10 | 6.31e-22 |
Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC) | 113 | 2.07e-30 | 8.41e-29 | 0.6060 | -3.92e-01 | 0.462000 | 5.64e-13 | 1.93e-17 |
Nonsense-Mediated Decay (NMD) | 113 | 2.07e-30 | 8.41e-29 | 0.6060 | -3.92e-01 | 0.462000 | 5.64e-13 | 1.93e-17 |
Complex I biogenesis | 57 | 8.21e-22 | 2.23e-20 | 0.7400 | -1.23e-01 | 0.729000 | 1.09e-01 | 1.49e-21 |
Biotin transport and metabolism | 11 | 8.11e-04 | 1.83e-03 | 0.6310 | 5.61e-01 | -0.290000 | 1.28e-03 | 9.61e-02 |
rRNA processing | 214 | 9.34e-54 | 2.74e-51 | 0.5890 | -3.97e-01 | 0.435000 | 1.09e-23 | 4.38e-28 |
ATF4 activates genes in response to endoplasmic reticulum stress | 26 | 4.79e-07 | 2.26e-06 | 0.5830 | -4.53e-01 | 0.367000 | 6.33e-05 | 1.20e-03 |
SLBP Dependent Processing of Replication-Dependent Histone Pre-mRNAs | 11 | 1.38e-03 | 2.94e-03 | 0.6070 | -5.43e-01 | 0.273000 | 1.83e-03 | 1.18e-01 |
SLBP independent Processing of Histone Pre-mRNAs | 10 | 3.65e-03 | 6.97e-03 | 0.5860 | -5.02e-01 | 0.303000 | 6.02e-03 | 9.69e-02 |
Regulation of expression of SLITs and ROBOs | 166 | 3.50e-39 | 2.33e-37 | 0.5700 | -3.56e-01 | 0.445000 | 2.19e-15 | 4.05e-23 |
CREB1 phosphorylation through the activation of Adenylate Cyclase | 10 | 1.71e-03 | 3.56e-03 | 0.6320 | 1.95e-01 | -0.602000 | 2.86e-01 | 9.85e-04 |
A tetrasaccharide linker sequence is required for GAG synthesis | 24 | 3.10e-06 | 1.21e-05 | 0.5670 | 3.25e-01 | -0.465000 | 5.89e-03 | 7.89e-05 |
Influenza Viral RNA Transcription and Replication | 134 | 3.21e-30 | 1.27e-28 | 0.5550 | -3.86e-01 | 0.398000 | 1.09e-14 | 1.59e-15 |
Chondroitin sulfate biosynthesis | 19 | 7.00e-05 | 1.98e-04 | 0.5530 | 3.50e-01 | -0.428000 | 8.18e-03 | 1.25e-03 |
PKA activation | 16 | 2.75e-05 | 8.39e-05 | 0.6460 | 1.45e-01 | -0.630000 | 3.17e-01 | 1.29e-05 |
Diseases associated with glycosaminoglycan metabolism | 35 | 2.97e-08 | 1.79e-07 | 0.5510 | 2.73e-01 | -0.479000 | 5.21e-03 | 9.35e-07 |
Respiratory electron transport | 103 | 4.70e-27 | 1.64e-25 | 0.6100 | -1.60e-01 | 0.589000 | 4.90e-03 | 4.56e-25 |
Regulation of localization of FOXO transcription factors | 12 | 1.54e-03 | 3.24e-03 | 0.5800 | 2.06e-01 | -0.542000 | 2.16e-01 | 1.15e-03 |
Ubiquitin Mediated Degradation of Phosphorylated Cdc25A | 50 | 6.88e-11 | 7.09e-10 | 0.5340 | -4.25e-01 | 0.323000 | 2.00e-07 | 7.81e-05 |
p53-Independent DNA Damage Response | 50 | 6.88e-11 | 7.09e-10 | 0.5340 | -4.25e-01 | 0.323000 | 2.00e-07 | 7.81e-05 |
p53-Independent G1/S DNA damage checkpoint | 50 | 6.88e-11 | 7.09e-10 | 0.5340 | -4.25e-01 | 0.323000 | 2.00e-07 | 7.81e-05 |
Vif-mediated degradation of APOBEC3G | 52 | 2.64e-11 | 2.95e-10 | 0.5340 | -4.31e-01 | 0.315000 | 7.39e-08 | 8.41e-05 |
CS/DS degradation | 13 | 1.34e-03 | 2.84e-03 | 0.5610 | 5.11e-01 | -0.233000 | 1.43e-03 | 1.46e-01 |
KSRP (KHSRP) binds and destabilizes mRNA | 17 | 3.75e-04 | 9.07e-04 | 0.5320 | -4.47e-01 | 0.289000 | 1.42e-03 | 3.89e-02 |
Autodegradation of the E3 ubiquitin ligase COP1 | 49 | 2.15e-10 | 2.06e-09 | 0.5260 | -4.25e-01 | 0.309000 | 2.54e-07 | 1.79e-04 |
Regulation of activated PAK-2p34 by proteasome mediated degradation | 48 | 3.40e-10 | 3.15e-09 | 0.5270 | -4.38e-01 | 0.293000 | 1.54e-07 | 4.48e-04 |
Cellular response to starvation | 150 | 2.14e-29 | 8.05e-28 | 0.5180 | -3.22e-01 | 0.406000 | 9.62e-12 | 9.26e-18 |
Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins. | 125 | 8.79e-33 | 4.03e-31 | 0.6150 | -1.21e-01 | 0.603000 | 1.91e-02 | 2.15e-31 |
Apoptotic cleavage of cellular proteins | 34 | 3.50e-08 | 2.05e-07 | 0.5620 | 1.90e-01 | -0.529000 | 5.47e-02 | 9.48e-08 |
Stabilization of p53 | 53 | 9.56e-11 | 9.52e-10 | 0.5150 | -4.25e-01 | 0.291000 | 8.54e-08 | 2.43e-04 |
APC/C:Cdc20 mediated degradation of Securin | 66 | 8.36e-13 | 1.12e-11 | 0.5060 | -3.68e-01 | 0.347000 | 2.36e-07 | 1.06e-06 |
MET promotes cell motility | 29 | 1.04e-10 | 1.03e-09 | 0.7250 | -1.10e-02 | -0.725000 | 9.19e-01 | 1.37e-11 |
Mitochondrial translation elongation | 90 | 3.60e-21 | 9.26e-20 | 0.5750 | -1.63e-01 | 0.551000 | 7.65e-03 | 1.50e-19 |
Mitochondrial translation initiation | 90 | 5.71e-21 | 1.42e-19 | 0.5720 | -1.61e-01 | 0.549000 | 8.28e-03 | 2.15e-19 |
ROS sensing by NFE2L2 | 55 | 1.02e-11 | 1.18e-10 | 0.5340 | -4.83e-01 | 0.226000 | 5.60e-10 | 3.69e-03 |
PKA-mediated phosphorylation of CREB | 18 | 1.23e-05 | 4.18e-05 | 0.6380 | 6.90e-02 | -0.634000 | 6.12e-01 | 3.14e-06 |
APC/C:Cdc20 mediated degradation of Cyclin B | 24 | 2.14e-05 | 6.76e-05 | 0.5270 | -2.16e-01 | 0.480000 | 6.68e-02 | 4.62e-05 |
HS-GAG biosynthesis | 27 | 6.29e-07 | 2.89e-06 | 0.5800 | 1.32e-01 | -0.565000 | 2.37e-01 | 3.75e-07 |
Response of EIF2AK1 (HRI) to heme deficiency | 15 | 7.54e-04 | 1.70e-03 | 0.5480 | -5.20e-01 | 0.174000 | 4.89e-04 | 2.43e-01 |
Autodegradation of Cdh1 by Cdh1:APC/C | 64 | 9.86e-12 | 1.15e-10 | 0.4900 | -3.54e-01 | 0.339000 | 9.46e-07 | 2.72e-06 |
APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1 | 72 | 4.45e-13 | 6.18e-12 | 0.4900 | -3.66e-01 | 0.326000 | 8.04e-08 | 1.71e-06 |
Regulation of gene expression by Hypoxia-inducible Factor | 10 | 4.08e-04 | 9.76e-04 | 0.7210 | -2.91e-02 | -0.720000 | 8.74e-01 | 7.95e-05 |
Mitochondrial translation termination | 90 | 5.11e-20 | 1.21e-18 | 0.5590 | -1.51e-01 | 0.538000 | 1.33e-02 | 1.05e-18 |
Platelet calcium homeostasis | 24 | 3.77e-05 | 1.12e-04 | 0.5110 | 2.30e-01 | -0.457000 | 5.10e-02 | 1.07e-04 |
mRNA decay by 3’ to 5’ exoribonuclease | 16 | 2.01e-03 | 4.07e-03 | 0.4850 | -3.11e-01 | 0.372000 | 3.11e-02 | 9.91e-03 |
PERK regulates gene expression | 31 | 1.33e-06 | 5.64e-06 | 0.5210 | -4.78e-01 | 0.205000 | 3.99e-06 | 4.82e-02 |
Vpu mediated degradation of CD4 | 50 | 2.77e-09 | 2.12e-08 | 0.4900 | -4.07e-01 | 0.274000 | 6.34e-07 | 8.11e-04 |
Influenza Infection | 153 | 7.01e-26 | 2.28e-24 | 0.4800 | -3.57e-01 | 0.320000 | 2.24e-14 | 7.58e-12 |
Negative regulation of NOTCH4 signaling | 54 | 1.04e-09 | 8.69e-09 | 0.4830 | -3.83e-01 | 0.293000 | 1.09e-06 | 1.91e-04 |
SCF-beta-TrCP mediated degradation of Emi1 | 53 | 7.99e-10 | 6.84e-09 | 0.4920 | -4.19e-01 | 0.257000 | 1.27e-07 | 1.20e-03 |
Heparan sulfate/heparin (HS-GAG) metabolism | 48 | 8.73e-09 | 5.79e-08 | 0.4850 | 2.78e-01 | -0.398000 | 8.49e-04 | 1.84e-06 |
RHOF GTPase cycle | 41 | 1.50e-10 | 1.46e-09 | 0.5970 | 8.37e-02 | -0.591000 | 3.54e-01 | 5.78e-11 |
Formation of ATP by chemiosmotic coupling | 18 | 1.94e-05 | 6.18e-05 | 0.6270 | -4.48e-02 | 0.626000 | 7.42e-01 | 4.27e-06 |
Regulation of Apoptosis | 51 | 2.62e-09 | 2.02e-08 | 0.4870 | -4.15e-01 | 0.255000 | 2.98e-07 | 1.60e-03 |
Interleukin-15 signaling | 14 | 3.64e-04 | 8.89e-04 | 0.6060 | 6.72e-02 | -0.602000 | 6.64e-01 | 9.64e-05 |
rRNA modification in the nucleus and cytosol | 60 | 2.08e-12 | 2.52e-11 | 0.5310 | -5.05e-01 | 0.163000 | 1.24e-11 | 2.94e-02 |
RHOJ GTPase cycle | 54 | 6.18e-13 | 8.46e-12 | 0.5780 | 9.79e-02 | -0.570000 | 2.13e-01 | 4.18e-13 |
The role of GTSE1 in G2/M progression after G2 checkpoint | 58 | 3.30e-10 | 3.08e-09 | 0.4790 | -3.92e-01 | 0.275000 | 2.38e-07 | 2.85e-04 |
Mitochondrial translation | 96 | 6.75e-20 | 1.57e-18 | 0.5390 | -1.48e-01 | 0.518000 | 1.21e-02 | 1.55e-18 |
APC/C:Cdc20 mediated degradation of mitotic proteins | 74 | 1.65e-12 | 2.07e-11 | 0.4720 | -3.51e-01 | 0.315000 | 1.72e-07 | 2.76e-06 |
VLDLR internalisation and degradation | 11 | 1.39e-02 | 2.39e-02 | 0.4880 | 2.40e-01 | -0.425000 | 1.68e-01 | 1.46e-02 |
Activation of APC/C and APC/C:Cdc20 mediated degradation of mitotic proteins | 75 | 1.46e-12 | 1.89e-11 | 0.4700 | -3.59e-01 | 0.303000 | 7.46e-08 | 5.60e-06 |
CDT1 association with the CDC6:ORC:origin complex | 57 | 1.21e-09 | 9.92e-09 | 0.4680 | -3.38e-01 | 0.323000 | 1.01e-05 | 2.43e-05 |
Degradation of DVL | 55 | 7.35e-10 | 6.33e-09 | 0.4850 | -4.25e-01 | 0.234000 | 5.01e-08 | 2.70e-03 |
FOXO-mediated transcription of cell cycle genes | 15 | 1.84e-05 | 5.97e-05 | 0.6970 | -3.90e-02 | -0.696000 | 7.94e-01 | 3.06e-06 |
TFAP2 (AP-2) family regulates transcription of growth factors and their receptors | 11 | 1.31e-02 | 2.27e-02 | 0.4940 | 2.06e-01 | -0.449000 | 2.37e-01 | 9.90e-03 |
Chondroitin sulfate/dermatan sulfate metabolism | 48 | 4.57e-08 | 2.58e-07 | 0.4630 | 2.95e-01 | -0.356000 | 4.08e-04 | 1.93e-05 |
Hh mutants are degraded by ERAD | 54 | 3.17e-09 | 2.38e-08 | 0.4710 | -4.04e-01 | 0.243000 | 2.79e-07 | 2.03e-03 |
Cohesin Loading onto Chromatin | 10 | 1.94e-05 | 6.18e-05 | 0.8650 | -1.96e-01 | -0.842000 | 2.83e-01 | 3.98e-06 |
STAT3 nuclear events downstream of ALK signaling | 10 | 9.72e-03 | 1.73e-02 | 0.5430 | 1.14e-01 | -0.531000 | 5.32e-01 | 3.61e-03 |
AUF1 (hnRNP D0) binds and destabilizes mRNA | 53 | 7.57e-09 | 5.11e-08 | 0.4640 | -3.83e-01 | 0.261000 | 1.37e-06 | 9.89e-04 |
Regulation of RUNX3 expression and activity | 54 | 7.29e-10 | 6.32e-09 | 0.4930 | -4.58e-01 | 0.183000 | 5.93e-09 | 2.02e-02 |
NOTCH4 Activation and Transmission of Signal to the Nucleus | 11 | 2.45e-02 | 3.97e-02 | 0.4520 | 3.47e-01 | -0.290000 | 4.64e-02 | 9.53e-02 |
APC:Cdc20 mediated degradation of cell cycle proteins prior to satisfation of the cell cycle checkpoint | 72 | 3.21e-11 | 3.49e-10 | 0.4520 | -3.41e-01 | 0.296000 | 5.74e-07 | 1.36e-05 |
Ubiquitin-dependent degradation of Cyclin D | 50 | 4.03e-08 | 2.32e-07 | 0.4550 | -3.66e-01 | 0.271000 | 7.51e-06 | 9.15e-04 |
FBXL7 down-regulates AURKA during mitotic entry and in early mitosis | 53 | 1.24e-08 | 8.05e-08 | 0.4580 | -3.78e-01 | 0.259000 | 1.94e-06 | 1.12e-03 |
mRNA Splicing - Minor Pathway | 52 | 3.23e-08 | 1.91e-07 | 0.4490 | -3.11e-01 | 0.323000 | 1.03e-04 | 5.51e-05 |
Cross-presentation of soluble exogenous antigens (endosomes) | 45 | 2.31e-07 | 1.18e-06 | 0.4550 | -3.78e-01 | 0.253000 | 1.12e-05 | 3.28e-03 |
rRNA processing in the mitochondrion | 24 | 8.25e-08 | 4.43e-07 | 0.6740 | 4.17e-02 | 0.673000 | 7.24e-01 | 1.14e-08 |
Regulation of ornithine decarboxylase (ODC) | 49 | 4.03e-08 | 2.32e-07 | 0.4620 | -4.01e-01 | 0.230000 | 1.22e-06 | 5.39e-03 |
Cdc20:Phospho-APC/C mediated degradation of Cyclin A | 71 | 7.49e-11 | 7.52e-10 | 0.4470 | -3.37e-01 | 0.293000 | 8.99e-07 | 1.93e-05 |
RND1 GTPase cycle | 42 | 1.49e-08 | 9.52e-08 | 0.5220 | 1.22e-01 | -0.508000 | 1.72e-01 | 1.22e-08 |
Translation | 293 | 3.38e-40 | 2.60e-38 | 0.4350 | -2.89e-01 | 0.326000 | 1.51e-17 | 7.64e-22 |
DCC mediated attractive signaling | 14 | 4.56e-05 | 1.34e-04 | 0.6940 | -7.57e-02 | -0.690000 | 6.24e-01 | 7.81e-06 |
Adherens junctions interactions | 29 | 1.22e-04 | 3.25e-04 | 0.4340 | 2.81e-01 | -0.331000 | 8.81e-03 | 2.02e-03 |
NIK–>noncanonical NF-kB signaling | 57 | 5.45e-09 | 3.82e-08 | 0.4530 | -4.02e-01 | 0.211000 | 1.55e-07 | 5.94e-03 |
Degradation of AXIN | 53 | 2.88e-08 | 1.75e-07 | 0.4490 | -3.98e-01 | 0.209000 | 5.45e-07 | 8.50e-03 |
CDK-mediated phosphorylation and removal of Cdc6 | 71 | 4.49e-10 | 4.04e-09 | 0.4290 | -3.11e-01 | 0.295000 | 5.75e-06 | 1.67e-05 |
ALK mutants bind TKIs | 12 | 5.44e-04 | 1.27e-03 | 0.6470 | -4.16e-02 | -0.646000 | 8.03e-01 | 1.06e-04 |
RND3 GTPase cycle | 41 | 1.42e-07 | 7.41e-07 | 0.4930 | 1.27e-01 | -0.477000 | 1.59e-01 | 1.26e-07 |
Signaling by Hippo | 20 | 1.90e-08 | 1.19e-07 | 0.7810 | -1.62e-01 | -0.764000 | 2.09e-01 | 3.23e-09 |
Membrane binding and targetting of GAG proteins | 14 | 2.14e-04 | 5.50e-04 | 0.6350 | -6.34e-01 | -0.032300 | 4.00e-05 | 8.34e-01 |
Synthesis And Processing Of GAG, GAGPOL Polyproteins | 14 | 2.14e-04 | 5.50e-04 | 0.6350 | -6.34e-01 | -0.032300 | 4.00e-05 | 8.34e-01 |
Signaling by FLT3 fusion proteins | 19 | 4.96e-06 | 1.85e-05 | 0.6570 | -5.33e-02 | -0.655000 | 6.88e-01 | 7.73e-07 |
Caspase-mediated cleavage of cytoskeletal proteins | 12 | 1.13e-02 | 2.00e-02 | 0.4850 | 1.35e-01 | -0.466000 | 4.20e-01 | 5.17e-03 |
p53-Dependent G1 DNA Damage Response | 62 | 4.70e-09 | 3.36e-08 | 0.4350 | -3.68e-01 | 0.232000 | 5.27e-07 | 1.60e-03 |
p53-Dependent G1/S DNA damage checkpoint | 62 | 4.70e-09 | 3.36e-08 | 0.4350 | -3.68e-01 | 0.232000 | 5.27e-07 | 1.60e-03 |
Dectin-1 mediated noncanonical NF-kB signaling | 59 | 4.29e-09 | 3.13e-08 | 0.4490 | -4.05e-01 | 0.194000 | 7.27e-08 | 9.81e-03 |
RHOQ GTPase cycle | 58 | 1.84e-12 | 2.27e-11 | 0.5520 | 4.17e-02 | -0.550000 | 5.83e-01 | 4.17e-13 |
Hyaluronan metabolism | 14 | 5.33e-03 | 9.99e-03 | 0.4870 | 4.73e-01 | -0.117000 | 2.18e-03 | 4.50e-01 |
PKA activation in glucagon signalling | 15 | 2.33e-03 | 4.65e-03 | 0.5090 | 8.80e-02 | -0.501000 | 5.55e-01 | 7.70e-04 |
RHOB GTPase cycle | 69 | 2.01e-12 | 2.46e-11 | 0.5000 | 9.99e-02 | -0.490000 | 1.51e-01 | 1.98e-12 |
RHOU GTPase cycle | 40 | 4.02e-10 | 3.66e-09 | 0.5990 | -1.03e-02 | -0.599000 | 9.10e-01 | 5.39e-11 |
Glycosaminoglycan metabolism | 109 | 1.72e-15 | 2.86e-14 | 0.4390 | 1.92e-01 | -0.395000 | 5.45e-04 | 9.56e-13 |
RNA Polymerase I Promoter Opening | 24 | 9.80e-04 | 2.16e-03 | 0.4190 | -2.44e-01 | 0.341000 | 3.87e-02 | 3.81e-03 |
Defective CFTR causes cystic fibrosis | 58 | 7.11e-09 | 4.89e-08 | 0.4490 | -4.16e-01 | 0.169000 | 4.27e-08 | 2.61e-02 |
G1/S DNA Damage Checkpoints | 64 | 8.32e-09 | 5.54e-08 | 0.4220 | -3.55e-01 | 0.228000 | 9.19e-07 | 1.59e-03 |
Regulation of commissural axon pathfinding by SLIT and ROBO | 10 | 1.14e-02 | 2.01e-02 | 0.5400 | 4.05e-02 | -0.539000 | 8.25e-01 | 3.18e-03 |
tRNA processing in the mitochondrion | 20 | 6.21e-08 | 3.42e-07 | 0.7550 | 1.60e-01 | 0.738000 | 2.16e-01 | 1.09e-08 |
Antigen activates B Cell Receptor (BCR) leading to generation of second messengers | 28 | 1.04e-05 | 3.59e-05 | 0.5150 | 6.77e-02 | -0.510000 | 5.35e-01 | 2.96e-06 |
Adenylate cyclase inhibitory pathway | 12 | 3.49e-04 | 8.58e-04 | 0.6700 | -8.82e-02 | -0.664000 | 5.97e-01 | 6.71e-05 |
Hh mutants abrogate ligand secretion | 57 | 7.78e-08 | 4.20e-07 | 0.4200 | -3.60e-01 | 0.215000 | 2.54e-06 | 4.93e-03 |
Metabolism of polyamines | 57 | 3.42e-08 | 2.01e-07 | 0.4320 | -3.92e-01 | 0.182000 | 3.00e-07 | 1.78e-02 |
Assembly Of The HIV Virion | 16 | 1.68e-04 | 4.39e-04 | 0.6020 | -6.01e-01 | -0.028600 | 3.10e-05 | 8.43e-01 |
APC-Cdc20 mediated degradation of Nek2A | 26 | 6.87e-04 | 1.57e-03 | 0.4140 | -2.25e-01 | 0.347000 | 4.73e-02 | 2.17e-03 |
Degradation of GLI1 by the proteasome | 57 | 7.94e-08 | 4.28e-07 | 0.4200 | -3.68e-01 | 0.203000 | 1.55e-06 | 8.13e-03 |
Molecules associated with elastic fibres | 25 | 1.02e-04 | 2.75e-04 | 0.4850 | 9.30e-02 | -0.476000 | 4.21e-01 | 3.77e-05 |
Insulin processing | 25 | 6.46e-06 | 2.34e-05 | 0.5620 | 2.24e-03 | -0.562000 | 9.85e-01 | 1.14e-06 |
Elastic fibre formation | 35 | 4.03e-06 | 1.52e-05 | 0.4760 | 9.77e-02 | -0.466000 | 3.17e-01 | 1.83e-06 |
VEGFR2 mediated cell proliferation | 19 | 2.74e-05 | 8.38e-05 | 0.6090 | -4.60e-02 | -0.607000 | 7.28e-01 | 4.58e-06 |
Integrin cell surface interactions | 57 | 2.12e-07 | 1.09e-06 | 0.4060 | 2.19e-01 | -0.342000 | 4.17e-03 | 8.06e-06 |
Erythropoietin activates Phosphoinositide-3-kinase (PI3K) | 11 | 1.15e-03 | 2.50e-03 | 0.6450 | -8.01e-02 | -0.640000 | 6.45e-01 | 2.36e-04 |
Regulation of APC/C activators between G1/S and early anaphase | 79 | 8.70e-10 | 7.36e-09 | 0.4010 | -3.28e-01 | 0.232000 | 4.73e-07 | 3.63e-04 |
APC/C-mediated degradation of cell cycle proteins | 86 | 2.19e-10 | 2.07e-09 | 0.3970 | -3.16e-01 | 0.240000 | 4.01e-07 | 1.17e-04 |
Regulation of mitotic cell cycle | 86 | 2.19e-10 | 2.07e-09 | 0.3970 | -3.16e-01 | 0.240000 | 4.01e-07 | 1.17e-04 |
Constitutive Signaling by Overexpressed ERBB2 | 11 | 1.41e-02 | 2.42e-02 | 0.5010 | 5.76e-02 | -0.498000 | 7.41e-01 | 4.25e-03 |
CDC42 GTPase cycle | 153 | 1.05e-22 | 3.02e-21 | 0.4590 | 1.07e-01 | -0.447000 | 2.26e-02 | 1.32e-21 |
Phosphorylation of the APC/C | 20 | 4.28e-03 | 8.12e-03 | 0.4100 | -1.84e-01 | 0.367000 | 1.55e-01 | 4.52e-03 |
FGFR2 alternative splicing | 25 | 7.43e-04 | 1.68e-03 | 0.4240 | -3.94e-01 | 0.155000 | 6.46e-04 | 1.78e-01 |
Gap junction trafficking and regulation | 20 | 2.45e-03 | 4.87e-03 | 0.4340 | 1.37e-01 | -0.412000 | 2.89e-01 | 1.42e-03 |
Miscellaneous transport and binding events | 23 | 3.63e-06 | 1.39e-05 | 0.6050 | -5.55e-02 | -0.603000 | 6.45e-01 | 5.57e-07 |
Regulation of HMOX1 expression and activity | 63 | 7.66e-09 | 5.15e-08 | 0.4320 | -4.10e-01 | 0.136000 | 1.83e-08 | 6.23e-02 |
The citric acid (TCA) cycle and respiratory electron transport | 173 | 1.18e-21 | 3.14e-20 | 0.4180 | -1.52e-01 | 0.389000 | 5.42e-04 | 1.04e-18 |
RHOD GTPase cycle | 52 | 4.60e-09 | 3.32e-08 | 0.4890 | 5.43e-02 | -0.486000 | 4.98e-01 | 1.27e-09 |
RHOH GTPase cycle | 35 | 5.00e-08 | 2.80e-07 | 0.5660 | -2.49e-02 | -0.565000 | 7.99e-01 | 6.96e-09 |
RNA Polymerase II Transcription Termination | 65 | 1.41e-07 | 7.36e-07 | 0.3840 | -2.99e-01 | 0.241000 | 3.01e-05 | 7.73e-04 |
Trafficking of GluR2-containing AMPA receptors | 16 | 2.01e-02 | 3.32e-02 | 0.3850 | 3.06e-01 | -0.234000 | 3.39e-02 | 1.06e-01 |
Abortive elongation of HIV-1 transcript in the absence of Tat | 23 | 4.02e-04 | 9.66e-04 | 0.4670 | -4.61e-01 | 0.077700 | 1.30e-04 | 5.19e-01 |
Formation of the Early Elongation Complex | 33 | 3.73e-05 | 1.12e-04 | 0.4430 | -4.30e-01 | 0.106000 | 1.91e-05 | 2.90e-01 |
Formation of the HIV-1 Early Elongation Complex | 33 | 3.73e-05 | 1.12e-04 | 0.4430 | -4.30e-01 | 0.106000 | 1.91e-05 | 2.90e-01 |
CLEC7A (Dectin-1) induces NFAT activation | 11 | 3.38e-06 | 1.31e-05 | 0.8970 | -3.08e-01 | -0.842000 | 7.70e-02 | 1.30e-06 |
Interleukin-7 signaling | 23 | 7.17e-04 | 1.63e-03 | 0.4480 | 9.62e-02 | -0.437000 | 4.24e-01 | 2.81e-04 |
RHOC GTPase cycle | 72 | 2.08e-14 | 3.27e-13 | 0.5390 | -5.20e-03 | -0.539000 | 9.39e-01 | 2.54e-15 |
Degradation of GLI2 by the proteasome | 57 | 1.10e-06 | 4.75e-06 | 0.3840 | -3.25e-01 | 0.205000 | 2.23e-05 | 7.47e-03 |
Regulated proteolysis of p75NTR | 11 | 1.82e-02 | 3.03e-02 | 0.4870 | 4.49e-02 | -0.484000 | 7.96e-01 | 5.39e-03 |
Regulation of RUNX2 expression and activity | 70 | 7.42e-09 | 5.04e-08 | 0.4090 | -3.82e-01 | 0.145000 | 3.16e-08 | 3.60e-02 |
Mitochondrial protein import | 64 | 2.31e-07 | 1.18e-06 | 0.3820 | -2.03e-01 | 0.324000 | 4.91e-03 | 7.42e-06 |
VEGFR2 mediated vascular permeability | 27 | 8.57e-05 | 2.36e-04 | 0.4740 | 5.46e-02 | -0.471000 | 6.23e-01 | 2.27e-05 |
Gap junction trafficking | 18 | 9.94e-03 | 1.77e-02 | 0.3990 | 1.57e-01 | -0.367000 | 2.50e-01 | 7.07e-03 |
YAP1- and WWTR1 (TAZ)-stimulated gene expression | 12 | 7.09e-04 | 1.62e-03 | 0.6420 | -1.11e-01 | -0.633000 | 5.04e-01 | 1.48e-04 |
Cell-cell junction organization | 50 | 1.13e-05 | 3.85e-05 | 0.3730 | 2.15e-01 | -0.305000 | 8.64e-03 | 1.92e-04 |
Glycosphingolipid metabolism | 42 | 6.19e-05 | 1.77e-04 | 0.3760 | 3.18e-01 | -0.201000 | 3.67e-04 | 2.45e-02 |
RHOA GTPase cycle | 146 | 3.70e-20 | 8.89e-19 | 0.4440 | 8.18e-02 | -0.436000 | 8.77e-02 | 8.34e-20 |
Cristae formation | 31 | 2.43e-05 | 7.57e-05 | 0.4720 | -4.86e-02 | 0.469000 | 6.39e-01 | 6.06e-06 |
ECM proteoglycans | 43 | 4.73e-06 | 1.77e-05 | 0.4250 | 1.06e-01 | -0.412000 | 2.28e-01 | 2.97e-06 |
LDL clearance | 16 | 2.30e-02 | 3.74e-02 | 0.3810 | 1.86e-01 | -0.332000 | 1.99e-01 | 2.14e-02 |
HIV elongation arrest and recovery | 32 | 5.19e-06 | 1.91e-05 | 0.5000 | -5.00e-01 | 0.016000 | 9.78e-07 | 8.75e-01 |
Pausing and recovery of HIV elongation | 32 | 5.19e-06 | 1.91e-05 | 0.5000 | -5.00e-01 | 0.016000 | 9.78e-07 | 8.75e-01 |
Pausing and recovery of Tat-mediated HIV elongation | 30 | 1.76e-05 | 5.73e-05 | 0.4890 | -4.88e-01 | 0.027600 | 3.67e-06 | 7.93e-01 |
Tat-mediated HIV elongation arrest and recovery | 30 | 1.76e-05 | 5.73e-05 | 0.4890 | -4.88e-01 | 0.027600 | 3.67e-06 | 7.93e-01 |
Assembly of the pre-replicative complex | 90 | 1.93e-09 | 1.50e-08 | 0.3690 | -2.19e-01 | 0.297000 | 3.38e-04 | 1.10e-06 |
Role of LAT2/NTAL/LAB on calcium mobilization | 13 | 5.82e-04 | 1.35e-03 | 0.6250 | -1.01e-01 | -0.616000 | 5.27e-01 | 1.18e-04 |
Receptor Mediated Mitophagy | 11 | 2.63e-05 | 8.10e-05 | 0.8190 | -7.76e-01 | -0.263000 | 8.30e-06 | 1.31e-01 |
Signaling by ROBO receptors | 210 | 1.76e-20 | 4.30e-19 | 0.3640 | -2.91e-01 | 0.219000 | 3.63e-13 | 4.27e-08 |
Asymmetric localization of PCP proteins | 62 | 1.30e-07 | 6.85e-07 | 0.4010 | -3.79e-01 | 0.129000 | 2.34e-07 | 8.00e-02 |
RAC1 GTPase cycle | 176 | 5.03e-26 | 1.67e-24 | 0.4650 | 4.44e-02 | -0.463000 | 3.09e-01 | 2.75e-26 |
S33 mutants of beta-catenin aren’t phosphorylated | 15 | 7.71e-07 | 3.45e-06 | 0.8110 | -2.60e-01 | -0.768000 | 8.08e-02 | 2.62e-07 |
S37 mutants of beta-catenin aren’t phosphorylated | 15 | 7.71e-07 | 3.45e-06 | 0.8110 | -2.60e-01 | -0.768000 | 8.08e-02 | 2.62e-07 |
S45 mutants of beta-catenin aren’t phosphorylated | 15 | 7.71e-07 | 3.45e-06 | 0.8110 | -2.60e-01 | -0.768000 | 8.08e-02 | 2.62e-07 |
Signaling by CTNNB1 phospho-site mutants | 15 | 7.71e-07 | 3.45e-06 | 0.8110 | -2.60e-01 | -0.768000 | 8.08e-02 | 2.62e-07 |
Signaling by GSK3beta mutants | 15 | 7.71e-07 | 3.45e-06 | 0.8110 | -2.60e-01 | -0.768000 | 8.08e-02 | 2.62e-07 |
T41 mutants of beta-catenin aren’t phosphorylated | 15 | 7.71e-07 | 3.45e-06 | 0.8110 | -2.60e-01 | -0.768000 | 8.08e-02 | 2.62e-07 |
RNA Pol II CTD phosphorylation and interaction with CE | 27 | 9.01e-04 | 2.01e-03 | 0.4040 | -3.85e-01 | 0.122000 | 5.28e-04 | 2.74e-01 |
RNA Pol II CTD phosphorylation and interaction with CE during HIV infection | 27 | 9.01e-04 | 2.01e-03 | 0.4040 | -3.85e-01 | 0.122000 | 5.28e-04 | 2.74e-01 |
Amine ligand-binding receptors | 22 | 9.60e-03 | 1.72e-02 | 0.3580 | 2.36e-01 | -0.269000 | 5.54e-02 | 2.88e-02 |
GLI3 is processed to GLI3R by the proteasome | 57 | 3.47e-06 | 1.34e-05 | 0.3680 | -3.21e-01 | 0.180000 | 2.76e-05 | 1.85e-02 |
Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha | 64 | 3.92e-07 | 1.88e-06 | 0.3780 | -3.44e-01 | 0.156000 | 1.91e-06 | 3.05e-02 |
Signaling by PDGFR in disease | 19 | 5.53e-07 | 2.59e-06 | 0.7260 | -1.98e-01 | -0.698000 | 1.35e-01 | 1.36e-07 |
Formation of HIV elongation complex in the absence of HIV Tat | 44 | 2.67e-07 | 1.32e-06 | 0.4750 | -4.74e-01 | 0.025900 | 5.22e-08 | 7.66e-01 |
CaM pathway | 31 | 1.91e-05 | 6.12e-05 | 0.4800 | 2.04e-02 | -0.479000 | 8.44e-01 | 3.83e-06 |
Calmodulin induced events | 31 | 1.91e-05 | 6.12e-05 | 0.4800 | 2.04e-02 | -0.479000 | 8.44e-01 | 3.83e-06 |
Formation of HIV-1 elongation complex containing HIV-1 Tat | 42 | 8.74e-07 | 3.86e-06 | 0.4660 | -4.64e-01 | 0.034700 | 1.89e-07 | 6.97e-01 |
HIV Transcription Elongation | 42 | 8.74e-07 | 3.86e-06 | 0.4660 | -4.64e-01 | 0.034700 | 1.89e-07 | 6.97e-01 |
Tat-mediated elongation of the HIV-1 transcript | 42 | 8.74e-07 | 3.86e-06 | 0.4660 | -4.64e-01 | 0.034700 | 1.89e-07 | 6.97e-01 |
mRNA Splicing - Major Pathway | 179 | 1.87e-17 | 3.51e-16 | 0.3640 | -3.13e-01 | 0.187000 | 5.22e-13 | 1.66e-05 |
MECP2 regulates neuronal receptors and channels | 17 | 2.74e-04 | 6.95e-04 | 0.5710 | -6.83e-02 | -0.567000 | 6.26e-01 | 5.16e-05 |
Growth hormone receptor signaling | 20 | 1.39e-04 | 3.70e-04 | 0.5460 | -4.84e-02 | -0.544000 | 7.08e-01 | 2.51e-05 |
mRNA Splicing | 187 | 1.09e-17 | 2.18e-16 | 0.3580 | -2.99e-01 | 0.196000 | 1.57e-12 | 3.59e-06 |
RND2 GTPase cycle | 41 | 1.41e-05 | 4.71e-05 | 0.4170 | 8.75e-02 | -0.408000 | 3.32e-01 | 6.24e-06 |
DAG and IP3 signaling | 37 | 6.07e-07 | 2.81e-06 | 0.5070 | -1.19e-02 | -0.507000 | 9.00e-01 | 9.38e-08 |
RUNX1 regulates transcription of genes involved in differentiation of HSCs | 87 | 1.47e-08 | 9.48e-08 | 0.3560 | -2.95e-01 | 0.199000 | 1.96e-06 | 1.31e-03 |
Signaling by FGFR3 fusions in cancer | 10 | 1.28e-03 | 2.75e-03 | 0.6780 | -1.64e-01 | -0.658000 | 3.69e-01 | 3.13e-04 |
Josephin domain DUBs | 10 | 2.90e-02 | 4.61e-02 | 0.4830 | -4.83e-01 | 0.011300 | 8.21e-03 | 9.50e-01 |
Orc1 removal from chromatin | 69 | 9.86e-07 | 4.31e-06 | 0.3490 | -2.36e-01 | 0.257000 | 7.00e-04 | 2.21e-04 |
Apoptotic execution phase | 47 | 1.06e-05 | 3.62e-05 | 0.3910 | 1.20e-01 | -0.373000 | 1.53e-01 | 9.87e-06 |
Switching of origins to a post-replicative state | 89 | 1.60e-08 | 1.01e-07 | 0.3510 | -2.17e-01 | 0.276000 | 4.11e-04 | 6.93e-06 |
Recycling pathway of L1 | 27 | 8.83e-06 | 3.10e-05 | 0.5380 | -4.56e-02 | -0.536000 | 6.81e-01 | 1.41e-06 |
Keratan sulfate/keratin metabolism | 29 | 2.02e-04 | 5.20e-04 | 0.4350 | 5.93e-02 | -0.431000 | 5.80e-01 | 5.81e-05 |
Activation of NF-kappaB in B cells | 65 | 1.21e-07 | 6.41e-07 | 0.3930 | -3.76e-01 | 0.114000 | 1.56e-07 | 1.11e-01 |
DNA methylation | 26 | 3.21e-03 | 6.24e-03 | 0.3700 | -1.54e-01 | 0.336000 | 1.73e-01 | 3.02e-03 |
DARPP-32 events | 23 | 1.52e-03 | 3.19e-03 | 0.4260 | 6.90e-02 | -0.420000 | 5.67e-01 | 4.83e-04 |
SCF(Skp2)-mediated degradation of p27/p21 | 60 | 6.61e-06 | 2.37e-05 | 0.3480 | -2.73e-01 | 0.215000 | 2.51e-04 | 3.92e-03 |
Signaling by Leptin | 10 | 7.15e-03 | 1.31e-02 | 0.5790 | -8.57e-02 | -0.573000 | 6.39e-01 | 1.70e-03 |
Signaling by FGFR2 IIIa TM | 19 | 1.36e-02 | 2.35e-02 | 0.3750 | -3.50e-01 | 0.137000 | 8.35e-03 | 3.01e-01 |
RAC2 GTPase cycle | 85 | 1.86e-17 | 3.51e-16 | 0.5540 | -6.36e-02 | -0.550000 | 3.10e-01 | 1.71e-18 |
Condensation of Prophase Chromosomes | 34 | 1.32e-03 | 2.82e-03 | 0.3440 | -2.51e-01 | 0.235000 | 1.14e-02 | 1.75e-02 |
Myogenesis | 25 | 6.74e-04 | 1.55e-03 | 0.4350 | 5.42e-02 | -0.431000 | 6.39e-01 | 1.88e-04 |
Metabolism of RNA | 677 | 2.53e-61 | 1.24e-58 | 0.3600 | -3.20e-01 | 0.166000 | 5.42e-46 | 1.74e-13 |
Mitophagy | 28 | 6.80e-06 | 2.42e-05 | 0.5350 | -5.32e-01 | -0.047600 | 1.07e-06 | 6.63e-01 |
UCH proteinases | 90 | 4.12e-09 | 3.02e-08 | 0.3650 | -3.31e-01 | 0.153000 | 5.58e-08 | 1.22e-02 |
Conversion from APC/C:Cdc20 to APC/C:Cdh1 in late anaphase | 20 | 1.77e-02 | 2.95e-02 | 0.3510 | -1.83e-01 | 0.300000 | 1.57e-01 | 2.02e-02 |
Hyaluronan uptake and degradation | 10 | 2.27e-02 | 3.70e-02 | 0.5020 | 5.02e-01 | 0.022200 | 5.98e-03 | 9.03e-01 |
RHOG GTPase cycle | 74 | 1.84e-13 | 2.59e-12 | 0.5160 | -3.51e-02 | -0.514000 | 6.02e-01 | 1.91e-14 |
mRNA Capping | 29 | 5.04e-04 | 1.19e-03 | 0.4100 | -4.03e-01 | 0.075500 | 1.75e-04 | 4.82e-01 |
SUMOylation of intracellular receptors | 27 | 1.92e-03 | 3.94e-03 | 0.3820 | 1.08e-01 | -0.367000 | 3.33e-01 | 9.71e-04 |
Cell junction organization | 75 | 4.87e-09 | 3.46e-08 | 0.4040 | 7.64e-02 | -0.397000 | 2.53e-01 | 2.67e-09 |
RHOV GTPase cycle | 37 | 8.06e-10 | 6.87e-09 | 0.6240 | -1.36e-01 | -0.609000 | 1.51e-01 | 1.41e-10 |
PINK1-PRKN Mediated Mitophagy | 21 | 2.10e-03 | 4.26e-03 | 0.4370 | -4.36e-01 | 0.036100 | 5.43e-04 | 7.75e-01 |
Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA | 17 | 1.28e-02 | 2.24e-02 | 0.4050 | -3.99e-01 | 0.072800 | 4.42e-03 | 6.03e-01 |
Ca-dependent events | 33 | 3.31e-06 | 1.29e-05 | 0.5060 | -3.51e-02 | -0.505000 | 7.27e-01 | 5.11e-07 |
mRNA 3’-end processing | 56 | 3.39e-05 | 1.02e-04 | 0.3340 | -2.63e-01 | 0.206000 | 6.60e-04 | 7.51e-03 |
Interleukin receptor SHC signaling | 21 | 1.42e-03 | 3.00e-03 | 0.4530 | 1.52e-02 | -0.453000 | 9.04e-01 | 3.26e-04 |
PECAM1 interactions | 11 | 1.71e-02 | 2.88e-02 | 0.4970 | -2.91e-02 | -0.496000 | 8.67e-01 | 4.35e-03 |
Formation of TC-NER Pre-Incision Complex | 53 | 5.23e-06 | 1.91e-05 | 0.3810 | -3.69e-01 | 0.096700 | 3.36e-06 | 2.23e-01 |
RORA activates gene expression | 18 | 9.75e-06 | 3.38e-05 | 0.6670 | -1.79e-01 | -0.643000 | 1.89e-01 | 2.34e-06 |
NOTCH4 Intracellular Domain Regulates Transcription | 19 | 1.93e-02 | 3.19e-02 | 0.3600 | 1.25e-01 | -0.338000 | 3.47e-01 | 1.07e-02 |
Signaling by cytosolic FGFR1 fusion mutants | 18 | 7.09e-04 | 1.62e-03 | 0.5210 | -5.62e-02 | -0.518000 | 6.80e-01 | 1.40e-04 |
Signaling by MET | 66 | 7.37e-11 | 7.45e-10 | 0.4860 | -2.43e-02 | -0.485000 | 7.32e-01 | 8.78e-12 |
Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA | 17 | 2.26e-02 | 3.69e-02 | 0.3760 | -3.63e-01 | 0.096500 | 9.54e-03 | 4.91e-01 |
RAC3 GTPase cycle | 89 | 4.30e-18 | 9.00e-17 | 0.5540 | -8.72e-02 | -0.547000 | 1.55e-01 | 4.58e-19 |
Defective B3GALTL causes PpS | 36 | 1.22e-03 | 2.63e-03 | 0.3390 | 3.00e-01 | -0.158000 | 1.86e-03 | 1.01e-01 |
Processing of Capped Intron-Containing Pre-mRNA | 238 | 1.80e-21 | 4.70e-20 | 0.3550 | -3.32e-01 | 0.125000 | 9.00e-19 | 8.85e-04 |
ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression | 37 | 9.88e-04 | 2.17e-03 | 0.3400 | -3.03e-01 | 0.153000 | 1.42e-03 | 1.06e-01 |
Extracellular matrix organization | 249 | 5.50e-22 | 1.52e-20 | 0.3510 | 1.28e-01 | -0.327000 | 4.90e-04 | 5.56e-19 |
Deactivation of the beta-catenin transactivating complex | 41 | 3.69e-04 | 8.98e-04 | 0.3460 | 1.37e-01 | -0.318000 | 1.30e-01 | 4.28e-04 |
Synthesis of very long-chain fatty acyl-CoAs | 22 | 1.39e-02 | 2.39e-02 | 0.3480 | 1.33e-01 | -0.321000 | 2.81e-01 | 9.08e-03 |
Signaling by PDGFRA extracellular domain mutants | 12 | 4.81e-05 | 1.41e-04 | 0.7630 | -2.63e-01 | -0.716000 | 1.14e-01 | 1.74e-05 |
Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants | 12 | 4.81e-05 | 1.41e-04 | 0.7630 | -2.63e-01 | -0.716000 | 1.14e-01 | 1.74e-05 |
Inhibition of DNA recombination at telomere | 39 | 9.43e-04 | 2.09e-03 | 0.3310 | -2.88e-01 | 0.164000 | 1.87e-03 | 7.67e-02 |
RNA Polymerase I Promoter Escape | 52 | 1.64e-04 | 4.31e-04 | 0.3190 | -2.23e-01 | 0.228000 | 5.39e-03 | 4.45e-03 |
Prolonged ERK activation events | 14 | 3.85e-04 | 9.29e-04 | 0.6230 | -1.54e-01 | -0.604000 | 3.17e-01 | 9.13e-05 |
Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation | 34 | 3.81e-04 | 9.21e-04 | 0.3850 | -3.79e-01 | 0.070700 | 1.32e-04 | 4.75e-01 |
PRC2 methylates histones and DNA | 34 | 3.48e-03 | 6.69e-03 | 0.3180 | -2.11e-01 | 0.237000 | 3.28e-02 | 1.66e-02 |
L1CAM interactions | 92 | 3.02e-14 | 4.66e-13 | 0.4760 | -2.88e-02 | -0.475000 | 6.33e-01 | 3.10e-15 |
Inactivation of APC/C via direct inhibition of the APC/C complex | 21 | 2.72e-02 | 4.36e-02 | 0.3240 | -1.71e-01 | 0.275000 | 1.74e-01 | 2.92e-02 |
Inhibition of the proteolytic activity of APC/C required for the onset of anaphase by mitotic spindle checkpoint components | 21 | 2.72e-02 | 4.36e-02 | 0.3240 | -1.71e-01 | 0.275000 | 1.74e-01 | 2.92e-02 |
O-linked glycosylation of mucins | 48 | 1.94e-04 | 5.03e-04 | 0.3310 | 1.51e-01 | -0.295000 | 7.06e-02 | 4.04e-04 |
Regulation of mRNA stability by proteins that bind AU-rich elements | 87 | 3.13e-08 | 1.86e-07 | 0.3540 | -3.36e-01 | 0.109000 | 5.79e-08 | 7.86e-02 |
G-protein mediated events | 48 | 5.57e-09 | 3.89e-08 | 0.5180 | -6.95e-02 | -0.514000 | 4.05e-01 | 7.30e-10 |
Regulation of beta-cell development | 29 | 7.66e-03 | 1.40e-02 | 0.3200 | 1.74e-01 | -0.269000 | 1.05e-01 | 1.22e-02 |
DNA Replication Pre-Initiation | 107 | 7.36e-09 | 5.04e-08 | 0.3290 | -1.45e-01 | 0.295000 | 9.36e-03 | 1.29e-07 |
Establishment of Sister Chromatid Cohesion | 11 | 5.26e-05 | 1.53e-04 | 0.7950 | -2.98e-01 | -0.737000 | 8.65e-02 | 2.30e-05 |
Beta-catenin phosphorylation cascade | 17 | 8.19e-07 | 3.66e-06 | 0.7620 | -2.73e-01 | -0.711000 | 5.12e-02 | 3.79e-07 |
PLC beta mediated events | 44 | 5.86e-08 | 3.27e-07 | 0.5060 | -6.47e-02 | -0.502000 | 4.57e-01 | 8.07e-09 |
VEGFA-VEGFR2 Pathway | 91 | 4.15e-16 | 7.15e-15 | 0.5140 | -7.20e-02 | -0.509000 | 2.35e-01 | 4.25e-17 |
Translocation of SLC2A4 (GLUT4) to the plasma membrane | 50 | 4.90e-10 | 4.35e-09 | 0.5410 | -9.61e-02 | -0.533000 | 2.39e-01 | 6.95e-11 |
Hedgehog ligand biogenesis | 63 | 3.20e-05 | 9.70e-05 | 0.3170 | -2.70e-01 | 0.166000 | 2.05e-04 | 2.27e-02 |
O-glycosylation of TSR domain-containing proteins | 37 | 2.31e-03 | 4.62e-03 | 0.3170 | 2.69e-01 | -0.167000 | 4.57e-03 | 7.90e-02 |
Cargo concentration in the ER | 31 | 1.74e-05 | 5.71e-05 | 0.4880 | -5.14e-02 | -0.486000 | 6.20e-01 | 2.85e-06 |
FCGR3A-mediated IL10 synthesis | 32 | 4.09e-06 | 1.54e-05 | 0.5130 | -7.50e-02 | -0.508000 | 4.63e-01 | 6.58e-07 |
NoRC negatively regulates rRNA expression | 67 | 2.83e-05 | 8.62e-05 | 0.3090 | -2.45e-01 | 0.188000 | 5.24e-04 | 7.90e-03 |
TNFR2 non-canonical NF-kB pathway | 89 | 5.23e-07 | 2.46e-06 | 0.3160 | -2.73e-01 | 0.159000 | 8.36e-06 | 9.54e-03 |
Signaling by ERBB2 ECD mutants | 16 | 1.28e-02 | 2.24e-02 | 0.4240 | 8.55e-03 | -0.423000 | 9.53e-01 | 3.36e-03 |
ER-Phagosome pathway | 86 | 3.29e-07 | 1.60e-06 | 0.3290 | -3.02e-01 | 0.130000 | 1.32e-06 | 3.66e-02 |
O-linked glycosylation | 95 | 3.52e-07 | 1.70e-06 | 0.3090 | 1.82e-01 | -0.250000 | 2.16e-03 | 2.59e-05 |
FCERI mediated NF-kB activation | 75 | 4.56e-08 | 2.58e-07 | 0.3820 | -3.79e-01 | 0.050100 | 1.40e-08 | 4.53e-01 |
Hedgehog ‘on’ state | 84 | 2.42e-07 | 1.22e-06 | 0.3370 | -3.19e-01 | 0.109000 | 4.14e-07 | 8.40e-02 |
Netrin-1 signaling | 45 | 1.13e-09 | 9.39e-09 | 0.5610 | -1.21e-01 | -0.548000 | 1.59e-01 | 1.96e-10 |
Negative epigenetic regulation of rRNA expression | 70 | 1.97e-05 | 6.25e-05 | 0.3080 | -2.59e-01 | 0.166000 | 1.79e-04 | 1.60e-02 |
Signaling by PDGF | 51 | 3.43e-08 | 2.01e-07 | 0.4770 | -4.95e-02 | -0.474000 | 5.40e-01 | 4.55e-09 |
RAF-independent MAPK1/3 activation | 22 | 1.85e-05 | 5.97e-05 | 0.5850 | -1.43e-01 | -0.567000 | 2.44e-01 | 4.05e-06 |
Signaling by VEGF | 99 | 1.95e-17 | 3.61e-16 | 0.5150 | -8.45e-02 | -0.508000 | 1.46e-01 | 2.18e-18 |
Interaction between L1 and Ankyrins | 25 | 2.47e-02 | 3.99e-02 | 0.3000 | 2.22e-01 | -0.201000 | 5.45e-02 | 8.16e-02 |
Cell-Cell communication | 105 | 2.33e-14 | 3.63e-13 | 0.4480 | -2.52e-02 | -0.447000 | 6.55e-01 | 2.40e-15 |
RNA Polymerase I Promoter Clearance | 71 | 1.56e-05 | 5.17e-05 | 0.3100 | -2.71e-01 | 0.150000 | 7.83e-05 | 2.90e-02 |
RNA Polymerase I Transcription | 71 | 1.56e-05 | 5.17e-05 | 0.3100 | -2.71e-01 | 0.150000 | 7.83e-05 | 2.90e-02 |
Packaging Of Telomere Ends | 24 | 1.53e-02 | 2.61e-02 | 0.3300 | -3.13e-01 | 0.107000 | 8.03e-03 | 3.63e-01 |
SIRT1 negatively regulates rRNA expression | 29 | 1.49e-02 | 2.56e-02 | 0.2970 | -1.88e-01 | 0.229000 | 7.91e-02 | 3.25e-02 |
ERKs are inactivated | 13 | 4.26e-06 | 1.60e-05 | 0.8210 | -3.33e-01 | -0.751000 | 3.74e-02 | 2.76e-06 |
Synthesis of PIPs at the early endosome membrane | 16 | 1.36e-06 | 5.69e-06 | 0.7730 | -2.98e-01 | -0.713000 | 3.91e-02 | 7.87e-07 |
RHO GTPase cycle | 433 | 1.74e-48 | 3.19e-46 | 0.4130 | -5.48e-05 | -0.413000 | 9.98e-01 | 2.34e-49 |
Diseases of glycosylation | 129 | 1.55e-08 | 9.85e-08 | 0.2910 | 1.99e-01 | -0.213000 | 9.74e-05 | 2.89e-05 |
Regulation of RAS by GAPs | 64 | 9.56e-06 | 3.32e-05 | 0.3390 | -3.29e-01 | 0.082000 | 5.40e-06 | 2.56e-01 |
DNA Damage Recognition in GG-NER | 38 | 2.66e-03 | 5.26e-03 | 0.3110 | -2.86e-01 | 0.123000 | 2.30e-03 | 1.88e-01 |
G alpha (z) signalling events | 39 | 8.99e-05 | 2.46e-04 | 0.3970 | 1.24e-02 | -0.396000 | 8.93e-01 | 1.83e-05 |
Transport of bile salts and organic acids, metal ions and amine compounds | 58 | 2.16e-05 | 6.79e-05 | 0.3440 | 7.21e-02 | -0.336000 | 3.42e-01 | 9.37e-06 |
CRMPs in Sema3A signaling | 16 | 2.47e-02 | 3.99e-02 | 0.3900 | 1.89e-02 | -0.389000 | 8.96e-01 | 7.04e-03 |
HDACs deacetylate histones | 52 | 3.95e-06 | 1.50e-05 | 0.3970 | -3.97e-01 | 0.009870 | 7.25e-07 | 9.02e-01 |
EPH-ephrin mediated repulsion of cells | 48 | 5.92e-05 | 1.70e-04 | 0.3620 | 4.72e-02 | -0.359000 | 5.72e-01 | 1.66e-05 |
Signaling by KIT in disease | 19 | 7.69e-06 | 2.73e-05 | 0.6590 | -2.17e-01 | -0.623000 | 1.02e-01 | 2.62e-06 |
Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants | 19 | 7.69e-06 | 2.73e-05 | 0.6590 | -2.17e-01 | -0.623000 | 1.02e-01 | 2.62e-06 |
Notch-HLH transcription pathway | 28 | 4.82e-04 | 1.14e-03 | 0.4270 | -2.10e-02 | -0.426000 | 8.48e-01 | 9.43e-05 |
Glutamate binding, activation of AMPA receptors and synaptic plasticity | 27 | 1.76e-02 | 2.94e-02 | 0.3040 | 1.29e-01 | -0.275000 | 2.44e-01 | 1.33e-02 |
Trafficking of AMPA receptors | 27 | 1.76e-02 | 2.94e-02 | 0.3040 | 1.29e-01 | -0.275000 | 2.44e-01 | 1.33e-02 |
Retrograde transport at the Trans-Golgi-Network | 49 | 1.50e-06 | 6.22e-06 | 0.4280 | -2.25e-02 | -0.427000 | 7.86e-01 | 2.29e-07 |
APC truncation mutants have impaired AXIN binding | 14 | 1.34e-06 | 5.64e-06 | 0.8280 | -3.48e-01 | -0.752000 | 2.43e-02 | 1.10e-06 |
AXIN missense mutants destabilize the destruction complex | 14 | 1.34e-06 | 5.64e-06 | 0.8280 | -3.48e-01 | -0.752000 | 2.43e-02 | 1.10e-06 |
Signaling by AMER1 mutants | 14 | 1.34e-06 | 5.64e-06 | 0.8280 | -3.48e-01 | -0.752000 | 2.43e-02 | 1.10e-06 |
Signaling by APC mutants | 14 | 1.34e-06 | 5.64e-06 | 0.8280 | -3.48e-01 | -0.752000 | 2.43e-02 | 1.10e-06 |
Signaling by AXIN mutants | 14 | 1.34e-06 | 5.64e-06 | 0.8280 | -3.48e-01 | -0.752000 | 2.43e-02 | 1.10e-06 |
Truncations of AMER1 destabilize the destruction complex | 14 | 1.34e-06 | 5.64e-06 | 0.8280 | -3.48e-01 | -0.752000 | 2.43e-02 | 1.10e-06 |
HIV Transcription Initiation | 47 | 5.12e-04 | 1.20e-03 | 0.3180 | -3.01e-01 | 0.103000 | 3.57e-04 | 2.23e-01 |
RNA Polymerase II HIV Promoter Escape | 47 | 5.12e-04 | 1.20e-03 | 0.3180 | -3.01e-01 | 0.103000 | 3.57e-04 | 2.23e-01 |
RNA Polymerase II Promoter Escape | 47 | 5.12e-04 | 1.20e-03 | 0.3180 | -3.01e-01 | 0.103000 | 3.57e-04 | 2.23e-01 |
RNA Polymerase II Transcription Initiation | 47 | 5.12e-04 | 1.20e-03 | 0.3180 | -3.01e-01 | 0.103000 | 3.57e-04 | 2.23e-01 |
RNA Polymerase II Transcription Initiation And Promoter Clearance | 47 | 5.12e-04 | 1.20e-03 | 0.3180 | -3.01e-01 | 0.103000 | 3.57e-04 | 2.23e-01 |
RNA Polymerase II Transcription Pre-Initiation And Promoter Opening | 47 | 5.12e-04 | 1.20e-03 | 0.3180 | -3.01e-01 | 0.103000 | 3.57e-04 | 2.23e-01 |
ABC transporter disorders | 73 | 2.16e-05 | 6.79e-05 | 0.3020 | -2.72e-01 | 0.132000 | 6.00e-05 | 5.19e-02 |
Ion homeostasis | 45 | 1.63e-03 | 3.42e-03 | 0.2960 | 1.42e-01 | -0.260000 | 9.93e-02 | 2.55e-03 |
Prefoldin mediated transfer of substrate to CCT/TriC | 27 | 1.79e-02 | 2.98e-02 | 0.3040 | -2.78e-01 | 0.123000 | 1.24e-02 | 2.68e-01 |
Frs2-mediated activation | 12 | 2.00e-03 | 4.07e-03 | 0.6010 | -1.74e-01 | -0.575000 | 2.96e-01 | 5.63e-04 |
Processing of Capped Intronless Pre-mRNA | 28 | 6.59e-03 | 1.22e-02 | 0.3380 | -3.31e-01 | 0.068900 | 2.40e-03 | 5.28e-01 |
G alpha (12/13) signalling events | 75 | 2.45e-06 | 9.72e-06 | 0.3310 | 7.84e-02 | -0.322000 | 2.40e-01 | 1.45e-06 |
Interleukin-2 family signaling | 34 | 5.64e-04 | 1.31e-03 | 0.3800 | 2.00e-02 | -0.379000 | 8.40e-01 | 1.29e-04 |
Sensory processing of sound by outer hair cells of the cochlea | 43 | 1.46e-03 | 3.08e-03 | 0.3080 | 1.12e-01 | -0.287000 | 2.06e-01 | 1.13e-03 |
NOTCH3 Intracellular Domain Regulates Transcription | 22 | 2.01e-03 | 4.07e-03 | 0.4360 | -3.76e-02 | -0.434000 | 7.60e-01 | 4.25e-04 |
RNA Polymerase III Transcription Termination | 23 | 6.86e-03 | 1.26e-02 | 0.3770 | -3.77e-01 | 0.017100 | 1.76e-03 | 8.87e-01 |
Ion transport by P-type ATPases | 47 | 1.65e-03 | 3.45e-03 | 0.2900 | 1.39e-01 | -0.254000 | 9.90e-02 | 2.59e-03 |
RUNX3 regulates NOTCH signaling | 14 | 2.15e-03 | 4.34e-03 | 0.5510 | -1.40e-01 | -0.533000 | 3.64e-01 | 5.51e-04 |
Regulation of PTEN stability and activity | 67 | 9.25e-06 | 3.23e-05 | 0.3330 | -3.26e-01 | 0.066400 | 3.90e-06 | 3.47e-01 |
Assembly of the ORC complex at the origin of replication | 30 | 2.23e-02 | 3.65e-02 | 0.2770 | -2.05e-01 | 0.187000 | 5.19e-02 | 7.66e-02 |
RNA Polymerase I Transcription Termination | 30 | 1.80e-02 | 2.99e-02 | 0.2870 | -2.48e-01 | 0.144000 | 1.86e-02 | 1.74e-01 |
Synthesis of PIPs at the plasma membrane | 50 | 3.81e-09 | 2.82e-08 | 0.5170 | -1.14e-01 | -0.504000 | 1.63e-01 | 6.82e-10 |
Deposition of new CENPA-containing nucleosomes at the centromere | 44 | 1.23e-03 | 2.64e-03 | 0.3090 | -9.58e-02 | 0.294000 | 2.71e-01 | 7.33e-04 |
Nucleosome assembly | 44 | 1.23e-03 | 2.64e-03 | 0.3090 | -9.58e-02 | 0.294000 | 2.71e-01 | 7.33e-04 |
Sema3A PAK dependent Axon repulsion | 16 | 4.75e-03 | 8.95e-03 | 0.4780 | -8.09e-02 | -0.471000 | 5.76e-01 | 1.11e-03 |
MET activates RAS signaling | 11 | 1.73e-02 | 2.91e-02 | 0.5030 | -1.03e-01 | -0.492000 | 5.55e-01 | 4.67e-03 |
Transport of Mature Transcript to Cytoplasm | 81 | 1.61e-07 | 8.33e-07 | 0.3550 | -3.53e-01 | 0.036400 | 4.02e-08 | 5.71e-01 |
RUNX2 regulates osteoblast differentiation | 22 | 3.20e-04 | 7.96e-04 | 0.5010 | -1.02e-01 | -0.491000 | 4.09e-01 | 6.74e-05 |
Signaling by ALK | 26 | 4.49e-04 | 1.07e-03 | 0.4480 | -5.61e-02 | -0.444000 | 6.20e-01 | 8.71e-05 |
Synthesis of active ubiquitin: roles of E1 and E2 enzymes | 30 | 3.20e-07 | 1.56e-06 | 0.5900 | -5.63e-01 | -0.175000 | 9.25e-08 | 9.71e-02 |
NRAGE signals death through JNK | 59 | 1.78e-05 | 5.80e-05 | 0.3460 | 4.38e-02 | -0.344000 | 5.60e-01 | 4.94e-06 |
Oncogenic MAPK signaling | 75 | 5.44e-11 | 5.73e-10 | 0.4630 | -7.07e-02 | -0.458000 | 2.90e-01 | 6.81e-12 |
RUNX2 regulates bone development | 29 | 1.61e-04 | 4.24e-04 | 0.4520 | -6.12e-02 | -0.448000 | 5.69e-01 | 2.98e-05 |
Interferon alpha/beta signaling | 56 | 5.90e-05 | 1.70e-04 | 0.3350 | -3.30e-01 | 0.054900 | 1.93e-05 | 4.77e-01 |
Insertion of tail-anchored proteins into the endoplasmic reticulum membrane | 22 | 1.35e-04 | 3.60e-04 | 0.5290 | -5.13e-01 | -0.129000 | 3.08e-05 | 2.95e-01 |
Defective pyroptosis | 34 | 7.65e-03 | 1.40e-02 | 0.2990 | -1.02e-01 | 0.282000 | 3.05e-01 | 4.48e-03 |
Transport of Mature mRNA derived from an Intron-Containing Transcript | 72 | 2.55e-06 | 1.01e-05 | 0.3400 | -3.37e-01 | 0.044700 | 7.35e-07 | 5.12e-01 |
Keratan sulfate biosynthesis | 24 | 5.37e-04 | 1.25e-03 | 0.4620 | -7.45e-02 | -0.456000 | 5.27e-01 | 1.09e-04 |
FCERI mediated Ca+2 mobilization | 28 | 2.54e-05 | 7.84e-05 | 0.5100 | -1.16e-01 | -0.497000 | 2.88e-01 | 5.26e-06 |
Sphingolipid metabolism | 84 | 5.03e-06 | 1.87e-05 | 0.3030 | 8.92e-02 | -0.289000 | 1.58e-01 | 4.55e-06 |
Metabolism of amino acids and derivatives | 337 | 1.43e-18 | 3.12e-17 | 0.2750 | -1.45e-01 | 0.234000 | 5.01e-06 | 1.59e-13 |
Cellular response to hypoxia | 72 | 5.56e-06 | 2.03e-05 | 0.3290 | -3.25e-01 | 0.051400 | 1.83e-06 | 4.51e-01 |
Platelet sensitization by LDL | 15 | 2.23e-05 | 7.00e-05 | 0.7110 | -2.78e-01 | -0.654000 | 6.24e-02 | 1.14e-05 |
Metal ion SLC transporters | 22 | 8.27e-04 | 1.86e-03 | 0.4700 | -8.64e-02 | -0.462000 | 4.83e-01 | 1.77e-04 |
EGR2 and SOX10-mediated initiation of Schwann cell myelination | 25 | 2.63e-06 | 1.04e-05 | 0.6000 | -1.93e-01 | -0.568000 | 9.51e-02 | 8.71e-07 |
SHC1 events in ERBB2 signaling | 20 | 7.50e-03 | 1.37e-02 | 0.4050 | -2.98e-02 | -0.404000 | 8.18e-01 | 1.76e-03 |
Fatty acyl-CoA biosynthesis | 35 | 1.26e-03 | 2.70e-03 | 0.3540 | 1.93e-02 | -0.353000 | 8.44e-01 | 2.99e-04 |
Cytoprotection by HMOX1 | 118 | 6.08e-08 | 3.36e-07 | 0.2980 | -2.85e-01 | 0.086500 | 8.34e-08 | 1.04e-01 |
PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases | 14 | 1.18e-02 | 2.08e-02 | 0.4660 | -8.72e-02 | -0.458000 | 5.72e-01 | 3.03e-03 |
Nephrin family interactions | 20 | 9.91e-06 | 3.42e-05 | 0.6370 | -2.26e-01 | -0.596000 | 8.06e-02 | 3.99e-06 |
Aflatoxin activation and detoxification | 14 | 1.43e-03 | 3.02e-03 | 0.5720 | 1.75e-01 | 0.544000 | 2.57e-01 | 4.21e-04 |
Synthesis of PIPs at the Golgi membrane | 15 | 7.24e-05 | 2.04e-04 | 0.6700 | -2.52e-01 | -0.621000 | 9.07e-02 | 3.14e-05 |
Regulation of signaling by CBL | 18 | 1.73e-05 | 5.69e-05 | 0.6560 | -2.42e-01 | -0.609000 | 7.58e-02 | 7.56e-06 |
Diseases associated with O-glycosylation of proteins | 60 | 3.97e-04 | 9.56e-04 | 0.2860 | 2.68e-01 | -0.099200 | 3.30e-04 | 1.84e-01 |
Transcriptional Regulation by MECP2 | 55 | 1.44e-04 | 3.81e-04 | 0.3220 | 4.85e-02 | -0.318000 | 5.34e-01 | 4.39e-05 |
Cyclin E associated events during G1/S transition | 83 | 5.97e-05 | 1.71e-04 | 0.2690 | -2.34e-01 | 0.131000 | 2.24e-04 | 3.87e-02 |
Cyclin A:Cdk2-associated events at S phase entry | 85 | 3.45e-05 | 1.04e-04 | 0.2730 | -2.46e-01 | 0.119000 | 8.74e-05 | 5.71e-02 |
RNA Polymerase I Transcription Initiation | 47 | 1.03e-03 | 2.25e-03 | 0.3050 | -2.98e-01 | 0.067400 | 4.08e-04 | 4.24e-01 |
Synthesis of DNA | 118 | 2.44e-08 | 1.50e-07 | 0.3090 | -6.24e-02 | 0.302000 | 2.42e-01 | 1.40e-08 |
Retinoid metabolism and transport | 32 | 2.19e-02 | 3.60e-02 | 0.2710 | 1.22e-01 | -0.242000 | 2.32e-01 | 1.77e-02 |
Downstream signaling events of B Cell Receptor (BCR) | 79 | 1.94e-06 | 7.93e-06 | 0.3290 | -3.27e-01 | 0.036500 | 5.01e-07 | 5.75e-01 |
Post NMDA receptor activation events | 56 | 2.51e-07 | 1.25e-06 | 0.4300 | -6.31e-02 | -0.425000 | 4.14e-01 | 3.70e-08 |
Metabolism of carbohydrates | 262 | 7.77e-17 | 1.39e-15 | 0.3020 | 6.63e-02 | -0.294000 | 6.44e-02 | 2.26e-16 |
Signaling by FLT3 ITD and TKD mutants | 16 | 1.83e-04 | 4.76e-04 | 0.6150 | -2.16e-01 | -0.576000 | 1.35e-01 | 6.60e-05 |
Interleukin-3, Interleukin-5 and GM-CSF signaling | 38 | 5.07e-06 | 1.88e-05 | 0.4700 | -9.98e-02 | -0.459000 | 2.87e-01 | 9.64e-07 |
MET activates RAP1 and RAC1 | 11 | 1.26e-05 | 4.27e-05 | 0.8560 | -3.99e-01 | -0.758000 | 2.20e-02 | 1.35e-05 |
Transcription of the HIV genome | 69 | 3.36e-07 | 1.63e-06 | 0.3800 | -3.80e-01 | -0.021800 | 4.85e-08 | 7.54e-01 |
Disassembly of the destruction complex and recruitment of AXIN to the membrane | 30 | 5.16e-06 | 1.91e-05 | 0.5320 | -1.54e-01 | -0.509000 | 1.45e-01 | 1.38e-06 |
Activated NTRK2 signals through FRS2 and FRS3 | 11 | 1.73e-02 | 2.90e-02 | 0.5060 | -1.33e-01 | -0.488000 | 4.45e-01 | 5.06e-03 |
DNA Replication | 150 | 4.83e-10 | 4.31e-09 | 0.3030 | -5.70e-02 | 0.298000 | 2.28e-01 | 2.95e-10 |
IGF1R signaling cascade | 47 | 2.97e-04 | 7.47e-04 | 0.3370 | 1.76e-02 | -0.336000 | 8.34e-01 | 6.65e-05 |
Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) | 47 | 2.97e-04 | 7.47e-04 | 0.3370 | 1.76e-02 | -0.336000 | 8.34e-01 | 6.65e-05 |
mRNA decay by 5’ to 3’ exoribonuclease | 15 | 8.97e-03 | 1.62e-02 | 0.4650 | -4.54e-01 | -0.101000 | 2.33e-03 | 4.99e-01 |
Downstream TCR signaling | 88 | 3.70e-06 | 1.41e-05 | 0.3020 | -2.97e-01 | 0.056200 | 1.48e-06 | 3.62e-01 |
Caspase activation via Dependence Receptors in the absence of ligand | 10 | 1.11e-03 | 2.41e-03 | 0.6950 | -2.83e-01 | -0.635000 | 1.22e-01 | 5.07e-04 |
Semaphorin interactions | 60 | 1.52e-05 | 5.07e-05 | 0.3500 | 1.82e-03 | -0.350000 | 9.81e-01 | 2.75e-06 |
Activation of RAC1 | 13 | 2.04e-05 | 6.47e-05 | 0.7700 | -3.40e-01 | -0.690000 | 3.36e-02 | 1.63e-05 |
Ca2+ pathway | 56 | 1.02e-06 | 4.44e-06 | 0.4090 | -5.54e-02 | -0.405000 | 4.73e-01 | 1.55e-07 |
Dual incision in TC-NER | 65 | 1.26e-03 | 2.70e-03 | 0.2510 | -2.07e-01 | 0.140000 | 3.81e-03 | 5.01e-02 |
Constitutive Signaling by EGFRvIII | 15 | 1.70e-02 | 2.87e-02 | 0.4310 | -7.65e-02 | -0.424000 | 6.08e-01 | 4.47e-03 |
Signaling by EGFRvIII in Cancer | 15 | 1.70e-02 | 2.87e-02 | 0.4310 | -7.65e-02 | -0.424000 | 6.08e-01 | 4.47e-03 |
Cellular response to chemical stress | 147 | 7.05e-08 | 3.84e-07 | 0.2640 | -2.43e-01 | 0.105000 | 3.74e-07 | 2.85e-02 |
Diseases of carbohydrate metabolism | 30 | 8.99e-03 | 1.62e-02 | 0.3200 | 3.19e-01 | -0.026300 | 2.49e-03 | 8.03e-01 |
Collagen formation | 80 | 3.72e-04 | 9.02e-04 | 0.2450 | 1.90e-01 | -0.155000 | 3.33e-03 | 1.64e-02 |
RNA Polymerase III Abortive And Retractive Initiation | 41 | 2.69e-04 | 6.85e-04 | 0.3660 | -3.66e-01 | -0.022300 | 5.06e-05 | 8.05e-01 |
RNA Polymerase III Transcription | 41 | 2.69e-04 | 6.85e-04 | 0.3660 | -3.66e-01 | -0.022300 | 5.06e-05 | 8.05e-01 |
Platelet homeostasis | 72 | 1.53e-05 | 5.10e-05 | 0.3170 | 2.66e-02 | -0.316000 | 6.96e-01 | 3.53e-06 |
Golgi Associated Vesicle Biogenesis | 55 | 1.01e-06 | 4.41e-06 | 0.4140 | -6.73e-02 | -0.408000 | 3.88e-01 | 1.61e-07 |
Effects of PIP2 hydrolysis | 24 | 1.16e-02 | 2.05e-02 | 0.3520 | -1.21e-02 | -0.351000 | 9.18e-01 | 2.89e-03 |
G2/M Checkpoints | 140 | 1.66e-06 | 6.85e-06 | 0.2410 | -1.54e-01 | 0.185000 | 1.59e-03 | 1.60e-04 |
CLEC7A (Dectin-1) signaling | 97 | 9.10e-10 | 7.66e-09 | 0.3810 | -3.79e-01 | -0.039800 | 1.10e-10 | 4.98e-01 |
PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling | 89 | 1.44e-10 | 1.42e-09 | 0.4180 | -7.35e-02 | -0.411000 | 2.31e-01 | 2.00e-11 |
VxPx cargo-targeting to cilium | 19 | 2.71e-03 | 5.33e-03 | 0.4640 | -1.13e-01 | -0.450000 | 3.95e-01 | 6.85e-04 |
Glutathione conjugation | 29 | 3.04e-04 | 7.61e-04 | 0.4380 | 9.20e-02 | 0.428000 | 3.91e-01 | 6.50e-05 |
trans-Golgi Network Vesicle Budding | 71 | 2.73e-06 | 1.07e-05 | 0.3470 | -1.03e-02 | -0.347000 | 8.81e-01 | 4.36e-07 |
Negative regulation of the PI3K/AKT network | 96 | 3.32e-11 | 3.58e-10 | 0.4150 | -7.23e-02 | -0.408000 | 2.21e-01 | 4.49e-12 |
Transcription-Coupled Nucleotide Excision Repair (TC-NER) | 78 | 4.30e-04 | 1.02e-03 | 0.2480 | -2.19e-01 | 0.115000 | 8.21e-04 | 7.81e-02 |
Activation of NMDA receptors and postsynaptic events | 69 | 3.22e-08 | 1.91e-07 | 0.4140 | -7.28e-02 | -0.407000 | 2.96e-01 | 4.87e-09 |
Intra-Golgi traffic | 43 | 1.54e-05 | 5.13e-05 | 0.4200 | -7.85e-02 | -0.413000 | 3.73e-01 | 2.81e-06 |
Signaling by SCF-KIT | 41 | 2.32e-07 | 1.18e-06 | 0.5100 | -1.54e-01 | -0.486000 | 8.79e-02 | 7.00e-08 |
Uptake and function of anthrax toxins | 11 | 7.80e-03 | 1.42e-02 | 0.5570 | -1.91e-01 | -0.523000 | 2.73e-01 | 2.66e-03 |
Diseases of metabolism | 213 | 3.97e-09 | 2.92e-08 | 0.2360 | 1.83e-01 | -0.149000 | 4.06e-06 | 1.86e-04 |
GPVI-mediated activation cascade | 29 | 3.42e-04 | 8.41e-04 | 0.4350 | -9.36e-02 | -0.425000 | 3.83e-01 | 7.42e-05 |
Interleukin-27 signaling | 10 | 2.01e-02 | 3.31e-02 | 0.5230 | -1.65e-01 | -0.496000 | 3.66e-01 | 6.59e-03 |
Regulation of MECP2 expression and activity | 29 | 8.64e-04 | 1.94e-03 | 0.4080 | -7.05e-02 | -0.401000 | 5.11e-01 | 1.82e-04 |
Post-translational protein phosphorylation | 85 | 5.22e-04 | 1.22e-03 | 0.2320 | 1.66e-01 | -0.162000 | 7.97e-03 | 9.67e-03 |
Signal transduction by L1 | 21 | 3.76e-06 | 1.44e-05 | 0.6500 | -2.66e-01 | -0.593000 | 3.49e-02 | 2.54e-06 |
Positive epigenetic regulation of rRNA expression | 67 | 3.97e-04 | 9.56e-04 | 0.2730 | -2.66e-01 | 0.060500 | 1.64e-04 | 3.92e-01 |
Metabolism of fat-soluble vitamins | 36 | 1.64e-02 | 2.77e-02 | 0.2690 | 6.53e-02 | -0.261000 | 4.98e-01 | 6.67e-03 |
Gap-filling DNA repair synthesis and ligation in TC-NER | 64 | 3.46e-03 | 6.65e-03 | 0.2320 | -1.84e-01 | 0.142000 | 1.10e-02 | 4.96e-02 |
Interleukin-6 signaling | 11 | 3.64e-04 | 8.89e-04 | 0.7160 | -3.18e-01 | -0.642000 | 6.81e-02 | 2.26e-04 |
HDMs demethylate histones | 22 | 1.14e-08 | 7.46e-08 | 0.7710 | -3.58e-01 | -0.683000 | 3.61e-03 | 2.94e-08 |
Opioid Signalling | 78 | 2.80e-09 | 2.13e-08 | 0.4170 | -8.55e-02 | -0.408000 | 1.92e-01 | 4.59e-10 |
IRS-related events triggered by IGF1R | 46 | 6.60e-04 | 1.52e-03 | 0.3250 | -3.13e-03 | -0.325000 | 9.71e-01 | 1.37e-04 |
Formation of RNA Pol II elongation complex | 57 | 2.17e-06 | 8.78e-06 | 0.3950 | -3.90e-01 | -0.068100 | 3.60e-07 | 3.74e-01 |
RNA Polymerase II Transcription Elongation | 57 | 2.17e-06 | 8.78e-06 | 0.3950 | -3.90e-01 | -0.068100 | 3.60e-07 | 3.74e-01 |
Insulin receptor signalling cascade | 48 | 8.22e-05 | 2.26e-04 | 0.3640 | -4.07e-02 | -0.362000 | 6.25e-01 | 1.45e-05 |
Host Interactions of HIV factors | 124 | 3.03e-10 | 2.84e-09 | 0.3450 | -3.44e-01 | -0.024300 | 3.60e-11 | 6.41e-01 |
Interleukin-1 signaling | 95 | 4.85e-07 | 2.29e-06 | 0.3190 | -3.19e-01 | 0.000406 | 7.91e-08 | 9.95e-01 |
Vasopressin regulates renal water homeostasis via Aquaporins | 35 | 1.02e-02 | 1.82e-02 | 0.2920 | 2.79e-02 | -0.291000 | 7.75e-01 | 2.92e-03 |
Signaling by Erythropoietin | 24 | 2.94e-05 | 8.95e-05 | 0.5530 | -1.99e-01 | -0.517000 | 9.19e-02 | 1.18e-05 |
Cell surface interactions at the vascular wall | 97 | 1.19e-06 | 5.16e-06 | 0.3040 | 1.38e-02 | -0.304000 | 8.14e-01 | 2.29e-07 |
Protein methylation | 15 | 2.89e-03 | 5.67e-03 | 0.5230 | -4.93e-01 | -0.175000 | 9.48e-04 | 2.40e-01 |
CTLA4 inhibitory signaling | 17 | 1.05e-05 | 3.60e-05 | 0.6930 | -3.05e-01 | -0.623000 | 2.93e-02 | 8.78e-06 |
tRNA modification in the nucleus and cytosol | 43 | 2.51e-02 | 4.05e-02 | 0.2290 | -1.26e-01 | 0.191000 | 1.52e-01 | 3.04e-02 |
Separation of Sister Chromatids | 168 | 2.25e-07 | 1.15e-06 | 0.2380 | -2.15e-01 | 0.102000 | 1.48e-06 | 2.29e-02 |
RHO GTPases Activate WASPs and WAVEs | 36 | 8.07e-09 | 5.40e-08 | 0.6060 | -2.40e-01 | -0.556000 | 1.28e-02 | 7.57e-09 |
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand | 37 | 9.31e-06 | 3.24e-05 | 0.4670 | -1.32e-01 | -0.448000 | 1.66e-01 | 2.39e-06 |
Zinc transporters | 14 | 1.14e-03 | 2.48e-03 | 0.5850 | -2.24e-01 | -0.540000 | 1.46e-01 | 4.62e-04 |
Interleukin-12 signaling | 43 | 9.30e-04 | 2.06e-03 | 0.3290 | -3.29e-01 | -0.012800 | 1.90e-04 | 8.85e-01 |
Signaling by NOTCH1 | 72 | 2.46e-07 | 1.23e-06 | 0.3800 | -5.90e-02 | -0.375000 | 3.86e-01 | 3.69e-08 |
Cell death signalling via NRAGE, NRIF and NADE | 76 | 7.93e-05 | 2.20e-04 | 0.2840 | 3.34e-02 | -0.282000 | 6.15e-01 | 2.12e-05 |
Signaling by Receptor Tyrosine Kinases | 468 | 1.35e-34 | 6.59e-33 | 0.3370 | -2.07e-02 | -0.336000 | 4.42e-01 | 9.18e-36 |
Heme signaling | 42 | 5.08e-10 | 4.45e-09 | 0.6010 | -2.39e-01 | -0.552000 | 7.42e-03 | 6.08e-10 |
ERK/MAPK targets | 22 | 2.93e-08 | 1.77e-07 | 0.7510 | -3.52e-01 | -0.663000 | 4.27e-03 | 7.08e-08 |
WNT ligand biogenesis and trafficking | 24 | 1.31e-02 | 2.27e-02 | 0.3490 | -3.67e-02 | -0.347000 | 7.55e-01 | 3.23e-03 |
Ephrin signaling | 19 | 3.10e-05 | 9.41e-05 | 0.6230 | -2.58e-01 | -0.567000 | 5.18e-02 | 1.86e-05 |
GAB1 signalosome | 15 | 8.90e-04 | 1.99e-03 | 0.5760 | -2.23e-01 | -0.531000 | 1.35e-01 | 3.72e-04 |
Aquaporin-mediated transport | 37 | 1.33e-02 | 2.31e-02 | 0.2750 | 3.27e-02 | -0.273000 | 7.31e-01 | 4.04e-03 |
Glucagon-like Peptide-1 (GLP1) regulates insulin secretion | 34 | 1.49e-02 | 2.56e-02 | 0.2840 | 2.12e-02 | -0.283000 | 8.30e-01 | 4.24e-03 |
PI Metabolism | 77 | 8.85e-13 | 1.18e-11 | 0.5030 | -1.70e-01 | -0.474000 | 1.01e-02 | 6.17e-13 |
RET signaling | 37 | 1.90e-05 | 6.12e-05 | 0.4520 | -1.29e-01 | -0.434000 | 1.74e-01 | 4.99e-06 |
Mitotic Telophase/Cytokinesis | 13 | 1.14e-03 | 2.48e-03 | 0.6090 | -2.51e-01 | -0.554000 | 1.17e-01 | 5.37e-04 |
TICAM1,TRAF6-dependent induction of TAK1 complex | 11 | 1.29e-02 | 2.25e-02 | 0.5280 | -4.93e-01 | -0.189000 | 4.66e-03 | 2.77e-01 |
Constitutive Signaling by Aberrant PI3K in Cancer | 62 | 1.38e-05 | 4.64e-05 | 0.3500 | -4.45e-02 | -0.347000 | 5.45e-01 | 2.27e-06 |
Signaling by ERBB4 | 50 | 5.80e-03 | 1.08e-02 | 0.2570 | 5.09e-02 | -0.252000 | 5.33e-01 | 2.08e-03 |
HATs acetylate histones | 99 | 3.21e-09 | 2.40e-08 | 0.3680 | -3.62e-01 | -0.060900 | 4.50e-10 | 2.95e-01 |
Signaling by EGFR | 48 | 9.16e-07 | 4.02e-06 | 0.4490 | -1.29e-01 | -0.430000 | 1.21e-01 | 2.46e-07 |
RNA polymerase II transcribes snRNA genes | 71 | 1.96e-07 | 1.01e-06 | 0.3870 | -3.79e-01 | -0.077900 | 3.36e-08 | 2.56e-01 |
RNA Polymerase III Transcription Initiation | 36 | 5.80e-03 | 1.08e-02 | 0.3080 | -3.08e-01 | -0.007570 | 1.36e-03 | 9.37e-01 |
Assembly of collagen fibrils and other multimeric structures | 50 | 2.30e-02 | 3.74e-02 | 0.2140 | 1.73e-01 | -0.127000 | 3.48e-02 | 1.19e-01 |
Senescence-Associated Secretory Phenotype (SASP) | 71 | 3.18e-03 | 6.20e-03 | 0.2240 | -2.02e-01 | 0.097300 | 3.30e-03 | 1.56e-01 |
tRNA processing | 124 | 9.58e-05 | 2.61e-04 | 0.2140 | -1.25e-01 | 0.174000 | 1.66e-02 | 8.40e-04 |
Antigen processing-Cross presentation | 96 | 3.24e-04 | 8.00e-04 | 0.2280 | -2.11e-01 | 0.086600 | 3.43e-04 | 1.42e-01 |
B-WICH complex positively regulates rRNA expression | 52 | 1.67e-02 | 2.82e-02 | 0.2200 | -1.95e-01 | 0.102000 | 1.50e-02 | 2.02e-01 |
Peptide hormone metabolism | 65 | 2.67e-03 | 5.26e-03 | 0.2400 | 6.60e-02 | -0.231000 | 3.58e-01 | 1.28e-03 |
Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) | 95 | 9.66e-04 | 2.13e-03 | 0.2110 | 1.32e-01 | -0.164000 | 2.59e-02 | 5.58e-03 |
FLT3 signaling in disease | 28 | 1.32e-03 | 2.82e-03 | 0.4040 | -9.71e-02 | -0.393000 | 3.74e-01 | 3.22e-04 |
Signaling by BRAF and RAF1 fusions | 58 | 2.73e-07 | 1.34e-06 | 0.4260 | -1.15e-01 | -0.410000 | 1.31e-01 | 6.59e-08 |
Regulation of RUNX1 Expression and Activity | 18 | 1.01e-04 | 2.75e-04 | 0.6030 | -2.52e-01 | -0.547000 | 6.39e-02 | 5.81e-05 |
Hemostasis | 485 | 3.73e-27 | 1.33e-25 | 0.2900 | 4.08e-03 | -0.290000 | 8.77e-01 | 5.28e-28 |
Uptake and actions of bacterial toxins | 28 | 2.69e-02 | 4.32e-02 | 0.2920 | 1.80e-04 | -0.292000 | 9.99e-01 | 7.41e-03 |
Deadenylation-dependent mRNA decay | 53 | 2.51e-07 | 1.25e-06 | 0.4480 | -4.27e-01 | -0.135000 | 7.48e-08 | 9.02e-02 |
COPII-mediated vesicle transport | 66 | 2.86e-07 | 1.40e-06 | 0.3970 | -9.43e-02 | -0.386000 | 1.85e-01 | 5.78e-08 |
Regulation of cholesterol biosynthesis by SREBP (SREBF) | 55 | 7.08e-11 | 7.20e-10 | 0.5490 | -2.15e-01 | -0.505000 | 5.84e-03 | 9.09e-11 |
Downstream signal transduction | 29 | 5.13e-09 | 3.61e-08 | 0.6860 | -3.18e-01 | -0.608000 | 3.03e-03 | 1.44e-08 |
Epigenetic regulation of gene expression | 109 | 2.54e-05 | 7.84e-05 | 0.2500 | -2.46e-01 | 0.043400 | 8.89e-06 | 4.34e-01 |
Response to elevated platelet cytosolic Ca2+ | 114 | 1.37e-05 | 4.60e-05 | 0.2520 | 4.01e-02 | -0.249000 | 4.59e-01 | 4.48e-06 |
Signaling by WNT in cancer | 33 | 7.53e-08 | 4.09e-07 | 0.5950 | -2.51e-01 | -0.539000 | 1.27e-02 | 8.22e-08 |
Nucleotide Excision Repair | 110 | 2.62e-04 | 6.70e-04 | 0.2160 | -1.94e-01 | 0.093000 | 4.24e-04 | 9.17e-02 |
Synthesis of PIPs at the late endosome membrane | 11 | 1.09e-04 | 2.94e-04 | 0.7710 | -3.83e-01 | -0.670000 | 2.78e-02 | 1.20e-04 |
STAT5 activation downstream of FLT3 ITD mutants | 10 | 2.20e-03 | 4.43e-03 | 0.6610 | -3.03e-01 | -0.588000 | 9.75e-02 | 1.28e-03 |
Sensory processing of sound by inner hair cells of the cochlea | 57 | 1.30e-02 | 2.26e-02 | 0.2180 | 8.48e-02 | -0.200000 | 2.68e-01 | 8.83e-03 |
Degradation of beta-catenin by the destruction complex | 83 | 2.03e-06 | 8.29e-06 | 0.3270 | -3.25e-01 | -0.040200 | 3.10e-07 | 5.27e-01 |
Signaling by high-kinase activity BRAF mutants | 31 | 8.07e-03 | 1.46e-02 | 0.3240 | -3.76e-02 | -0.322000 | 7.17e-01 | 1.91e-03 |
Signaling by RAF1 mutants | 35 | 8.89e-04 | 1.99e-03 | 0.3720 | -7.94e-02 | -0.363000 | 4.16e-01 | 2.01e-04 |
Integrin signaling | 24 | 1.21e-04 | 3.25e-04 | 0.5150 | -1.94e-01 | -0.477000 | 9.98e-02 | 5.16e-05 |
Signaling by NTRK3 (TRKC) | 16 | 5.33e-03 | 9.99e-03 | 0.4800 | -1.67e-01 | -0.450000 | 2.48e-01 | 1.84e-03 |
Factors involved in megakaryocyte development and platelet production | 115 | 9.18e-06 | 3.21e-05 | 0.2560 | 2.62e-02 | -0.255000 | 6.27e-01 | 2.28e-06 |
RNA Polymerase II Pre-transcription Events | 80 | 8.69e-07 | 3.86e-06 | 0.3450 | -3.40e-01 | -0.059400 | 1.40e-07 | 3.58e-01 |
EPH-Ephrin signaling | 91 | 2.93e-08 | 1.77e-07 | 0.3620 | -7.37e-02 | -0.355000 | 2.24e-01 | 4.91e-09 |
Signaling by Rho GTPases | 625 | 3.81e-42 | 3.72e-40 | 0.3250 | -4.17e-02 | -0.322000 | 7.44e-02 | 2.52e-43 |
Erythropoietin activates RAS | 13 | 1.70e-03 | 3.55e-03 | 0.5910 | -2.54e-01 | -0.534000 | 1.13e-01 | 8.63e-04 |
PI3K Cascade | 39 | 5.46e-03 | 1.02e-02 | 0.2990 | -1.85e-02 | -0.299000 | 8.41e-01 | 1.25e-03 |
TP53 Regulates Transcription of DNA Repair Genes | 61 | 1.91e-03 | 3.91e-03 | 0.2590 | -2.58e-01 | 0.021100 | 4.89e-04 | 7.75e-01 |
CD209 (DC-SIGN) signaling | 19 | 8.89e-05 | 2.43e-04 | 0.5910 | -2.55e-01 | -0.534000 | 5.46e-02 | 5.65e-05 |
p75 NTR receptor-mediated signalling | 94 | 1.25e-06 | 5.36e-06 | 0.3130 | -3.24e-02 | -0.311000 | 5.87e-01 | 1.85e-07 |
Activation of BAD and translocation to mitochondria | 15 | 1.24e-02 | 2.17e-02 | 0.4530 | -1.50e-01 | -0.428000 | 3.14e-01 | 4.14e-03 |
Collagen biosynthesis and modifying enzymes | 58 | 1.65e-02 | 2.80e-02 | 0.2100 | 1.92e-01 | -0.085000 | 1.16e-02 | 2.63e-01 |
MHC class II antigen presentation | 97 | 5.64e-05 | 1.63e-04 | 0.2570 | 1.95e-02 | -0.256000 | 7.40e-01 | 1.29e-05 |
NCAM signaling for neurite out-growth | 54 | 6.65e-03 | 1.23e-02 | 0.2450 | 3.27e-02 | -0.243000 | 6.77e-01 | 2.02e-03 |
IRS-mediated signalling | 43 | 2.19e-03 | 4.41e-03 | 0.3100 | -3.32e-02 | -0.308000 | 7.07e-01 | 4.66e-04 |
Platelet degranulation | 109 | 3.81e-05 | 1.13e-04 | 0.2460 | 3.03e-02 | -0.244000 | 5.85e-01 | 1.04e-05 |
FGFR1 mutant receptor activation | 29 | 1.54e-03 | 3.23e-03 | 0.3940 | -1.05e-01 | -0.380000 | 3.27e-01 | 4.03e-04 |
Signaling by ALK fusions and activated point mutants | 55 | 3.21e-11 | 3.49e-10 | 0.5590 | -2.34e-01 | -0.508000 | 2.65e-03 | 7.25e-11 |
Signaling by ALK in cancer | 55 | 3.21e-11 | 3.49e-10 | 0.5590 | -2.34e-01 | -0.508000 | 2.65e-03 | 7.25e-11 |
TICAM1, RIP1-mediated IKK complex recruitment | 18 | 1.02e-02 | 1.82e-02 | 0.4220 | -4.02e-01 | -0.128000 | 3.17e-03 | 3.46e-01 |
G1/S Transition | 131 | 1.08e-04 | 2.91e-04 | 0.2090 | -8.09e-02 | 0.192000 | 1.10e-01 | 1.45e-04 |
Signaling by Rho GTPases, Miro GTPases and RHOBTB3 | 641 | 1.00e-42 | 1.05e-40 | 0.3240 | -4.79e-02 | -0.320000 | 3.82e-02 | 7.99e-44 |
p75NTR signals via NF-kB | 16 | 5.94e-03 | 1.11e-02 | 0.4750 | -4.43e-01 | -0.171000 | 2.14e-03 | 2.36e-01 |
Transcriptional regulation by small RNAs | 68 | 1.64e-04 | 4.31e-04 | 0.2930 | -2.93e-01 | -0.021000 | 2.99e-05 | 7.64e-01 |
Hedgehog ‘off’ state | 95 | 6.08e-04 | 1.41e-03 | 0.2230 | -2.15e-01 | 0.056300 | 2.86e-04 | 3.43e-01 |
Neurotransmitter receptors and postsynaptic signal transmission | 152 | 3.97e-07 | 1.90e-06 | 0.2520 | 2.03e-02 | -0.251000 | 6.66e-01 | 8.79e-08 |
Sensory processing of sound | 62 | 1.56e-02 | 2.65e-02 | 0.2040 | 8.63e-02 | -0.185000 | 2.40e-01 | 1.18e-02 |
BMAL1:CLOCK,NPAS2 activates circadian gene expression | 26 | 8.42e-06 | 2.97e-05 | 0.5660 | -2.41e-01 | -0.511000 | 3.31e-02 | 6.32e-06 |
Platelet activation, signaling and aggregation | 224 | 1.18e-15 | 1.99e-14 | 0.3240 | -5.07e-02 | -0.320000 | 1.91e-01 | 1.31e-16 |
Fanconi Anemia Pathway | 36 | 3.63e-03 | 6.96e-03 | 0.3260 | 5.24e-02 | 0.322000 | 5.87e-01 | 8.28e-04 |
HIV Infection | 222 | 6.65e-18 | 1.35e-16 | 0.3510 | -3.43e-01 | -0.074100 | 1.09e-18 | 5.68e-02 |
Signaling by ERBB2 in Cancer | 24 | 1.75e-02 | 2.93e-02 | 0.3400 | -6.50e-02 | -0.334000 | 5.82e-01 | 4.66e-03 |
Regulation of actin dynamics for phagocytic cup formation | 58 | 9.15e-10 | 7.66e-09 | 0.5040 | -1.96e-01 | -0.464000 | 9.64e-03 | 9.31e-10 |
FCGR3A-mediated phagocytosis | 56 | 1.53e-12 | 1.94e-11 | 0.5890 | -2.61e-01 | -0.528000 | 7.44e-04 | 7.96e-12 |
Leishmania phagocytosis | 56 | 1.53e-12 | 1.94e-11 | 0.5890 | -2.61e-01 | -0.528000 | 7.44e-04 | 7.96e-12 |
Parasite infection | 56 | 1.53e-12 | 1.94e-11 | 0.5890 | -2.61e-01 | -0.528000 | 7.44e-04 | 7.96e-12 |
Cholesterol biosynthesis | 24 | 7.17e-04 | 1.63e-03 | 0.4610 | -4.31e-01 | -0.164000 | 2.57e-04 | 1.65e-01 |
Regulation of insulin secretion | 65 | 1.80e-03 | 3.72e-03 | 0.2530 | 1.50e-02 | -0.252000 | 8.34e-01 | 4.39e-04 |
Cell Cycle Checkpoints | 260 | 2.55e-07 | 1.27e-06 | 0.1890 | -1.46e-01 | 0.121000 | 5.16e-05 | 8.03e-04 |
MAPK3 (ERK1) activation | 10 | 2.24e-02 | 3.67e-02 | 0.5190 | -2.09e-01 | -0.475000 | 2.52e-01 | 9.29e-03 |
Gastrin-CREB signalling pathway via PKC and MAPK | 17 | 1.16e-05 | 3.97e-05 | 0.6920 | -3.40e-01 | -0.603000 | 1.52e-02 | 1.66e-05 |
COPI-independent Golgi-to-ER retrograde traffic | 33 | 5.40e-06 | 1.97e-05 | 0.5110 | -2.05e-01 | -0.468000 | 4.15e-02 | 3.30e-06 |
RAF activation | 33 | 2.44e-06 | 9.72e-06 | 0.5270 | -2.18e-01 | -0.480000 | 3.02e-02 | 1.78e-06 |
Neurexins and neuroligins | 49 | 6.07e-03 | 1.13e-02 | 0.2630 | -1.80e-03 | -0.263000 | 9.83e-01 | 1.45e-03 |
Caspase activation via extrinsic apoptotic signalling pathway | 25 | 2.09e-02 | 3.43e-02 | 0.3250 | -5.92e-02 | -0.320000 | 6.08e-01 | 5.61e-03 |
Signaling by NOTCH4 | 81 | 4.55e-03 | 8.62e-03 | 0.2040 | -1.93e-01 | 0.067300 | 2.67e-03 | 2.95e-01 |
SARS-CoV-1 Infection | 49 | 1.21e-02 | 2.11e-02 | 0.2430 | 1.81e-02 | -0.242000 | 8.26e-01 | 3.37e-03 |
Signal regulatory protein family interactions | 11 | 2.40e-03 | 4.78e-03 | 0.6260 | -2.94e-01 | -0.553000 | 9.18e-02 | 1.48e-03 |
CD28 co-stimulation | 29 | 6.81e-05 | 1.93e-04 | 0.4840 | -1.88e-01 | -0.446000 | 8.03e-02 | 3.20e-05 |
PI3K/AKT Signaling in Cancer | 89 | 1.12e-08 | 7.41e-08 | 0.3790 | -1.06e-01 | -0.364000 | 8.44e-02 | 2.99e-09 |
TCR signaling | 108 | 1.86e-05 | 6.01e-05 | 0.2590 | -2.59e-01 | -0.003220 | 3.28e-06 | 9.54e-01 |
Signaling by FGFR4 in disease | 11 | 9.34e-03 | 1.68e-02 | 0.5500 | -2.40e-01 | -0.495000 | 1.68e-01 | 4.47e-03 |
CREB1 phosphorylation through NMDA receptor-mediated activation of RAS signaling | 26 | 9.27e-04 | 2.06e-03 | 0.4350 | -1.52e-01 | -0.407000 | 1.78e-01 | 3.25e-04 |
Role of phospholipids in phagocytosis | 22 | 5.81e-03 | 1.08e-02 | 0.4050 | -1.30e-01 | -0.384000 | 2.92e-01 | 1.84e-03 |
G2/M Transition | 181 | 1.76e-05 | 5.73e-05 | 0.1950 | -1.80e-01 | 0.073800 | 2.92e-05 | 8.67e-02 |
Nuclear Receptor transcription pathway | 46 | 2.21e-03 | 4.44e-03 | 0.3010 | -4.40e-02 | -0.297000 | 6.06e-01 | 4.80e-04 |
MET receptor recycling | 10 | 9.22e-03 | 1.66e-02 | 0.5790 | -2.63e-01 | -0.515000 | 1.50e-01 | 4.77e-03 |
Global Genome Nucleotide Excision Repair (GG-NER) | 84 | 1.09e-02 | 1.93e-02 | 0.1810 | -1.50e-01 | 0.102000 | 1.78e-02 | 1.04e-01 |
Intra-Golgi and retrograde Golgi-to-ER traffic | 179 | 4.86e-23 | 1.43e-21 | 0.4510 | -1.67e-01 | -0.419000 | 1.14e-04 | 3.49e-22 |
Extra-nuclear estrogen signaling | 66 | 1.59e-10 | 1.53e-09 | 0.4930 | -1.99e-01 | -0.451000 | 5.14e-03 | 2.35e-10 |
Mitotic G2-G2/M phases | 183 | 2.48e-05 | 7.69e-05 | 0.1900 | -1.74e-01 | 0.076600 | 4.85e-05 | 7.39e-02 |
ER to Golgi Anterograde Transport | 131 | 1.75e-17 | 3.37e-16 | 0.4570 | -1.73e-01 | -0.423000 | 6.41e-04 | 5.72e-17 |
Lysosphingolipid and LPA receptors | 11 | 6.23e-03 | 1.15e-02 | 0.5740 | -5.11e-01 | -0.261000 | 3.31e-03 | 1.34e-01 |
Tie2 Signaling | 17 | 1.29e-03 | 2.76e-03 | 0.5280 | -2.28e-01 | -0.476000 | 1.04e-01 | 6.72e-04 |
Transport to the Golgi and subsequent modification | 161 | 5.55e-21 | 1.40e-19 | 0.4530 | -1.71e-01 | -0.420000 | 1.78e-04 | 3.44e-20 |
Formation of Incision Complex in GG-NER | 43 | 1.71e-02 | 2.88e-02 | 0.2510 | -2.51e-01 | -0.003050 | 4.47e-03 | 9.72e-01 |
Cardiac conduction | 107 | 3.57e-03 | 6.85e-03 | 0.1800 | 9.28e-02 | -0.154000 | 9.71e-02 | 5.88e-03 |
Degradation of the extracellular matrix | 90 | 2.72e-04 | 6.91e-04 | 0.2460 | 1.73e-05 | -0.246000 | 1.00e+00 | 5.46e-05 |
RNA Polymerase III Transcription Initiation From Type 2 Promoter | 27 | 2.38e-02 | 3.86e-02 | 0.3080 | -3.03e-01 | -0.057100 | 6.51e-03 | 6.08e-01 |
CD28 dependent PI3K/Akt signaling | 18 | 2.57e-02 | 4.14e-02 | 0.3770 | -1.14e-01 | -0.359000 | 4.02e-01 | 8.34e-03 |
Fcgamma receptor (FCGR) dependent phagocytosis | 82 | 9.39e-14 | 1.38e-12 | 0.5110 | -2.19e-01 | -0.461000 | 6.15e-04 | 4.84e-13 |
Signalling to ERKs | 33 | 7.38e-05 | 2.07e-04 | 0.4520 | -1.75e-01 | -0.417000 | 8.18e-02 | 3.44e-05 |
Late Phase of HIV Life Cycle | 135 | 1.15e-13 | 1.65e-12 | 0.3940 | -3.72e-01 | -0.131000 | 8.16e-14 | 8.59e-03 |
Cellular responses to stress | 671 | 3.91e-26 | 1.33e-24 | 0.2440 | -2.43e-01 | -0.003840 | 4.01e-27 | 8.65e-01 |
Mitotic Metaphase and Anaphase | 229 | 4.59e-07 | 2.18e-06 | 0.2030 | -1.99e-01 | 0.040400 | 2.22e-07 | 2.92e-01 |
Cellular responses to stimuli | 680 | 9.62e-25 | 2.94e-23 | 0.2350 | -2.35e-01 | 0.003420 | 1.35e-25 | 8.79e-01 |
Sphingolipid de novo biosynthesis | 42 | 6.52e-05 | 1.86e-04 | 0.4020 | -1.40e-01 | -0.377000 | 1.17e-01 | 2.36e-05 |
HIV Life Cycle | 147 | 6.78e-14 | 1.01e-12 | 0.3810 | -3.61e-01 | -0.123000 | 4.29e-14 | 9.88e-03 |
Membrane Trafficking | 577 | 6.20e-62 | 4.54e-59 | 0.4190 | -1.53e-01 | -0.390000 | 3.46e-10 | 4.07e-58 |
SARS-CoV-2 Infection | 70 | 6.78e-06 | 2.42e-05 | 0.3440 | -9.37e-02 | -0.331000 | 1.75e-01 | 1.66e-06 |
Mitotic Anaphase | 228 | 6.05e-07 | 2.80e-06 | 0.2010 | -1.97e-01 | 0.039800 | 2.84e-07 | 3.00e-01 |
Interleukin-1 family signaling | 124 | 5.14e-06 | 1.90e-05 | 0.2570 | -2.56e-01 | -0.020900 | 8.01e-07 | 6.88e-01 |
Mitotic G1 phase and G1/S transition | 147 | 9.65e-04 | 2.13e-03 | 0.1700 | -9.14e-02 | 0.144000 | 5.56e-02 | 2.62e-03 |
Signaling by NOTCH3 | 46 | 2.91e-02 | 4.62e-02 | 0.2250 | 1.07e-02 | -0.224000 | 9.00e-01 | 8.43e-03 |
SLC-mediated transmembrane transport | 196 | 5.87e-06 | 2.13e-05 | 0.1990 | 4.05e-02 | -0.195000 | 3.28e-01 | 2.60e-06 |
Vesicle-mediated transport | 606 | 5.44e-58 | 1.99e-55 | 0.3950 | -1.36e-01 | -0.371000 | 1.01e-08 | 3.43e-55 |
Neuronal System | 326 | 3.89e-10 | 3.56e-09 | 0.2080 | 2.80e-02 | -0.207000 | 3.84e-01 | 1.38e-10 |
Circadian Clock | 67 | 1.05e-13 | 1.52e-12 | 0.5650 | -2.65e-01 | -0.499000 | 1.72e-04 | 1.54e-12 |
C-type lectin receptors (CLRs) | 123 | 4.96e-08 | 2.79e-07 | 0.3070 | -3.00e-01 | -0.066700 | 8.92e-09 | 2.01e-01 |
Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants | 57 | 3.22e-04 | 7.96e-04 | 0.3120 | -7.07e-02 | -0.304000 | 3.56e-01 | 7.17e-05 |
Constitutive Signaling by NOTCH1 PEST Domain Mutants | 57 | 3.22e-04 | 7.96e-04 | 0.3120 | -7.07e-02 | -0.304000 | 3.56e-01 | 7.17e-05 |
Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer | 57 | 3.22e-04 | 7.96e-04 | 0.3120 | -7.07e-02 | -0.304000 | 3.56e-01 | 7.17e-05 |
Signaling by NOTCH1 PEST Domain Mutants in Cancer | 57 | 3.22e-04 | 7.96e-04 | 0.3120 | -7.07e-02 | -0.304000 | 3.56e-01 | 7.17e-05 |
Signaling by NOTCH1 in Cancer | 57 | 3.22e-04 | 7.96e-04 | 0.3120 | -7.07e-02 | -0.304000 | 3.56e-01 | 7.17e-05 |
Interleukin-4 and Interleukin-13 signaling | 95 | 1.69e-04 | 4.41e-04 | 0.2480 | -1.48e-02 | -0.247000 | 8.03e-01 | 3.10e-05 |
Anti-inflammatory response favouring Leishmania parasite infection | 106 | 3.70e-04 | 8.98e-04 | 0.2220 | 1.06e-02 | -0.221000 | 8.51e-01 | 8.24e-05 |
Leishmania parasite growth and survival | 106 | 3.70e-04 | 8.98e-04 | 0.2220 | 1.06e-02 | -0.221000 | 8.51e-01 | 8.24e-05 |
Negative regulation of MAPK pathway | 42 | 1.15e-04 | 3.09e-04 | 0.3900 | -1.36e-01 | -0.366000 | 1.29e-01 | 4.12e-05 |
MAPK6/MAPK4 signaling | 87 | 6.31e-05 | 1.80e-04 | 0.2750 | -2.72e-01 | -0.042600 | 1.14e-05 | 4.92e-01 |
Regulation of KIT signaling | 15 | 2.63e-03 | 5.20e-03 | 0.5320 | -2.44e-01 | -0.473000 | 1.02e-01 | 1.52e-03 |
ABC-family proteins mediated transport | 97 | 7.92e-03 | 1.44e-02 | 0.1770 | -1.64e-01 | 0.064600 | 5.15e-03 | 2.72e-01 |
Chromosome Maintenance | 109 | 6.48e-04 | 1.49e-03 | 0.2100 | -1.99e-02 | 0.209000 | 7.20e-01 | 1.66e-04 |
Glycolysis | 67 | 4.30e-08 | 2.46e-07 | 0.4240 | -1.63e-01 | -0.391000 | 2.10e-02 | 3.10e-08 |
MAPK targets/ Nuclear events mediated by MAP kinases | 31 | 4.32e-08 | 2.46e-07 | 0.6270 | -3.15e-01 | -0.542000 | 2.42e-03 | 1.73e-07 |
Transmission across Chemical Synapses | 212 | 1.91e-06 | 7.82e-06 | 0.2010 | 2.83e-02 | -0.199000 | 4.77e-01 | 5.83e-07 |
PCP/CE pathway | 90 | 1.06e-04 | 2.85e-04 | 0.2630 | -2.61e-01 | -0.033800 | 1.90e-05 | 5.79e-01 |
NGF-stimulated transcription | 38 | 2.67e-03 | 5.26e-03 | 0.3290 | -3.17e-01 | -0.090300 | 7.27e-04 | 3.35e-01 |
GPCR downstream signalling | 420 | 2.62e-11 | 2.95e-10 | 0.1950 | 3.28e-02 | -0.192000 | 2.48e-01 | 1.48e-11 |
Cell-extracellular matrix interactions | 16 | 2.20e-06 | 8.89e-06 | 0.7660 | -4.18e-01 | -0.642000 | 3.77e-03 | 8.63e-06 |
Signaling by GPCR | 474 | 1.38e-12 | 1.80e-11 | 0.1940 | 3.01e-02 | -0.192000 | 2.62e-01 | 7.40e-13 |
Leishmania infection | 187 | 6.95e-11 | 7.12e-10 | 0.2940 | -6.54e-02 | -0.287000 | 1.23e-01 | 1.23e-11 |
S Phase | 160 | 1.10e-03 | 2.41e-03 | 0.1620 | -8.21e-02 | 0.140000 | 7.30e-02 | 2.30e-03 |
PPARA activates gene expression | 108 | 4.30e-10 | 3.89e-09 | 0.3750 | -1.30e-01 | -0.352000 | 1.91e-02 | 2.56e-10 |
NOTCH1 Intracellular Domain Regulates Transcription | 47 | 4.53e-05 | 1.33e-04 | 0.3880 | -1.40e-01 | -0.361000 | 9.64e-02 | 1.82e-05 |
Integration of energy metabolism | 93 | 3.60e-06 | 1.38e-05 | 0.3060 | -7.54e-02 | -0.296000 | 2.09e-01 | 7.77e-07 |
Telomere Maintenance | 84 | 6.86e-03 | 1.26e-02 | 0.1960 | -2.67e-02 | 0.194000 | 6.72e-01 | 2.10e-03 |
ADORA2B mediated anti-inflammatory cytokines production | 81 | 1.23e-02 | 2.16e-02 | 0.1870 | 3.66e-02 | -0.183000 | 5.69e-01 | 4.42e-03 |
Regulation of lipid metabolism by PPARalpha | 110 | 5.92e-10 | 5.16e-09 | 0.3690 | -1.28e-01 | -0.346000 | 2.06e-02 | 3.40e-10 |
Paradoxical activation of RAF signaling by kinase inactive BRAF | 39 | 3.33e-03 | 6.44e-03 | 0.3190 | -8.88e-02 | -0.306000 | 3.37e-01 | 9.24e-04 |
Signaling by RAS mutants | 39 | 3.33e-03 | 6.44e-03 | 0.3190 | -8.88e-02 | -0.306000 | 3.37e-01 | 9.24e-04 |
Signaling by moderate kinase activity BRAF mutants | 39 | 3.33e-03 | 6.44e-03 | 0.3190 | -8.88e-02 | -0.306000 | 3.37e-01 | 9.24e-04 |
Signaling downstream of RAS mutants | 39 | 3.33e-03 | 6.44e-03 | 0.3190 | -8.88e-02 | -0.306000 | 3.37e-01 | 9.24e-04 |
Muscle contraction | 159 | 2.29e-03 | 4.60e-03 | 0.1530 | 9.71e-02 | -0.118000 | 3.46e-02 | 1.02e-02 |
Viral Messenger RNA Synthesis | 44 | 7.31e-05 | 2.05e-04 | 0.3910 | -3.62e-01 | -0.147000 | 3.18e-05 | 9.05e-02 |
Signaling by FGFR1 in disease | 36 | 2.45e-04 | 6.25e-04 | 0.4050 | -1.58e-01 | -0.372000 | 1.01e-01 | 1.10e-04 |
Glucagon signaling in metabolic regulation | 26 | 1.48e-02 | 2.53e-02 | 0.3370 | -1.06e-01 | -0.320000 | 3.49e-01 | 4.76e-03 |
Signaling by NTRK2 (TRKB) | 24 | 3.09e-03 | 6.03e-03 | 0.4130 | -1.67e-01 | -0.378000 | 1.58e-01 | 1.33e-03 |
Transcriptional regulation by RUNX2 | 115 | 1.17e-04 | 3.14e-04 | 0.2300 | -2.30e-01 | -0.019500 | 2.10e-05 | 7.18e-01 |
Signal Transduction | 2157 | 1.77e-97 | 2.59e-94 | 0.2780 | -6.13e-02 | -0.271000 | 2.50e-06 | 3.81e-97 |
COPI-mediated anterograde transport | 79 | 5.32e-14 | 8.12e-13 | 0.5270 | -2.53e-01 | -0.462000 | 1.02e-04 | 1.17e-12 |
Glucose metabolism | 84 | 5.55e-05 | 1.61e-04 | 0.2840 | -6.68e-02 | -0.276000 | 2.90e-01 | 1.20e-05 |
JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1 | 17 | 3.12e-03 | 6.08e-03 | 0.4930 | -2.28e-01 | -0.437000 | 1.03e-01 | 1.82e-03 |
FOXO-mediated transcription | 58 | 5.71e-04 | 1.33e-03 | 0.2990 | -8.04e-02 | -0.288000 | 2.89e-01 | 1.46e-04 |
Interleukin-12 family signaling | 51 | 2.90e-03 | 5.68e-03 | 0.2810 | -2.74e-01 | -0.065900 | 7.23e-04 | 4.16e-01 |
G alpha (s) signalling events | 92 | 1.54e-02 | 2.62e-02 | 0.1700 | 4.28e-02 | -0.164000 | 4.78e-01 | 6.43e-03 |
DAP12 signaling | 26 | 4.58e-03 | 8.65e-03 | 0.3830 | -1.47e-01 | -0.354000 | 1.96e-01 | 1.80e-03 |
Platelet Aggregation (Plug Formation) | 29 | 1.06e-03 | 2.32e-03 | 0.4100 | -1.67e-01 | -0.374000 | 1.19e-01 | 4.91e-04 |
Nuclear events stimulated by ALK signaling in cancer | 19 | 2.25e-03 | 4.51e-03 | 0.4790 | -4.26e-01 | -0.219000 | 1.31e-03 | 9.79e-02 |
Costimulation by the CD28 family | 57 | 2.82e-04 | 7.13e-04 | 0.3170 | -9.74e-02 | -0.301000 | 2.03e-01 | 8.23e-05 |
FLT3 Signaling | 35 | 7.57e-05 | 2.12e-04 | 0.4400 | -1.92e-01 | -0.396000 | 4.94e-02 | 5.10e-05 |
Asparagine N-linked glycosylation | 278 | 3.87e-24 | 1.16e-22 | 0.3720 | -1.41e-01 | -0.344000 | 4.89e-05 | 4.83e-23 |
Signaling by Insulin receptor | 71 | 6.92e-03 | 1.27e-02 | 0.2170 | -1.72e-02 | -0.216000 | 8.02e-01 | 1.61e-03 |
NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux | 35 | 2.24e-03 | 4.49e-03 | 0.3510 | -1.29e-01 | -0.326000 | 1.87e-01 | 8.33e-04 |
STING mediated induction of host immune responses | 15 | 1.53e-02 | 2.62e-02 | 0.4460 | -3.97e-01 | -0.203000 | 7.74e-03 | 1.73e-01 |
FOXO-mediated transcription of cell death genes | 15 | 2.32e-03 | 4.63e-03 | 0.5390 | -4.65e-01 | -0.272000 | 1.80e-03 | 6.80e-02 |
Antigen Presentation: Folding, assembly and peptide loading of class I MHC | 25 | 2.47e-05 | 7.69e-05 | 0.5520 | -2.82e-01 | -0.475000 | 1.47e-02 | 3.91e-05 |
SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription | 31 | 2.48e-05 | 7.69e-05 | 0.4950 | -4.33e-01 | -0.241000 | 3.02e-05 | 2.02e-02 |
Metabolism of non-coding RNA | 53 | 1.47e-04 | 3.89e-04 | 0.3430 | -3.19e-01 | -0.127000 | 5.99e-05 | 1.09e-01 |
snRNP Assembly | 53 | 1.47e-04 | 3.89e-04 | 0.3430 | -3.19e-01 | -0.127000 | 5.99e-05 | 1.09e-01 |
Budding and maturation of HIV virion | 28 | 3.35e-03 | 6.48e-03 | 0.3800 | -3.47e-01 | -0.156000 | 1.48e-03 | 1.54e-01 |
RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function | 56 | 2.54e-02 | 4.09e-02 | 0.2100 | -2.09e-01 | -0.019100 | 6.72e-03 | 8.04e-01 |
Mitotic Spindle Checkpoint | 109 | 2.66e-02 | 4.27e-02 | 0.1440 | -1.31e-01 | 0.059000 | 1.79e-02 | 2.87e-01 |
FCERI mediated MAPK activation | 29 | 8.16e-04 | 1.84e-03 | 0.4180 | -1.85e-01 | -0.375000 | 8.42e-02 | 4.72e-04 |
Protein-protein interactions at synapses | 78 | 8.10e-05 | 2.24e-04 | 0.2910 | -8.76e-02 | -0.277000 | 1.81e-01 | 2.29e-05 |
tRNA processing in the nucleus | 59 | 6.94e-03 | 1.27e-02 | 0.2410 | -2.36e-01 | -0.048200 | 1.73e-03 | 5.22e-01 |
Regulation of FOXO transcriptional activity by acetylation | 10 | 1.20e-02 | 2.11e-02 | 0.5640 | -2.95e-01 | -0.481000 | 1.06e-01 | 8.47e-03 |
HSF1-dependent transactivation | 31 | 6.44e-03 | 1.19e-02 | 0.3390 | -1.29e-01 | -0.314000 | 2.13e-01 | 2.49e-03 |
Cargo recognition for clathrin-mediated endocytosis | 97 | 6.57e-08 | 3.60e-07 | 0.3480 | -1.36e-01 | -0.320000 | 2.06e-02 | 4.93e-08 |
Interleukin-35 Signalling | 12 | 2.94e-02 | 4.67e-02 | 0.4590 | -2.21e-01 | -0.402000 | 1.86e-01 | 1.58e-02 |
Ub-specific processing proteases | 175 | 4.13e-11 | 4.42e-10 | 0.3110 | -2.91e-01 | -0.110000 | 2.99e-11 | 1.23e-02 |
Ion channel transport | 152 | 1.60e-02 | 2.72e-02 | 0.1290 | 7.76e-02 | -0.103000 | 9.86e-02 | 2.83e-02 |
RHOBTB1 GTPase cycle | 23 | 2.21e-04 | 5.67e-04 | 0.5130 | -4.41e-01 | -0.261000 | 2.47e-04 | 3.00e-02 |
GRB2:SOS provides linkage to MAPK signaling for Integrins | 12 | 1.31e-03 | 2.80e-03 | 0.6320 | -3.49e-01 | -0.527000 | 3.66e-02 | 1.57e-03 |
Death Receptor Signalling | 137 | 2.74e-08 | 1.67e-07 | 0.3000 | -1.03e-01 | -0.281000 | 3.72e-02 | 1.29e-08 |
PTEN Regulation | 140 | 1.48e-08 | 9.52e-08 | 0.3020 | -2.83e-01 | -0.105000 | 7.59e-09 | 3.12e-02 |
Receptor-type tyrosine-protein phosphatases | 18 | 1.03e-02 | 1.82e-02 | 0.4270 | -2.00e-01 | -0.377000 | 1.42e-01 | 5.62e-03 |
DAP12 interactions | 33 | 2.83e-04 | 7.15e-04 | 0.4210 | -1.97e-01 | -0.372000 | 5.04e-02 | 2.15e-04 |
Signaling by ERBB2 | 48 | 2.31e-03 | 4.62e-03 | 0.2990 | -1.05e-01 | -0.280000 | 2.09e-01 | 8.02e-04 |
Gene Silencing by RNA | 95 | 1.97e-04 | 5.09e-04 | 0.2500 | -2.41e-01 | -0.066800 | 4.88e-05 | 2.60e-01 |
Removal of the Flap Intermediate | 14 | 1.09e-02 | 1.93e-02 | 0.4820 | 4.16e-01 | 0.242000 | 6.98e-03 | 1.17e-01 |
Postmitotic nuclear pore complex (NPC) reformation | 27 | 4.27e-05 | 1.26e-04 | 0.5180 | -4.42e-01 | -0.270000 | 6.92e-05 | 1.53e-02 |
Estrogen-dependent nuclear events downstream of ESR-membrane signaling | 22 | 1.97e-05 | 6.25e-05 | 0.5960 | -3.27e-01 | -0.498000 | 7.83e-03 | 5.18e-05 |
Attenuation phase | 23 | 1.37e-02 | 2.37e-02 | 0.3650 | -1.58e-01 | -0.329000 | 1.90e-01 | 6.36e-03 |
Cytosolic tRNA aminoacylation | 24 | 1.72e-02 | 2.89e-02 | 0.3470 | -3.15e-01 | -0.145000 | 7.49e-03 | 2.19e-01 |
Transcriptional regulation of white adipocyte differentiation | 81 | 6.52e-06 | 2.35e-05 | 0.3240 | -1.28e-01 | -0.297000 | 4.71e-02 | 3.70e-06 |
Signaling by NTRKs | 131 | 5.79e-15 | 9.33e-14 | 0.4240 | -2.03e-01 | -0.372000 | 5.92e-05 | 1.75e-13 |
Protein localization | 158 | 9.55e-03 | 1.71e-02 | 0.1370 | -1.31e-01 | 0.037600 | 4.34e-03 | 4.15e-01 |
M Phase | 370 | 1.70e-06 | 6.98e-06 | 0.1540 | -1.53e-01 | 0.013800 | 3.94e-07 | 6.49e-01 |
Cytosolic sensors of pathogen-associated DNA | 61 | 3.20e-04 | 7.96e-04 | 0.3060 | -2.83e-01 | -0.117000 | 1.34e-04 | 1.15e-01 |
Signaling by NTRK1 (TRKA) | 113 | 6.78e-13 | 9.19e-12 | 0.4220 | -2.05e-01 | -0.369000 | 1.72e-04 | 1.13e-11 |
Metabolism of lipids | 643 | 1.22e-17 | 2.42e-16 | 0.2060 | -3.95e-02 | -0.202000 | 8.72e-02 | 1.67e-18 |
Metabolism of vitamins and cofactors | 171 | 2.38e-02 | 3.86e-02 | 0.1160 | 7.39e-02 | -0.088800 | 9.53e-02 | 4.50e-02 |
Cooperation of PDCL (PhLP1) and TRiC/CCT in G-protein beta folding | 34 | 8.73e-03 | 1.58e-02 | 0.3150 | -2.88e-01 | -0.126000 | 3.64e-03 | 2.02e-01 |
Sensory Perception | 173 | 1.97e-02 | 3.25e-02 | 0.1180 | 5.70e-02 | -0.104000 | 1.96e-01 | 1.84e-02 |
Disorders of transmembrane transporters | 153 | 2.32e-05 | 7.26e-05 | 0.2200 | -2.14e-01 | -0.053000 | 5.02e-06 | 2.58e-01 |
Signaling by FGFR2 | 66 | 1.99e-03 | 4.06e-03 | 0.2570 | -2.43e-01 | -0.082800 | 6.23e-04 | 2.45e-01 |
Negative regulators of DDX58/IFIH1 signaling | 35 | 7.18e-05 | 2.02e-04 | 0.4430 | -3.83e-01 | -0.222000 | 8.85e-05 | 2.28e-02 |
Interferon gamma signaling | 78 | 2.96e-03 | 5.79e-03 | 0.2280 | -2.20e-01 | -0.060100 | 7.89e-04 | 3.59e-01 |
RHO GTPases activate KTN1 | 11 | 1.20e-03 | 2.60e-03 | 0.6650 | -3.84e-01 | -0.543000 | 2.75e-02 | 1.81e-03 |
activated TAK1 mediates p38 MAPK activation | 18 | 1.38e-02 | 2.38e-02 | 0.4130 | -2.01e-01 | -0.361000 | 1.39e-01 | 8.05e-03 |
Diseases of signal transduction by growth factor receptors and second messengers | 404 | 1.35e-33 | 6.38e-32 | 0.3680 | -1.69e-01 | -0.327000 | 5.80e-09 | 1.06e-29 |
Transport of small molecules | 598 | 4.33e-09 | 3.14e-08 | 0.1470 | 1.29e-02 | -0.146000 | 5.90e-01 | 1.01e-09 |
DNA Double Strand Break Response | 52 | 3.13e-02 | 4.94e-02 | 0.2150 | -2.09e-01 | -0.049900 | 9.23e-03 | 5.33e-01 |
Inositol phosphate metabolism | 45 | 3.42e-03 | 6.58e-03 | 0.2990 | -1.17e-01 | -0.275000 | 1.75e-01 | 1.39e-03 |
RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known | 36 | 7.69e-05 | 2.15e-04 | 0.4350 | -2.18e-01 | -0.376000 | 2.34e-02 | 9.33e-05 |
Nucleotide biosynthesis | 12 | 3.67e-03 | 7.00e-03 | 0.5810 | -4.82e-01 | -0.324000 | 3.83e-03 | 5.17e-02 |
Clathrin-mediated endocytosis | 135 | 9.09e-12 | 1.06e-10 | 0.3680 | -1.69e-01 | -0.326000 | 6.80e-04 | 5.67e-11 |
Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks | 51 | 1.93e-02 | 3.19e-02 | 0.2320 | -2.23e-01 | -0.066100 | 5.91e-03 | 4.14e-01 |
Signaling by FGFR1 | 46 | 9.84e-04 | 2.16e-03 | 0.3270 | -1.40e-01 | -0.296000 | 1.00e-01 | 5.11e-04 |
Cargo trafficking to the periciliary membrane | 47 | 3.56e-03 | 6.84e-03 | 0.2920 | -1.14e-01 | -0.268000 | 1.77e-01 | 1.45e-03 |
EPHA-mediated growth cone collapse | 15 | 1.56e-02 | 2.66e-02 | 0.4470 | -2.29e-01 | -0.383000 | 1.25e-01 | 1.01e-02 |
Constitutive Signaling by AKT1 E17K in Cancer | 26 | 6.77e-04 | 1.55e-03 | 0.4490 | -2.31e-01 | -0.385000 | 4.11e-02 | 6.70e-04 |
Fc epsilon receptor (FCERI) signaling | 126 | 1.67e-09 | 1.31e-08 | 0.3390 | -3.04e-01 | -0.150000 | 3.80e-09 | 3.58e-03 |
G alpha (i) signalling events | 194 | 4.58e-03 | 8.65e-03 | 0.1340 | 2.06e-02 | -0.133000 | 6.20e-01 | 1.45e-03 |
RAB geranylgeranylation | 62 | 3.75e-05 | 1.12e-04 | 0.3430 | -1.54e-01 | -0.306000 | 3.58e-02 | 3.03e-05 |
Golgi-to-ER retrograde transport | 111 | 4.47e-13 | 6.18e-12 | 0.4300 | -2.19e-01 | -0.370000 | 6.79e-05 | 1.60e-11 |
Signaling by Non-Receptor Tyrosine Kinases | 52 | 1.97e-03 | 4.02e-03 | 0.2920 | -1.17e-01 | -0.267000 | 1.44e-01 | 8.56e-04 |
Signaling by PTK6 | 52 | 1.97e-03 | 4.02e-03 | 0.2920 | -1.17e-01 | -0.267000 | 1.44e-01 | 8.56e-04 |
Transcriptional regulation by RUNX3 | 94 | 6.02e-07 | 2.80e-06 | 0.3300 | -2.96e-01 | -0.146000 | 7.02e-07 | 1.42e-02 |
Neutrophil degranulation | 406 | 3.72e-09 | 2.77e-08 | 0.1820 | -3.08e-02 | -0.179000 | 2.86e-01 | 5.29e-10 |
NR1H2 and NR1H3-mediated signaling | 43 | 1.61e-03 | 3.37e-03 | 0.3270 | -1.45e-01 | -0.293000 | 1.00e-01 | 8.86e-04 |
Oxidative Stress Induced Senescence | 82 | 2.85e-02 | 4.53e-02 | 0.1720 | -1.70e-01 | -0.022300 | 7.68e-03 | 7.26e-01 |
Processive synthesis on the lagging strand | 15 | 3.65e-03 | 6.97e-03 | 0.5200 | 4.33e-01 | 0.287000 | 3.66e-03 | 5.42e-02 |
Protein ubiquitination | 73 | 3.11e-08 | 1.86e-07 | 0.4130 | -3.55e-01 | -0.211000 | 1.56e-07 | 1.79e-03 |
Metabolism of steroids | 136 | 7.84e-05 | 2.18e-04 | 0.2210 | -6.75e-02 | -0.210000 | 1.74e-01 | 2.26e-05 |
Chromatin modifying enzymes | 222 | 3.74e-18 | 7.95e-17 | 0.3610 | -3.16e-01 | -0.175000 | 4.33e-16 | 7.25e-06 |
Chromatin organization | 222 | 3.74e-18 | 7.95e-17 | 0.3610 | -3.16e-01 | -0.175000 | 4.33e-16 | 7.25e-06 |
Signaling by Hedgehog | 132 | 7.68e-03 | 1.40e-02 | 0.1580 | -1.57e-01 | -0.015800 | 1.81e-03 | 7.54e-01 |
MAPK family signaling cascades | 292 | 9.16e-14 | 1.36e-12 | 0.2710 | -1.09e-01 | -0.248000 | 1.32e-03 | 2.59e-13 |
Mitochondrial biogenesis | 91 | 6.45e-04 | 1.49e-03 | 0.2390 | -2.23e-01 | -0.084100 | 2.29e-04 | 1.65e-01 |
Leading Strand Synthesis | 14 | 6.05e-03 | 1.12e-02 | 0.5130 | 4.26e-01 | 0.287000 | 5.81e-03 | 6.29e-02 |
Polymerase switching | 14 | 6.05e-03 | 1.12e-02 | 0.5130 | 4.26e-01 | 0.287000 | 5.81e-03 | 6.29e-02 |
Transcriptional regulation by RUNX1 | 184 | 6.54e-06 | 2.35e-05 | 0.2140 | -2.03e-01 | -0.065200 | 1.92e-06 | 1.27e-01 |
TNF signaling | 44 | 9.71e-03 | 1.73e-02 | 0.2740 | -2.49e-01 | -0.113000 | 4.21e-03 | 1.96e-01 |
Phospholipid metabolism | 186 | 3.53e-12 | 4.24e-11 | 0.3190 | -1.47e-01 | -0.283000 | 5.25e-04 | 2.57e-11 |
MAP kinase activation | 62 | 3.43e-10 | 3.16e-09 | 0.5040 | -2.83e-01 | -0.418000 | 1.18e-04 | 1.27e-08 |
HCMV Late Events | 76 | 3.86e-05 | 1.14e-04 | 0.3090 | -2.76e-01 | -0.141000 | 3.25e-05 | 3.39e-02 |
Unfolded Protein Response (UPR) | 89 | 6.86e-07 | 3.14e-06 | 0.3380 | -2.97e-01 | -0.163000 | 1.28e-06 | 7.96e-03 |
Protein folding | 89 | 8.20e-03 | 1.49e-02 | 0.1940 | -1.87e-01 | -0.052600 | 2.33e-03 | 3.91e-01 |
Interferon Signaling | 172 | 2.09e-09 | 1.62e-08 | 0.2890 | -2.60e-01 | -0.126000 | 4.12e-09 | 4.36e-03 |
Activation of HOX genes during differentiation | 81 | 1.76e-02 | 2.94e-02 | 0.1860 | -1.80e-01 | -0.047000 | 5.08e-03 | 4.64e-01 |
Activation of anterior HOX genes in hindbrain development during early embryogenesis | 81 | 1.76e-02 | 2.94e-02 | 0.1860 | -1.80e-01 | -0.047000 | 5.08e-03 | 4.64e-01 |
Signaling by the B Cell Receptor (BCR) | 106 | 5.99e-05 | 1.72e-04 | 0.2550 | -2.34e-01 | -0.102000 | 3.07e-05 | 6.99e-02 |
EPHB-mediated forward signaling | 34 | 1.78e-05 | 5.79e-05 | 0.4820 | -2.69e-01 | -0.400000 | 6.58e-03 | 5.38e-05 |
E3 ubiquitin ligases ubiquitinate target proteins | 53 | 3.03e-04 | 7.59e-04 | 0.3310 | -2.90e-01 | -0.160000 | 2.56e-04 | 4.44e-02 |
RAB GEFs exchange GTP for GDP on RABs | 88 | 6.36e-09 | 4.40e-08 | 0.3930 | -2.06e-01 | -0.335000 | 8.27e-04 | 5.42e-08 |
Transport of Mature mRNAs Derived from Intronless Transcripts | 43 | 1.36e-06 | 5.69e-06 | 0.4770 | -3.94e-01 | -0.268000 | 7.65e-06 | 2.36e-03 |
Lewis blood group biosynthesis | 14 | 2.65e-02 | 4.26e-02 | 0.4330 | -2.36e-01 | -0.362000 | 1.26e-01 | 1.89e-02 |
Citric acid cycle (TCA cycle) | 22 | 8.12e-05 | 2.24e-04 | 0.5570 | -4.51e-01 | -0.326000 | 2.48e-04 | 8.06e-03 |
Signaling by BMP | 23 | 1.21e-05 | 4.13e-05 | 0.5970 | -3.55e-01 | -0.480000 | 3.17e-03 | 6.74e-05 |
Unwinding of DNA | 12 | 5.50e-05 | 1.60e-04 | 0.7700 | 6.03e-01 | 0.480000 | 2.99e-04 | 4.02e-03 |
XBP1(S) activates chaperone genes | 48 | 2.04e-06 | 8.29e-06 | 0.4440 | -2.47e-01 | -0.369000 | 3.04e-03 | 9.55e-06 |
N-glycan trimming in the ER and Calnexin/Calreticulin cycle | 35 | 7.45e-03 | 1.36e-02 | 0.3170 | -1.55e-01 | -0.277000 | 1.13e-01 | 4.62e-03 |
Cell Cycle, Mitotic | 512 | 6.83e-04 | 1.56e-03 | 0.0954 | -9.02e-02 | 0.031100 | 4.71e-04 | 2.27e-01 |
Post-translational protein modification | 1261 | 1.50e-52 | 3.66e-50 | 0.2660 | -1.18e-01 | -0.238000 | 1.51e-12 | 1.84e-46 |
G alpha (q) signalling events | 152 | 1.07e-05 | 3.68e-05 | 0.2320 | -9.22e-02 | -0.212000 | 4.96e-02 | 6.10e-06 |
Activation of gene expression by SREBF (SREBP) | 42 | 7.43e-09 | 5.04e-08 | 0.5680 | -3.37e-01 | -0.458000 | 1.54e-04 | 2.86e-07 |
Signaling by Activin | 15 | 7.85e-05 | 2.18e-04 | 0.6760 | -5.34e-01 | -0.414000 | 3.40e-04 | 5.44e-03 |
Spry regulation of FGF signaling | 16 | 3.46e-04 | 8.50e-04 | 0.6010 | -4.80e-01 | -0.361000 | 8.77e-04 | 1.24e-02 |
SARS-CoV Infections | 150 | 2.75e-11 | 3.05e-10 | 0.3420 | -1.75e-01 | -0.294000 | 2.07e-04 | 5.04e-10 |
IRE1alpha activates chaperones | 50 | 3.90e-07 | 1.87e-06 | 0.4620 | -2.62e-01 | -0.381000 | 1.34e-03 | 3.19e-06 |
Neddylation | 222 | 2.81e-09 | 2.13e-08 | 0.2520 | -2.27e-01 | -0.109000 | 5.04e-09 | 5.05e-03 |
Transcriptional Regulation by TP53 | 356 | 1.29e-08 | 8.39e-08 | 0.1900 | -1.80e-01 | -0.061900 | 5.14e-09 | 4.48e-02 |
G1/S-Specific Transcription | 29 | 2.57e-03 | 5.10e-03 | 0.3850 | 3.25e-01 | 0.207000 | 2.45e-03 | 5.39e-02 |
Infectious disease | 733 | 5.37e-25 | 1.67e-23 | 0.2360 | -2.15e-01 | -0.097200 | 2.82e-23 | 7.16e-06 |
Pre-NOTCH Processing in Golgi | 18 | 2.08e-02 | 3.41e-02 | 0.3940 | -2.14e-01 | -0.331000 | 1.17e-01 | 1.50e-02 |
Interleukin-17 signaling | 67 | 1.55e-08 | 9.85e-08 | 0.4410 | -2.48e-01 | -0.364000 | 4.44e-04 | 2.46e-07 |
Interactions of Rev with host cellular proteins | 37 | 3.83e-05 | 1.14e-04 | 0.4460 | -3.67e-01 | -0.253000 | 1.11e-04 | 7.64e-03 |
HCMV Early Events | 80 | 7.37e-07 | 3.36e-06 | 0.3570 | -3.03e-01 | -0.189000 | 2.84e-06 | 3.39e-03 |
Nonhomologous End-Joining (NHEJ) | 43 | 3.41e-03 | 6.57e-03 | 0.3080 | -2.67e-01 | -0.154000 | 2.45e-03 | 8.02e-02 |
DDX58/IFIH1-mediated induction of interferon-alpha/beta | 66 | 6.43e-05 | 1.83e-04 | 0.3250 | -2.79e-01 | -0.167000 | 9.04e-05 | 1.92e-02 |
Cell Cycle | 636 | 6.30e-04 | 1.46e-03 | 0.0860 | -8.01e-02 | 0.031500 | 5.57e-04 | 1.74e-01 |
p130Cas linkage to MAPK signaling for integrins | 12 | 1.86e-03 | 3.83e-03 | 0.6160 | -3.77e-01 | -0.488000 | 2.39e-02 | 3.42e-03 |
Interleukin-20 family signaling | 19 | 2.74e-02 | 4.37e-02 | 0.3700 | -2.00e-01 | -0.311000 | 1.32e-01 | 1.89e-02 |
Sialic acid metabolism | 31 | 4.34e-03 | 8.23e-03 | 0.3560 | -1.90e-01 | -0.301000 | 6.68e-02 | 3.76e-03 |
SUMOylation of DNA replication proteins | 46 | 8.22e-05 | 2.26e-04 | 0.3840 | -3.21e-01 | -0.212000 | 1.68e-04 | 1.28e-02 |
Transport of Mature mRNA Derived from an Intronless Transcript | 42 | 2.92e-06 | 1.15e-05 | 0.4690 | -3.81e-01 | -0.273000 | 1.93e-05 | 2.16e-03 |
Signal amplification | 28 | 3.29e-04 | 8.11e-04 | 0.4550 | -2.64e-01 | -0.371000 | 1.55e-02 | 6.77e-04 |
Rev-mediated nuclear export of HIV RNA | 35 | 3.50e-05 | 1.05e-04 | 0.4610 | -3.74e-01 | -0.269000 | 1.27e-04 | 5.86e-03 |
RHO GTPases activate PKNs | 52 | 3.07e-02 | 4.85e-02 | 0.2190 | -1.98e-01 | -0.093200 | 1.36e-02 | 2.45e-01 |
COPI-dependent Golgi-to-ER retrograde traffic | 78 | 4.33e-08 | 2.46e-07 | 0.3970 | -2.24e-01 | -0.328000 | 6.22e-04 | 5.63e-07 |
Adaptive Immune System | 639 | 3.12e-25 | 9.93e-24 | 0.2540 | -1.21e-01 | -0.224000 | 1.80e-07 | 3.43e-22 |
SUMOylation of SUMOylation proteins | 35 | 3.03e-06 | 1.18e-05 | 0.5130 | -4.10e-01 | -0.308000 | 2.63e-05 | 1.61e-03 |
Synaptic adhesion-like molecules | 21 | 1.01e-02 | 1.79e-02 | 0.3980 | -2.26e-01 | -0.327000 | 7.28e-02 | 9.37e-03 |
Regulation of PTEN mRNA translation | 12 | 2.08e-04 | 5.35e-04 | 0.7160 | -4.54e-01 | -0.554000 | 6.49e-03 | 8.83e-04 |
Inflammasomes | 19 | 2.84e-02 | 4.53e-02 | 0.3680 | -3.06e-01 | -0.205000 | 2.11e-02 | 1.22e-01 |
Regulation of IFNA signaling | 12 | 2.37e-02 | 3.85e-02 | 0.4750 | -2.82e-01 | -0.382000 | 9.03e-02 | 2.18e-02 |
Deubiquitination | 246 | 2.48e-15 | 4.04e-14 | 0.3150 | -2.66e-01 | -0.169000 | 5.99e-13 | 5.06e-06 |
Immune System | 1611 | 9.35e-47 | 1.37e-44 | 0.2240 | -1.02e-01 | -0.199000 | 7.38e-12 | 5.32e-41 |
MAPK1/MAPK3 signaling | 253 | 3.16e-09 | 2.38e-08 | 0.2360 | -1.12e-01 | -0.208000 | 2.18e-03 | 1.12e-08 |
Competing endogenous RNAs (ceRNAs) regulate PTEN translation | 11 | 7.22e-04 | 1.64e-03 | 0.6910 | -4.38e-01 | -0.534000 | 1.18e-02 | 2.15e-03 |
DNA strand elongation | 32 | 2.68e-07 | 1.32e-06 | 0.5860 | 4.59e-01 | 0.365000 | 7.01e-06 | 3.58e-04 |
RAF/MAP kinase cascade | 247 | 4.97e-09 | 3.52e-08 | 0.2370 | -1.14e-01 | -0.207000 | 2.07e-03 | 1.91e-08 |
Assembly and cell surface presentation of NMDA receptors | 23 | 2.31e-02 | 3.77e-02 | 0.3440 | -1.92e-01 | -0.286000 | 1.11e-01 | 1.78e-02 |
Macroautophagy | 111 | 5.73e-06 | 2.08e-05 | 0.2800 | -1.47e-01 | -0.239000 | 7.51e-03 | 1.37e-05 |
Cellular Senescence | 152 | 8.17e-04 | 1.84e-03 | 0.1830 | -1.66e-01 | -0.077000 | 4.13e-04 | 1.01e-01 |
Gene expression (Transcription) | 1368 | 1.52e-39 | 1.11e-37 | 0.2220 | -1.95e-01 | -0.107000 | 7.29e-34 | 2.23e-11 |
Intracellular signaling by second messengers | 287 | 9.44e-19 | 2.09e-17 | 0.3250 | -1.83e-01 | -0.269000 | 9.73e-08 | 4.49e-15 |
Nuclear import of Rev protein | 34 | 7.17e-05 | 2.02e-04 | 0.4510 | -3.58e-01 | -0.275000 | 3.02e-04 | 5.53e-03 |
Synthesis of substrates in N-glycan biosythesis | 61 | 1.86e-03 | 3.83e-03 | 0.2730 | -1.47e-01 | -0.230000 | 4.69e-02 | 1.90e-03 |
RNA Polymerase II Transcription | 1234 | 7.75e-31 | 3.34e-29 | 0.2060 | -1.80e-01 | -0.098400 | 8.96e-27 | 5.31e-09 |
PCNA-Dependent Long Patch Base Excision Repair | 21 | 2.89e-02 | 4.60e-02 | 0.3500 | 2.03e-01 | 0.285000 | 1.07e-01 | 2.40e-02 |
Regulation of TP53 Degradation | 35 | 1.20e-03 | 2.60e-03 | 0.3730 | -3.00e-01 | -0.222000 | 2.11e-03 | 2.32e-02 |
Biosynthesis of the N-glycan precursor (dolichol lipid-linked oligosaccharide, LLO) and transfer to a nascent protein | 76 | 1.88e-02 | 3.11e-02 | 0.1940 | -9.25e-02 | -0.170000 | 1.63e-01 | 1.02e-02 |
SUMOylation | 170 | 1.09e-07 | 5.82e-07 | 0.2620 | -1.42e-01 | -0.219000 | 1.34e-03 | 7.86e-07 |
Lagging Strand Synthesis | 20 | 2.01e-03 | 4.07e-03 | 0.4750 | 3.72e-01 | 0.295000 | 3.97e-03 | 2.23e-02 |
Signaling by FGFR3 | 38 | 9.76e-04 | 2.15e-03 | 0.3640 | -2.16e-01 | -0.293000 | 2.13e-02 | 1.79e-03 |
Mitotic Prophase | 103 | 3.55e-06 | 1.37e-05 | 0.2970 | -2.45e-01 | -0.168000 | 1.71e-05 | 3.16e-03 |
RHO GTPase Effectors | 254 | 1.36e-07 | 7.12e-07 | 0.2120 | -1.07e-01 | -0.184000 | 3.33e-03 | 4.56e-07 |
SUMOylation of RNA binding proteins | 47 | 4.50e-04 | 1.07e-03 | 0.3450 | -2.78e-01 | -0.204000 | 9.64e-04 | 1.56e-02 |
Innate Immune System | 838 | 3.33e-22 | 9.38e-21 | 0.2090 | -1.07e-01 | -0.180000 | 1.39e-07 | 6.82e-19 |
Endosomal Sorting Complex Required For Transport (ESCRT) | 31 | 2.96e-02 | 4.69e-02 | 0.2870 | -2.36e-01 | -0.163000 | 2.31e-02 | 1.16e-01 |
Toll Like Receptor 9 (TLR9) Cascade | 90 | 1.36e-09 | 1.10e-08 | 0.4060 | -2.50e-01 | -0.320000 | 4.21e-05 | 1.47e-07 |
Transport of the SLBP Dependant Mature mRNA | 36 | 1.24e-06 | 5.35e-06 | 0.5240 | -4.04e-01 | -0.334000 | 2.73e-05 | 5.26e-04 |
Rab regulation of trafficking | 120 | 4.21e-12 | 5.02e-11 | 0.3990 | -2.45e-01 | -0.315000 | 3.62e-06 | 2.54e-09 |
Developmental Biology | 843 | 2.54e-16 | 4.43e-15 | 0.1780 | -8.61e-02 | -0.155000 | 2.07e-05 | 1.55e-14 |
TNFR1-induced NFkappaB signaling pathway | 26 | 1.58e-02 | 2.68e-02 | 0.3400 | -2.73e-01 | -0.204000 | 1.61e-02 | 7.23e-02 |
ESR-mediated signaling | 170 | 5.47e-14 | 8.26e-13 | 0.3620 | -2.19e-01 | -0.288000 | 8.17e-07 | 8.87e-11 |
TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation | 85 | 2.08e-08 | 1.29e-07 | 0.3890 | -2.38e-01 | -0.307000 | 1.43e-04 | 9.57e-07 |
Toll-like Receptor Cascades | 139 | 2.05e-08 | 1.28e-07 | 0.3040 | -1.78e-01 | -0.247000 | 2.86e-04 | 4.97e-07 |
Disease | 1437 | 1.81e-29 | 6.97e-28 | 0.1870 | -9.45e-02 | -0.162000 | 1.73e-09 | 6.57e-25 |
Activation of the pre-replicative complex | 33 | 1.74e-03 | 3.61e-03 | 0.3740 | 2.29e-01 | 0.295000 | 2.27e-02 | 3.31e-03 |
MyD88 cascade initiated on plasma membrane | 80 | 1.67e-09 | 1.31e-08 | 0.4290 | -2.68e-01 | -0.334000 | 3.29e-05 | 2.31e-07 |
Toll Like Receptor 10 (TLR10) Cascade | 80 | 1.67e-09 | 1.31e-08 | 0.4290 | -2.68e-01 | -0.334000 | 3.29e-05 | 2.31e-07 |
Toll Like Receptor 5 (TLR5) Cascade | 80 | 1.67e-09 | 1.31e-08 | 0.4290 | -2.68e-01 | -0.334000 | 3.29e-05 | 2.31e-07 |
EGFR downregulation | 29 | 1.90e-03 | 3.91e-03 | 0.3960 | -2.46e-01 | -0.311000 | 2.20e-02 | 3.77e-03 |
Chaperonin-mediated protein folding | 83 | 8.32e-03 | 1.51e-02 | 0.2040 | -1.73e-01 | -0.109000 | 6.50e-03 | 8.62e-02 |
Signaling by FGFR4 | 37 | 4.87e-03 | 9.16e-03 | 0.3230 | -1.95e-01 | -0.258000 | 4.05e-02 | 6.61e-03 |
SUMO E3 ligases SUMOylate target proteins | 164 | 4.62e-07 | 2.19e-06 | 0.2540 | -1.46e-01 | -0.208000 | 1.23e-03 | 4.15e-06 |
SLC transporter disorders | 80 | 2.77e-04 | 7.01e-04 | 0.2730 | -1.60e-01 | -0.221000 | 1.36e-02 | 6.27e-04 |
HCMV Infection | 104 | 5.76e-07 | 2.69e-06 | 0.3170 | -2.52e-01 | -0.192000 | 8.92e-06 | 6.93e-04 |
Autophagy | 124 | 4.03e-08 | 2.32e-07 | 0.3160 | -1.92e-01 | -0.251000 | 2.18e-04 | 1.35e-06 |
Generic Transcription Pathway | 1116 | 2.74e-27 | 1.00e-25 | 0.2030 | -1.70e-01 | -0.111000 | 6.46e-22 | 2.99e-10 |
Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors | 33 | 2.07e-02 | 3.41e-02 | 0.2920 | -2.34e-01 | -0.175000 | 2.02e-02 | 8.17e-02 |
Thrombin signalling through proteinase activated receptors (PARs) | 27 | 3.65e-03 | 6.97e-03 | 0.3890 | -2.44e-01 | -0.302000 | 2.82e-02 | 6.51e-03 |
Negative regulation of FGFR1 signaling | 29 | 2.96e-03 | 5.79e-03 | 0.3820 | -2.98e-01 | -0.239000 | 5.55e-03 | 2.56e-02 |
SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion | 14 | 2.83e-02 | 4.52e-02 | 0.4300 | -2.74e-01 | -0.332000 | 7.61e-02 | 3.16e-02 |
N-glycan antennae elongation in the medial/trans-Golgi | 25 | 8.58e-04 | 1.93e-03 | 0.4530 | -2.91e-01 | -0.347000 | 1.17e-02 | 2.65e-03 |
Antiviral mechanism by IFN-stimulated genes | 80 | 1.52e-09 | 1.23e-08 | 0.4300 | -3.31e-01 | -0.275000 | 3.17e-07 | 2.12e-05 |
Mitochondrial Fatty Acid Beta-Oxidation | 34 | 9.47e-03 | 1.70e-02 | 0.3150 | 1.94e-01 | 0.249000 | 5.07e-02 | 1.19e-02 |
MyD88-independent TLR4 cascade | 93 | 1.24e-09 | 1.01e-08 | 0.4010 | -2.54e-01 | -0.310000 | 2.23e-05 | 2.40e-07 |
TRIF(TICAM1)-mediated TLR4 signaling | 93 | 1.24e-09 | 1.01e-08 | 0.4010 | -2.54e-01 | -0.310000 | 2.23e-05 | 2.40e-07 |
RHOBTB2 GTPase cycle | 23 | 2.74e-02 | 4.37e-02 | 0.3370 | -2.64e-01 | -0.210000 | 2.84e-02 | 8.18e-02 |
Downregulation of SMAD2/3:SMAD4 transcriptional activity | 28 | 4.01e-06 | 1.52e-05 | 0.5680 | -3.74e-01 | -0.428000 | 6.15e-04 | 8.87e-05 |
Selective autophagy | 58 | 1.67e-04 | 4.38e-04 | 0.3300 | -2.59e-01 | -0.205000 | 6.48e-04 | 6.92e-03 |
Regulation of HSF1-mediated heat shock response | 78 | 3.68e-08 | 2.14e-07 | 0.4000 | -3.08e-01 | -0.255000 | 2.54e-06 | 9.92e-05 |
Signaling by NOTCH | 193 | 1.05e-04 | 2.84e-04 | 0.1860 | -1.55e-01 | -0.102000 | 2.01e-04 | 1.42e-02 |
tRNA Aminoacylation | 42 | 2.36e-02 | 3.84e-02 | 0.2540 | -2.04e-01 | -0.152000 | 2.19e-02 | 8.93e-02 |
Signaling by WNT | 276 | 1.42e-13 | 2.01e-12 | 0.2800 | -1.70e-01 | -0.223000 | 1.15e-06 | 1.82e-10 |
N-Glycan antennae elongation | 14 | 1.75e-03 | 3.62e-03 | 0.5740 | -3.79e-01 | -0.432000 | 1.41e-02 | 5.18e-03 |
Transport of Ribonucleoproteins into the Host Nucleus | 32 | 2.67e-05 | 8.19e-05 | 0.4890 | -3.19e-01 | -0.371000 | 1.80e-03 | 2.79e-04 |
Pyruvate metabolism and Citric Acid (TCA) cycle | 52 | 1.75e-03 | 3.62e-03 | 0.2980 | -2.35e-01 | -0.183000 | 3.34e-03 | 2.25e-02 |
TGF-beta receptor signaling activates SMADs | 32 | 3.78e-05 | 1.13e-04 | 0.4810 | -3.65e-01 | -0.314000 | 3.52e-04 | 2.14e-03 |
Signaling by Nuclear Receptors | 236 | 1.69e-12 | 2.10e-11 | 0.2900 | -1.78e-01 | -0.229000 | 2.47e-06 | 1.33e-09 |
Toll Like Receptor 3 (TLR3) Cascade | 89 | 1.59e-10 | 1.53e-09 | 0.4300 | -2.77e-01 | -0.328000 | 6.05e-06 | 8.53e-08 |
Signaling by TGF-beta Receptor Complex | 74 | 9.30e-13 | 1.23e-11 | 0.5220 | -3.43e-01 | -0.394000 | 3.29e-07 | 4.71e-09 |
Nuclear Envelope Breakdown | 53 | 4.21e-05 | 1.24e-04 | 0.3720 | -2.37e-01 | -0.287000 | 2.86e-03 | 3.03e-04 |
MyD88 dependent cascade initiated on endosome | 86 | 2.40e-08 | 1.47e-07 | 0.3860 | -2.46e-01 | -0.296000 | 7.74e-05 | 1.99e-06 |
Toll Like Receptor 7/8 (TLR7/8) Cascade | 86 | 2.40e-08 | 1.47e-07 | 0.3860 | -2.46e-01 | -0.296000 | 7.74e-05 | 1.99e-06 |
Toll Like Receptor 4 (TLR4) Cascade | 121 | 5.94e-08 | 3.30e-07 | 0.3170 | -1.98e-01 | -0.247000 | 1.69e-04 | 2.63e-06 |
Downregulation of TGF-beta receptor signaling | 26 | 5.37e-05 | 1.56e-04 | 0.5250 | -3.95e-01 | -0.346000 | 4.95e-04 | 2.29e-03 |
TCF dependent signaling in response to WNT | 186 | 3.89e-07 | 1.87e-06 | 0.2410 | -1.93e-01 | -0.144000 | 5.69e-06 | 7.01e-04 |
Beta-catenin independent WNT signaling | 138 | 4.60e-06 | 1.73e-05 | 0.2550 | -2.03e-01 | -0.154000 | 3.91e-05 | 1.74e-03 |
Regulation of TP53 Activity through Acetylation | 29 | 4.05e-04 | 9.71e-04 | 0.4430 | -3.36e-01 | -0.288000 | 1.72e-03 | 7.27e-03 |
Programmed Cell Death | 195 | 1.99e-03 | 4.06e-03 | 0.1520 | -8.13e-02 | -0.129000 | 5.01e-02 | 1.94e-03 |
SUMOylation of transcription cofactors | 44 | 6.32e-04 | 1.46e-03 | 0.3490 | -2.22e-01 | -0.269000 | 1.08e-02 | 2.00e-03 |
Signaling by TGFB family members | 98 | 6.70e-15 | 1.07e-13 | 0.4930 | -3.24e-01 | -0.371000 | 2.90e-08 | 2.12e-10 |
Transport of the SLBP independent Mature mRNA | 35 | 2.53e-06 | 1.00e-05 | 0.5180 | -3.88e-01 | -0.342000 | 7.04e-05 | 4.54e-04 |
ER Quality Control Compartment (ERQC) | 21 | 1.15e-02 | 2.02e-02 | 0.3930 | -2.99e-01 | -0.255000 | 1.75e-02 | 4.30e-02 |
Vpr-mediated nuclear import of PICs | 34 | 4.88e-06 | 1.82e-05 | 0.5120 | -3.83e-01 | -0.339000 | 1.09e-04 | 6.25e-04 |
RHOBTB GTPase Cycle | 35 | 1.72e-04 | 4.49e-04 | 0.4250 | -2.79e-01 | -0.320000 | 4.28e-03 | 1.05e-03 |
Transcriptional activation of mitochondrial biogenesis | 53 | 1.16e-08 | 7.56e-08 | 0.5010 | -3.33e-01 | -0.374000 | 2.66e-05 | 2.46e-06 |
Signaling by FGFR | 78 | 2.76e-03 | 5.43e-03 | 0.2340 | -1.85e-01 | -0.145000 | 4.82e-03 | 2.73e-02 |
Regulation of TP53 Activity | 155 | 9.01e-06 | 3.16e-05 | 0.2340 | -1.84e-01 | -0.144000 | 7.67e-05 | 1.90e-03 |
SUMOylation of ubiquitinylation proteins | 39 | 1.39e-05 | 4.64e-05 | 0.4570 | -3.42e-01 | -0.303000 | 2.20e-04 | 1.05e-03 |
Nuclear Envelope (NE) Reassembly | 73 | 3.68e-03 | 7.01e-03 | 0.2360 | -1.85e-01 | -0.147000 | 6.33e-03 | 2.94e-02 |
Export of Viral Ribonucleoproteins from Nucleus | 33 | 1.23e-04 | 3.27e-04 | 0.4460 | -2.96e-01 | -0.333000 | 3.22e-03 | 9.30e-04 |
Signaling by NODAL | 19 | 5.24e-04 | 1.23e-03 | 0.5380 | -3.62e-01 | -0.398000 | 6.34e-03 | 2.66e-03 |
ISG15 antiviral mechanism | 72 | 1.81e-08 | 1.14e-07 | 0.4250 | -3.18e-01 | -0.282000 | 3.08e-06 | 3.53e-05 |
Antigen processing: Ubiquitination & Proteasome degradation | 292 | 4.00e-17 | 7.32e-16 | 0.3080 | -2.35e-01 | -0.200000 | 4.88e-12 | 4.23e-09 |
NS1 Mediated Effects on Host Pathways | 40 | 2.66e-05 | 8.17e-05 | 0.4380 | -3.27e-01 | -0.292000 | 3.49e-04 | 1.41e-03 |
Deadenylation of mRNA | 22 | 1.59e-07 | 8.27e-07 | 0.7200 | -4.91e-01 | -0.526000 | 6.62e-05 | 1.96e-05 |
ADP signalling through P2Y purinoceptor 1 | 21 | 9.19e-03 | 1.65e-02 | 0.4030 | -2.68e-01 | -0.301000 | 3.36e-02 | 1.68e-02 |
Signaling by FGFR in disease | 59 | 5.20e-03 | 9.77e-03 | 0.2550 | -1.64e-01 | -0.195000 | 2.96e-02 | 9.51e-03 |
MyD88:MAL(TIRAP) cascade initiated on plasma membrane | 94 | 2.40e-06 | 9.59e-06 | 0.3170 | -2.08e-01 | -0.239000 | 4.84e-04 | 6.22e-05 |
Toll Like Receptor 2 (TLR2) Cascade | 94 | 2.40e-06 | 9.59e-06 | 0.3170 | -2.08e-01 | -0.239000 | 4.84e-04 | 6.22e-05 |
Toll Like Receptor TLR1:TLR2 Cascade | 94 | 2.40e-06 | 9.59e-06 | 0.3170 | -2.08e-01 | -0.239000 | 4.84e-04 | 6.22e-05 |
Toll Like Receptor TLR6:TLR2 Cascade | 94 | 2.40e-06 | 9.59e-06 | 0.3170 | -2.08e-01 | -0.239000 | 4.84e-04 | 6.22e-05 |
Nervous system development | 522 | 8.27e-12 | 9.77e-11 | 0.1900 | -1.19e-01 | -0.149000 | 3.47e-06 | 5.53e-09 |
Estrogen-dependent gene expression | 107 | 1.62e-05 | 5.34e-05 | 0.2740 | -2.07e-01 | -0.180000 | 2.20e-04 | 1.26e-03 |
PIP3 activates AKT signaling | 251 | 2.31e-15 | 3.80e-14 | 0.3140 | -2.09e-01 | -0.234000 | 1.22e-08 | 1.52e-10 |
HDR through Homologous Recombination (HRR) | 66 | 1.50e-03 | 3.17e-03 | 0.2680 | 1.77e-01 | 0.202000 | 1.31e-02 | 4.63e-03 |
Regulation of TP53 Expression and Degradation | 36 | 1.67e-03 | 3.49e-03 | 0.3600 | -2.66e-01 | -0.242000 | 5.67e-03 | 1.21e-02 |
Metabolism | 1856 | 4.20e-04 | 1.00e-03 | 0.0570 | -5.01e-02 | -0.027000 | 3.24e-04 | 5.24e-02 |
HSF1 activation | 26 | 1.46e-02 | 2.51e-02 | 0.3440 | -2.32e-01 | -0.254000 | 4.08e-02 | 2.48e-02 |
Cytokine Signaling in Immune system | 596 | 8.21e-19 | 1.85e-17 | 0.2280 | -1.72e-01 | -0.150000 | 6.83e-13 | 3.93e-10 |
Cellular response to heat stress | 94 | 4.47e-11 | 4.74e-10 | 0.4300 | -3.14e-01 | -0.294000 | 1.39e-07 | 8.51e-07 |
Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways | 49 | 2.40e-03 | 4.78e-03 | 0.2990 | -2.01e-01 | -0.222000 | 1.48e-02 | 7.25e-03 |
Association of TriC/CCT with target proteins during biosynthesis | 37 | 1.32e-03 | 2.82e-03 | 0.3610 | -2.45e-01 | -0.265000 | 9.89e-03 | 5.21e-03 |
SUMOylation of DNA damage response and repair proteins | 76 | 2.12e-05 | 6.70e-05 | 0.3210 | -2.17e-01 | -0.237000 | 1.06e-03 | 3.53e-04 |
Apoptosis | 169 | 4.71e-03 | 8.88e-03 | 0.1520 | -9.73e-02 | -0.117000 | 2.90e-02 | 8.60e-03 |
Axon guidance | 500 | 1.60e-09 | 1.28e-08 | 0.1730 | -1.12e-01 | -0.132000 | 1.62e-05 | 4.32e-07 |
Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer | 45 | 6.16e-09 | 4.28e-08 | 0.5530 | -4.00e-01 | -0.382000 | 3.36e-06 | 9.34e-06 |
PKMTs methylate histone lysines | 45 | 8.74e-05 | 2.40e-04 | 0.3890 | -2.84e-01 | -0.266000 | 9.74e-04 | 2.04e-03 |
Ovarian tumor domain proteases | 37 | 2.37e-05 | 7.40e-05 | 0.4580 | -3.15e-01 | -0.333000 | 9.25e-04 | 4.61e-04 |
Synthesis of PA | 32 | 1.63e-02 | 2.77e-02 | 0.3060 | -2.24e-01 | -0.208000 | 2.80e-02 | 4.16e-02 |
Metabolism of proteins | 1731 | 1.62e-36 | 8.49e-35 | 0.1930 | -1.44e-01 | -0.128000 | 1.33e-23 | 5.62e-19 |
Signaling by Interleukins | 384 | 1.14e-11 | 1.30e-10 | 0.2200 | -1.48e-01 | -0.163000 | 6.13e-07 | 4.15e-08 |
Glycerophospholipid biosynthesis | 110 | 1.74e-03 | 3.61e-03 | 0.2050 | -1.38e-01 | -0.152000 | 1.24e-02 | 5.81e-03 |
Potential therapeutics for SARS | 81 | 2.35e-07 | 1.19e-06 | 0.3710 | -2.55e-01 | -0.269000 | 7.11e-05 | 2.84e-05 |
Nuclear Events (kinase and transcription factor activation) | 60 | 9.77e-08 | 5.23e-07 | 0.4430 | -3.20e-01 | -0.306000 | 1.83e-05 | 4.02e-05 |
Resolution of D-Loop Structures | 33 | 3.94e-03 | 7.48e-03 | 0.3500 | 2.41e-01 | 0.253000 | 1.66e-02 | 1.18e-02 |
Resolution of D-loop Structures through Holliday Junction Intermediates | 32 | 1.07e-02 | 1.90e-02 | 0.3210 | 2.21e-01 | 0.233000 | 3.05e-02 | 2.23e-02 |
Nuclear Pore Complex (NPC) Disassembly | 36 | 3.56e-04 | 8.73e-04 | 0.4010 | -2.89e-01 | -0.277000 | 2.64e-03 | 3.99e-03 |
Golgi Cisternae Pericentriolar Stack Reorganization | 14 | 1.17e-03 | 2.55e-03 | 0.5920 | -4.24e-01 | -0.413000 | 5.97e-03 | 7.43e-03 |
Regulation of PTEN gene transcription | 61 | 1.20e-03 | 2.60e-03 | 0.2840 | -1.95e-01 | -0.206000 | 8.31e-03 | 5.48e-03 |
SUMOylation of chromatin organization proteins | 57 | 6.72e-05 | 1.91e-04 | 0.3510 | -2.43e-01 | -0.252000 | 1.49e-03 | 9.77e-04 |
NEP/NS2 Interacts with the Cellular Export Machinery | 32 | 5.08e-05 | 1.48e-04 | 0.4740 | -3.31e-01 | -0.340000 | 1.18e-03 | 8.85e-04 |
RHO GTPases activate CIT | 19 | 3.06e-02 | 4.85e-02 | 0.3650 | -2.56e-01 | -0.261000 | 5.38e-02 | 4.87e-02 |
Negative regulation of FGFR3 signaling | 27 | 1.92e-02 | 3.18e-02 | 0.3270 | -2.33e-01 | -0.228000 | 3.58e-02 | 4.00e-02 |
Activation of ATR in response to replication stress | 37 | 6.12e-03 | 1.13e-02 | 0.3170 | 2.27e-01 | 0.221000 | 1.71e-02 | 1.97e-02 |
Class I MHC mediated antigen processing & presentation | 352 | 1.25e-17 | 2.44e-16 | 0.2850 | -1.99e-01 | -0.204000 | 1.23e-10 | 4.32e-11 |
Interactions of Vpr with host cellular proteins | 37 | 6.60e-06 | 2.37e-05 | 0.4850 | -3.44e-01 | -0.341000 | 2.87e-04 | 3.33e-04 |
TBC/RABGAPs | 43 | 6.20e-07 | 2.86e-06 | 0.4920 | -3.46e-01 | -0.350000 | 8.54e-05 | 7.21e-05 |
Defective TPR may confer susceptibility towards thyroid papillary carcinoma (TPC) | 32 | 1.00e-04 | 2.72e-04 | 0.4580 | -3.25e-01 | -0.323000 | 1.48e-03 | 1.57e-03 |
Regulation of Glucokinase by Glucokinase Regulatory Protein | 32 | 1.00e-04 | 2.72e-04 | 0.4580 | -3.25e-01 | -0.323000 | 1.48e-03 | 1.57e-03 |
Peptide chain elongation
metric | value |
---|---|
setSize | 87 |
pMANOVA | 2.79e-43 |
p.adjustMANOVA | 3.4e-41 |
s.dist | 0.83 |
s.KO | -0.422 |
s.drug | 0.715 |
p.KO | 9.35e-12 |
p.drug | 8.26e-31 |
Gene | KO | drug |
---|---|---|
RPL22L1 | -10448 | 12221 |
RPL9 | -9659 | 12806 |
RPS17 | -10534 | 11631 |
RPL34 | -9357 | 12996 |
RPL12 | -9329 | 12992 |
RPL26L1 | -9387 | 12770 |
RPS13 | -9450 | 12652 |
RPS25 | -9371 | 12690 |
RPL37A | -9347 | 12675 |
RPS18 | -9122 | 12984 |
RPL17 | -8989 | 12909 |
RPL31 | -8781 | 13131 |
RPS6 | -9225 | 12405 |
RPS15A | -8754 | 12989 |
RPL36 | -8818 | 12868 |
FAU | -8610 | 13102 |
RPL26 | -8797 | 12658 |
RPLP2 | -8225 | 12999 |
RPL11 | -8529 | 12382 |
RPL35 | -8027 | 13097 |
KO | drug | |
---|---|---|
EEF1A1 | -9758 | -7439 |
EEF2 | -6416 | -8810 |
FAU | -8610 | 13102 |
RPL10 | -3821 | 1598 |
RPL10A | -9707 | -8212 |
RPL11 | -8529 | 12382 |
RPL12 | -9329 | 12992 |
RPL13 | -3469 | 12598 |
RPL13A | -6854 | 6955 |
RPL14 | -6386 | 13137 |
RPL15 | -786 | 12153 |
RPL17 | -8989 | 12909 |
RPL18 | -6672 | 12800 |
RPL18A | -6976 | 11926 |
RPL19 | 3924 | 12911 |
RPL21 | -6322 | 5141 |
RPL22 | -5554 | 9520 |
RPL22L1 | -10448 | 12221 |
RPL23 | 5769 | 12922 |
RPL23A | 11361 | -5257 |
RPL24 | -4591 | 12995 |
RPL26 | -8797 | 12658 |
RPL26L1 | -9387 | 12770 |
RPL27 | 6735 | 11625 |
RPL27A | -7818 | 13051 |
RPL28 | -5809 | 12962 |
RPL29 | -4515 | 12915 |
RPL3 | -6827 | -4536 |
RPL30 | -3907 | 11096 |
RPL31 | -8781 | 13131 |
RPL32 | -5028 | 12983 |
RPL34 | -9357 | 12996 |
RPL35 | -8027 | 13097 |
RPL35A | -1449 | 12789 |
RPL36 | -8818 | 12868 |
RPL36A | -4480 | 13010 |
RPL36AL | -8216 | 12702 |
RPL37 | -4624 | 13134 |
RPL37A | -9347 | 12675 |
RPL38 | 1558 | 13140 |
RPL39 | -6168 | 11962 |
RPL39L | -6608 | -6269 |
RPL3L | -510 | 7904 |
RPL4 | 11351 | 12558 |
RPL41 | -4616 | -6075 |
RPL5 | 4679 | 12075 |
RPL6 | -6903 | 12730 |
RPL7 | -3327 | -8789 |
RPL7A | -6163 | 11708 |
RPL8 | -7572 | 10323 |
RPL9 | -9659 | 12806 |
RPLP0 | -1504 | -7331 |
RPLP1 | 9026 | 12731 |
RPLP2 | -8225 | 12999 |
RPS10 | -8384 | 10665 |
RPS11 | -7725 | 12935 |
RPS12 | -7872 | 11600 |
RPS13 | -9450 | 12652 |
RPS14 | -1180 | 12428 |
RPS15 | -7430 | 12908 |
RPS15A | -8754 | 12989 |
RPS16 | -3844 | 12941 |
RPS17 | -10534 | 11631 |
RPS18 | -9122 | 12984 |
RPS19 | -7633 | 12888 |
RPS2 | -10222 | 8916 |
RPS20 | -4961 | 13095 |
RPS21 | -3001 | 13022 |
RPS23 | 6940 | 11907 |
RPS24 | 2369 | 13034 |
RPS25 | -9371 | 12690 |
RPS26 | -2615 | 13114 |
RPS27 | 651 | 11270 |
RPS27A | 5357 | 6464 |
RPS27L | 7330 | 12750 |
RPS28 | 2716 | 12485 |
RPS29 | -652 | 9078 |
RPS3 | -7756 | 12135 |
RPS3A | -9170 | 5257 |
RPS4X | -8542 | 12239 |
RPS5 | -6283 | -7965 |
RPS6 | -9225 | 12405 |
RPS7 | 5142 | 12976 |
RPS8 | -5812 | 12745 |
RPS9 | -8815 | 10189 |
RPSA | 292 | 11576 |
UBA52 | -6807 | 11639 |
Viral mRNA Translation
metric | value |
---|---|
setSize | 87 |
pMANOVA | 3.07e-43 |
p.adjustMANOVA | 3.46e-41 |
s.dist | 0.83 |
s.KO | -0.42 |
s.drug | 0.715 |
p.KO | 1.17e-11 |
p.drug | 7.1e-31 |
Gene | KO | drug |
---|---|---|
RPL22L1 | -10448 | 12221 |
RPL9 | -9659 | 12806 |
RPS17 | -10534 | 11631 |
RPL34 | -9357 | 12996 |
RPL12 | -9329 | 12992 |
RPL26L1 | -9387 | 12770 |
RPS13 | -9450 | 12652 |
RPS25 | -9371 | 12690 |
RPL37A | -9347 | 12675 |
RPS18 | -9122 | 12984 |
RPL17 | -8989 | 12909 |
RPL31 | -8781 | 13131 |
RPS6 | -9225 | 12405 |
RPS15A | -8754 | 12989 |
RPL36 | -8818 | 12868 |
FAU | -8610 | 13102 |
RPL26 | -8797 | 12658 |
RPLP2 | -8225 | 12999 |
RPL11 | -8529 | 12382 |
RPL35 | -8027 | 13097 |
KO | drug | |
---|---|---|
DNAJC3 | -2895 | -7549 |
FAU | -8610 | 13102 |
GRSF1 | -11152 | -7843 |
RPL10 | -3821 | 1598 |
RPL10A | -9707 | -8212 |
RPL11 | -8529 | 12382 |
RPL12 | -9329 | 12992 |
RPL13 | -3469 | 12598 |
RPL13A | -6854 | 6955 |
RPL14 | -6386 | 13137 |
RPL15 | -786 | 12153 |
RPL17 | -8989 | 12909 |
RPL18 | -6672 | 12800 |
RPL18A | -6976 | 11926 |
RPL19 | 3924 | 12911 |
RPL21 | -6322 | 5141 |
RPL22 | -5554 | 9520 |
RPL22L1 | -10448 | 12221 |
RPL23 | 5769 | 12922 |
RPL23A | 11361 | -5257 |
RPL24 | -4591 | 12995 |
RPL26 | -8797 | 12658 |
RPL26L1 | -9387 | 12770 |
RPL27 | 6735 | 11625 |
RPL27A | -7818 | 13051 |
RPL28 | -5809 | 12962 |
RPL29 | -4515 | 12915 |
RPL3 | -6827 | -4536 |
RPL30 | -3907 | 11096 |
RPL31 | -8781 | 13131 |
RPL32 | -5028 | 12983 |
RPL34 | -9357 | 12996 |
RPL35 | -8027 | 13097 |
RPL35A | -1449 | 12789 |
RPL36 | -8818 | 12868 |
RPL36A | -4480 | 13010 |
RPL36AL | -8216 | 12702 |
RPL37 | -4624 | 13134 |
RPL37A | -9347 | 12675 |
RPL38 | 1558 | 13140 |
RPL39 | -6168 | 11962 |
RPL39L | -6608 | -6269 |
RPL3L | -510 | 7904 |
RPL4 | 11351 | 12558 |
RPL41 | -4616 | -6075 |
RPL5 | 4679 | 12075 |
RPL6 | -6903 | 12730 |
RPL7 | -3327 | -8789 |
RPL7A | -6163 | 11708 |
RPL8 | -7572 | 10323 |
RPL9 | -9659 | 12806 |
RPLP0 | -1504 | -7331 |
RPLP1 | 9026 | 12731 |
RPLP2 | -8225 | 12999 |
RPS10 | -8384 | 10665 |
RPS11 | -7725 | 12935 |
RPS12 | -7872 | 11600 |
RPS13 | -9450 | 12652 |
RPS14 | -1180 | 12428 |
RPS15 | -7430 | 12908 |
RPS15A | -8754 | 12989 |
RPS16 | -3844 | 12941 |
RPS17 | -10534 | 11631 |
RPS18 | -9122 | 12984 |
RPS19 | -7633 | 12888 |
RPS2 | -10222 | 8916 |
RPS20 | -4961 | 13095 |
RPS21 | -3001 | 13022 |
RPS23 | 6940 | 11907 |
RPS24 | 2369 | 13034 |
RPS25 | -9371 | 12690 |
RPS26 | -2615 | 13114 |
RPS27 | 651 | 11270 |
RPS27A | 5357 | 6464 |
RPS27L | 7330 | 12750 |
RPS28 | 2716 | 12485 |
RPS29 | -652 | 9078 |
RPS3 | -7756 | 12135 |
RPS3A | -9170 | 5257 |
RPS4X | -8542 | 12239 |
RPS5 | -6283 | -7965 |
RPS6 | -9225 | 12405 |
RPS7 | 5142 | 12976 |
RPS8 | -5812 | 12745 |
RPS9 | -8815 | 10189 |
RPSA | 292 | 11576 |
UBA52 | -6807 | 11639 |
Formation of a pool of free 40S subunits
metric | value |
---|---|
setSize | 99 |
pMANOVA | 1.26e-44 |
p.adjustMANOVA | 1.68e-42 |
s.dist | 0.789 |
s.KO | -0.444 |
s.drug | 0.652 |
p.KO | 2.03e-14 |
p.drug | 3.21e-29 |
Gene | KO | drug |
---|---|---|
RPL22L1 | -10448 | 12221 |
RPL9 | -9659 | 12806 |
RPS17 | -10534 | 11631 |
RPL34 | -9357 | 12996 |
RPL12 | -9329 | 12992 |
RPL26L1 | -9387 | 12770 |
RPS13 | -9450 | 12652 |
RPS25 | -9371 | 12690 |
RPL37A | -9347 | 12675 |
RPS18 | -9122 | 12984 |
RPL17 | -8989 | 12909 |
RPL31 | -8781 | 13131 |
RPS6 | -9225 | 12405 |
RPS15A | -8754 | 12989 |
RPL36 | -8818 | 12868 |
FAU | -8610 | 13102 |
RPL26 | -8797 | 12658 |
RPLP2 | -8225 | 12999 |
RPL11 | -8529 | 12382 |
RPL35 | -8027 | 13097 |
KO | drug | |
---|---|---|
EIF1AX | -5479 | 11112 |
EIF3A | -5233 | -9195 |
EIF3B | -4779 | -8277 |
EIF3C | -8843 | 11244 |
EIF3D | -10400 | -7621 |
EIF3E | -9070 | 10545 |
EIF3F | -1343 | -5879 |
EIF3G | -7655 | 4326 |
EIF3H | -8110 | -1879 |
EIF3I | -7897 | 12235 |
EIF3J | -4825 | -4367 |
EIF3K | -2668 | 9951 |
EIF3L | -9160 | -8016 |
EIF3M | -10718 | 9044 |
FAU | -8610 | 13102 |
RPL10 | -3821 | 1598 |
RPL10A | -9707 | -8212 |
RPL11 | -8529 | 12382 |
RPL12 | -9329 | 12992 |
RPL13 | -3469 | 12598 |
RPL13A | -6854 | 6955 |
RPL14 | -6386 | 13137 |
RPL15 | -786 | 12153 |
RPL17 | -8989 | 12909 |
RPL18 | -6672 | 12800 |
RPL18A | -6976 | 11926 |
RPL19 | 3924 | 12911 |
RPL21 | -6322 | 5141 |
RPL22 | -5554 | 9520 |
RPL22L1 | -10448 | 12221 |
RPL23 | 5769 | 12922 |
RPL23A | 11361 | -5257 |
RPL24 | -4591 | 12995 |
RPL26 | -8797 | 12658 |
RPL26L1 | -9387 | 12770 |
RPL27 | 6735 | 11625 |
RPL27A | -7818 | 13051 |
RPL28 | -5809 | 12962 |
RPL29 | -4515 | 12915 |
RPL3 | -6827 | -4536 |
RPL30 | -3907 | 11096 |
RPL31 | -8781 | 13131 |
RPL32 | -5028 | 12983 |
RPL34 | -9357 | 12996 |
RPL35 | -8027 | 13097 |
RPL35A | -1449 | 12789 |
RPL36 | -8818 | 12868 |
RPL36A | -4480 | 13010 |
RPL36AL | -8216 | 12702 |
RPL37 | -4624 | 13134 |
RPL37A | -9347 | 12675 |
RPL38 | 1558 | 13140 |
RPL39 | -6168 | 11962 |
RPL39L | -6608 | -6269 |
RPL3L | -510 | 7904 |
RPL4 | 11351 | 12558 |
RPL41 | -4616 | -6075 |
RPL5 | 4679 | 12075 |
RPL6 | -6903 | 12730 |
RPL7 | -3327 | -8789 |
RPL7A | -6163 | 11708 |
RPL8 | -7572 | 10323 |
RPL9 | -9659 | 12806 |
RPLP0 | -1504 | -7331 |
RPLP1 | 9026 | 12731 |
RPLP2 | -8225 | 12999 |
RPS10 | -8384 | 10665 |
RPS11 | -7725 | 12935 |
RPS12 | -7872 | 11600 |
RPS13 | -9450 | 12652 |
RPS14 | -1180 | 12428 |
RPS15 | -7430 | 12908 |
RPS15A | -8754 | 12989 |
RPS16 | -3844 | 12941 |
RPS17 | -10534 | 11631 |
RPS18 | -9122 | 12984 |
RPS19 | -7633 | 12888 |
RPS2 | -10222 | 8916 |
RPS20 | -4961 | 13095 |
RPS21 | -3001 | 13022 |
RPS23 | 6940 | 11907 |
RPS24 | 2369 | 13034 |
RPS25 | -9371 | 12690 |
RPS26 | -2615 | 13114 |
RPS27 | 651 | 11270 |
RPS27A | 5357 | 6464 |
RPS27L | 7330 | 12750 |
RPS28 | 2716 | 12485 |
RPS29 | -652 | 9078 |
RPS3 | -7756 | 12135 |
RPS3A | -9170 | 5257 |
RPS4X | -8542 | 12239 |
RPS5 | -6283 | -7965 |
RPS6 | -9225 | 12405 |
RPS7 | 5142 | 12976 |
RPS8 | -5812 | 12745 |
RPS9 | -8815 | 10189 |
RPSA | 292 | 11576 |
UBA52 | -6807 | 11639 |
Eukaryotic Translation Termination
metric | value |
---|---|
setSize | 91 |
pMANOVA | 2.19e-41 |
p.adjustMANOVA | 1.89e-39 |
s.dist | 0.794 |
s.KO | -0.402 |
s.drug | 0.684 |
p.KO | 3.27e-11 |
p.drug | 1.32e-29 |
Gene | KO | drug |
---|---|---|
RPL22L1 | -10448 | 12221 |
RPL9 | -9659 | 12806 |
RPS17 | -10534 | 11631 |
RPL34 | -9357 | 12996 |
RPL12 | -9329 | 12992 |
RPL26L1 | -9387 | 12770 |
RPS13 | -9450 | 12652 |
RPS25 | -9371 | 12690 |
RPL37A | -9347 | 12675 |
RPS18 | -9122 | 12984 |
RPL17 | -8989 | 12909 |
RPL31 | -8781 | 13131 |
RPS6 | -9225 | 12405 |
RPS15A | -8754 | 12989 |
RPL36 | -8818 | 12868 |
FAU | -8610 | 13102 |
RPL26 | -8797 | 12658 |
RPLP2 | -8225 | 12999 |
RPL11 | -8529 | 12382 |
RPL35 | -8027 | 13097 |
KO | drug | |
---|---|---|
APEH | 9298 | -8571 |
ETF1 | -5515 | -9496 |
FAU | -8610 | 13102 |
GSPT1 | -11018 | -10261 |
GSPT2 | -5509 | -6727 |
N6AMT1 | 7099 | 10581 |
RPL10 | -3821 | 1598 |
RPL10A | -9707 | -8212 |
RPL11 | -8529 | 12382 |
RPL12 | -9329 | 12992 |
RPL13 | -3469 | 12598 |
RPL13A | -6854 | 6955 |
RPL14 | -6386 | 13137 |
RPL15 | -786 | 12153 |
RPL17 | -8989 | 12909 |
RPL18 | -6672 | 12800 |
RPL18A | -6976 | 11926 |
RPL19 | 3924 | 12911 |
RPL21 | -6322 | 5141 |
RPL22 | -5554 | 9520 |
RPL22L1 | -10448 | 12221 |
RPL23 | 5769 | 12922 |
RPL23A | 11361 | -5257 |
RPL24 | -4591 | 12995 |
RPL26 | -8797 | 12658 |
RPL26L1 | -9387 | 12770 |
RPL27 | 6735 | 11625 |
RPL27A | -7818 | 13051 |
RPL28 | -5809 | 12962 |
RPL29 | -4515 | 12915 |
RPL3 | -6827 | -4536 |
RPL30 | -3907 | 11096 |
RPL31 | -8781 | 13131 |
RPL32 | -5028 | 12983 |
RPL34 | -9357 | 12996 |
RPL35 | -8027 | 13097 |
RPL35A | -1449 | 12789 |
RPL36 | -8818 | 12868 |
RPL36A | -4480 | 13010 |
RPL36AL | -8216 | 12702 |
RPL37 | -4624 | 13134 |
RPL37A | -9347 | 12675 |
RPL38 | 1558 | 13140 |
RPL39 | -6168 | 11962 |
RPL39L | -6608 | -6269 |
RPL3L | -510 | 7904 |
RPL4 | 11351 | 12558 |
RPL41 | -4616 | -6075 |
RPL5 | 4679 | 12075 |
RPL6 | -6903 | 12730 |
RPL7 | -3327 | -8789 |
RPL7A | -6163 | 11708 |
RPL8 | -7572 | 10323 |
RPL9 | -9659 | 12806 |
RPLP0 | -1504 | -7331 |
RPLP1 | 9026 | 12731 |
RPLP2 | -8225 | 12999 |
RPS10 | -8384 | 10665 |
RPS11 | -7725 | 12935 |
RPS12 | -7872 | 11600 |
RPS13 | -9450 | 12652 |
RPS14 | -1180 | 12428 |
RPS15 | -7430 | 12908 |
RPS15A | -8754 | 12989 |
RPS16 | -3844 | 12941 |
RPS17 | -10534 | 11631 |
RPS18 | -9122 | 12984 |
RPS19 | -7633 | 12888 |
RPS2 | -10222 | 8916 |
RPS20 | -4961 | 13095 |
RPS21 | -3001 | 13022 |
RPS23 | 6940 | 11907 |
RPS24 | 2369 | 13034 |
RPS25 | -9371 | 12690 |
RPS26 | -2615 | 13114 |
RPS27 | 651 | 11270 |
RPS27A | 5357 | 6464 |
RPS27L | 7330 | 12750 |
RPS28 | 2716 | 12485 |
RPS29 | -652 | 9078 |
RPS3 | -7756 | 12135 |
RPS3A | -9170 | 5257 |
RPS4X | -8542 | 12239 |
RPS5 | -6283 | -7965 |
RPS6 | -9225 | 12405 |
RPS7 | 5142 | 12976 |
RPS8 | -5812 | 12745 |
RPS9 | -8815 | 10189 |
RPSA | 292 | 11576 |
TRMT112 | -5741 | 13057 |
UBA52 | -6807 | 11639 |
Eukaryotic Translation Elongation
metric | value |
---|---|
setSize | 92 |
pMANOVA | 1.82e-41 |
p.adjustMANOVA | 1.67e-39 |
s.dist | 0.79 |
s.KO | -0.412 |
s.drug | 0.674 |
p.KO | 8.16e-12 |
p.drug | 4.97e-29 |
Gene | KO | drug |
---|---|---|
RPL22L1 | -10448 | 12221 |
RPL9 | -9659 | 12806 |
RPS17 | -10534 | 11631 |
RPL34 | -9357 | 12996 |
RPL12 | -9329 | 12992 |
RPL26L1 | -9387 | 12770 |
RPS13 | -9450 | 12652 |
RPS25 | -9371 | 12690 |
RPL37A | -9347 | 12675 |
RPS18 | -9122 | 12984 |
RPL17 | -8989 | 12909 |
RPL31 | -8781 | 13131 |
RPS6 | -9225 | 12405 |
RPS15A | -8754 | 12989 |
RPL36 | -8818 | 12868 |
FAU | -8610 | 13102 |
RPL26 | -8797 | 12658 |
RPLP2 | -8225 | 12999 |
RPL11 | -8529 | 12382 |
RPL35 | -8027 | 13097 |
KO | drug | |
---|---|---|
EEF1A1 | -9758 | -7439 |
EEF1A1P5 | -2416 | -8237 |
EEF1A2 | 11418 | -3449 |
EEF1B2 | -9424 | 8464 |
EEF1D | -2336 | 11037 |
EEF1G | -7846 | -5785 |
EEF2 | -6416 | -8810 |
FAU | -8610 | 13102 |
RPL10 | -3821 | 1598 |
RPL10A | -9707 | -8212 |
RPL11 | -8529 | 12382 |
RPL12 | -9329 | 12992 |
RPL13 | -3469 | 12598 |
RPL13A | -6854 | 6955 |
RPL14 | -6386 | 13137 |
RPL15 | -786 | 12153 |
RPL17 | -8989 | 12909 |
RPL18 | -6672 | 12800 |
RPL18A | -6976 | 11926 |
RPL19 | 3924 | 12911 |
RPL21 | -6322 | 5141 |
RPL22 | -5554 | 9520 |
RPL22L1 | -10448 | 12221 |
RPL23 | 5769 | 12922 |
RPL23A | 11361 | -5257 |
RPL24 | -4591 | 12995 |
RPL26 | -8797 | 12658 |
RPL26L1 | -9387 | 12770 |
RPL27 | 6735 | 11625 |
RPL27A | -7818 | 13051 |
RPL28 | -5809 | 12962 |
RPL29 | -4515 | 12915 |
RPL3 | -6827 | -4536 |
RPL30 | -3907 | 11096 |
RPL31 | -8781 | 13131 |
RPL32 | -5028 | 12983 |
RPL34 | -9357 | 12996 |
RPL35 | -8027 | 13097 |
RPL35A | -1449 | 12789 |
RPL36 | -8818 | 12868 |
RPL36A | -4480 | 13010 |
RPL36AL | -8216 | 12702 |
RPL37 | -4624 | 13134 |
RPL37A | -9347 | 12675 |
RPL38 | 1558 | 13140 |
RPL39 | -6168 | 11962 |
RPL39L | -6608 | -6269 |
RPL3L | -510 | 7904 |
RPL4 | 11351 | 12558 |
RPL41 | -4616 | -6075 |
RPL5 | 4679 | 12075 |
RPL6 | -6903 | 12730 |
RPL7 | -3327 | -8789 |
RPL7A | -6163 | 11708 |
RPL8 | -7572 | 10323 |
RPL9 | -9659 | 12806 |
RPLP0 | -1504 | -7331 |
RPLP1 | 9026 | 12731 |
RPLP2 | -8225 | 12999 |
RPS10 | -8384 | 10665 |
RPS11 | -7725 | 12935 |
RPS12 | -7872 | 11600 |
RPS13 | -9450 | 12652 |
RPS14 | -1180 | 12428 |
RPS15 | -7430 | 12908 |
RPS15A | -8754 | 12989 |
RPS16 | -3844 | 12941 |
RPS17 | -10534 | 11631 |
RPS18 | -9122 | 12984 |
RPS19 | -7633 | 12888 |
RPS2 | -10222 | 8916 |
RPS20 | -4961 | 13095 |
RPS21 | -3001 | 13022 |
RPS23 | 6940 | 11907 |
RPS24 | 2369 | 13034 |
RPS25 | -9371 | 12690 |
RPS26 | -2615 | 13114 |
RPS27 | 651 | 11270 |
RPS27A | 5357 | 6464 |
RPS27L | 7330 | 12750 |
RPS28 | 2716 | 12485 |
RPS29 | -652 | 9078 |
RPS3 | -7756 | 12135 |
RPS3A | -9170 | 5257 |
RPS4X | -8542 | 12239 |
RPS5 | -6283 | -7965 |
RPS6 | -9225 | 12405 |
RPS7 | 5142 | 12976 |
RPS8 | -5812 | 12745 |
RPS9 | -8815 | 10189 |
RPSA | 292 | 11576 |
UBA52 | -6807 | 11639 |
Defective EXT1 causes exostoses 1, TRPS2 and CHDS
metric | value |
---|---|
setSize | 13 |
pMANOVA | 1.43e-06 |
p.adjustMANOVA | 5.93e-06 |
s.dist | 0.799 |
s.KO | 0.358 |
s.drug | -0.714 |
p.KO | 0.0255 |
p.drug | 8.23e-06 |
Gene | KO | drug |
---|---|---|
AGRN | 12518 | -11205 |
SDC4 | 12322 | -10633 |
EXT2 | 11023 | -9224 |
GPC4 | 11190 | -8942 |
SDC1 | 12230 | -7104 |
SDC3 | 12401 | -6760 |
EXT1 | 10114 | -6275 |
GPC5 | 7673 | -3135 |
GPC1 | 1951 | -7922 |
KO | drug | |
---|---|---|
AGRN | 12518 | -11205 |
EXT1 | 10114 | -6275 |
EXT2 | 11023 | -9224 |
GPC1 | 1951 | -7922 |
GPC2 | -3913 | -3279 |
GPC4 | 11190 | -8942 |
GPC5 | 7673 | -3135 |
GPC6 | -6095 | -11229 |
HSPG2 | -9046 | -9768 |
SDC1 | 12230 | -7104 |
SDC2 | -6754 | -5737 |
SDC3 | 12401 | -6760 |
SDC4 | 12322 | -10633 |
Defective EXT2 causes exostoses 2
metric | value |
---|---|
setSize | 13 |
pMANOVA | 1.43e-06 |
p.adjustMANOVA | 5.93e-06 |
s.dist | 0.799 |
s.KO | 0.358 |
s.drug | -0.714 |
p.KO | 0.0255 |
p.drug | 8.23e-06 |
Gene | KO | drug |
---|---|---|
AGRN | 12518 | -11205 |
SDC4 | 12322 | -10633 |
EXT2 | 11023 | -9224 |
GPC4 | 11190 | -8942 |
SDC1 | 12230 | -7104 |
SDC3 | 12401 | -6760 |
EXT1 | 10114 | -6275 |
GPC5 | 7673 | -3135 |
GPC1 | 1951 | -7922 |
KO | drug | |
---|---|---|
AGRN | 12518 | -11205 |
EXT1 | 10114 | -6275 |
EXT2 | 11023 | -9224 |
GPC1 | 1951 | -7922 |
GPC2 | -3913 | -3279 |
GPC4 | 11190 | -8942 |
GPC5 | 7673 | -3135 |
GPC6 | -6095 | -11229 |
HSPG2 | -9046 | -9768 |
SDC1 | 12230 | -7104 |
SDC2 | -6754 | -5737 |
SDC3 | 12401 | -6760 |
SDC4 | 12322 | -10633 |
Laminin interactions
metric | value |
---|---|
setSize | 23 |
pMANOVA | 1.23e-11 |
p.adjustMANOVA | 1.39e-10 |
s.dist | 0.827 |
s.KO | 0.269 |
s.drug | -0.782 |
p.KO | 0.0258 |
p.drug | 8.23e-11 |
Gene | KO | drug |
---|---|---|
LAMC1 | 12854 | -11227 |
LAMB2 | 12607 | -10832 |
LAMA5 | 12583 | -10447 |
ITGA1 | 12258 | -10552 |
LAMA1 | 12802 | -10091 |
ITGA3 | 12831 | -9596 |
NID1 | 9752 | -11078 |
ITGB4 | 12465 | -8452 |
ITGA7 | 12807 | -7517 |
ITGA2 | 8062 | -11213 |
LAMB3 | 7018 | -11255 |
LAMC2 | 10786 | -6533 |
COL18A1 | 10348 | -6371 |
LAMC3 | 11660 | -2369 |
ITGAV | 144 | -11011 |
KO | drug | |
---|---|---|
COL18A1 | 10348 | -6371 |
HSPG2 | -9046 | -9768 |
ITGA1 | 12258 | -10552 |
ITGA2 | 8062 | -11213 |
ITGA3 | 12831 | -9596 |
ITGA6 | -7384 | -11184 |
ITGA7 | 12807 | -7517 |
ITGAV | 144 | -11011 |
ITGB1 | -3655 | -11215 |
ITGB4 | 12465 | -8452 |
LAMA1 | 12802 | -10091 |
LAMA2 | -8729 | -4164 |
LAMA3 | -11238 | 4464 |
LAMA4 | -7403 | -10348 |
LAMA5 | 12583 | -10447 |
LAMB1 | -9087 | -10329 |
LAMB2 | 12607 | -10832 |
LAMB3 | 7018 | -11255 |
LAMC1 | 12854 | -11227 |
LAMC2 | 10786 | -6533 |
LAMC3 | 11660 | -2369 |
NID1 | 9752 | -11078 |
NID2 | -11453 | -7028 |
Response of EIF2AK4 (GCN2) to amino acid deficiency
metric | value |
---|---|
setSize | 99 |
pMANOVA | 6.6e-41 |
p.adjustMANOVA | 5.37e-39 |
s.dist | 0.755 |
s.KO | -0.423 |
s.drug | 0.625 |
p.KO | 3.36e-13 |
p.drug | 5.07e-27 |
Gene | KO | drug |
---|---|---|
ASNS | -10878 | 12349 |
RPL22L1 | -10448 | 12221 |
RPL9 | -9659 | 12806 |
RPS17 | -10534 | 11631 |
RPL34 | -9357 | 12996 |
RPL12 | -9329 | 12992 |
RPL26L1 | -9387 | 12770 |
RPS13 | -9450 | 12652 |
RPS25 | -9371 | 12690 |
RPL37A | -9347 | 12675 |
RPS18 | -9122 | 12984 |
RPL17 | -8989 | 12909 |
RPL31 | -8781 | 13131 |
RPS6 | -9225 | 12405 |
RPS15A | -8754 | 12989 |
RPL36 | -8818 | 12868 |
FAU | -8610 | 13102 |
RPL26 | -8797 | 12658 |
RPLP2 | -8225 | 12999 |
RPL11 | -8529 | 12382 |
KO | drug | |
---|---|---|
ASNS | -10878 | 12349 |
ATF2 | -8942 | -9289 |
ATF3 | -4081 | -4353 |
ATF4 | -6768 | 11948 |
CEBPB | -7116 | 12656 |
CEBPG | -9940 | 6581 |
DDIT3 | -9395 | 10987 |
EIF2AK4 | 10865 | -7766 |
EIF2S1 | -8950 | -8774 |
EIF2S2 | -10653 | -6089 |
EIF2S3 | -10174 | -5022 |
FAU | -8610 | 13102 |
GCN1 | 10665 | -8257 |
IMPACT | -1732 | -8127 |
RPL10 | -3821 | 1598 |
RPL10A | -9707 | -8212 |
RPL11 | -8529 | 12382 |
RPL12 | -9329 | 12992 |
RPL13 | -3469 | 12598 |
RPL13A | -6854 | 6955 |
RPL14 | -6386 | 13137 |
RPL15 | -786 | 12153 |
RPL17 | -8989 | 12909 |
RPL18 | -6672 | 12800 |
RPL18A | -6976 | 11926 |
RPL19 | 3924 | 12911 |
RPL21 | -6322 | 5141 |
RPL22 | -5554 | 9520 |
RPL22L1 | -10448 | 12221 |
RPL23 | 5769 | 12922 |
RPL23A | 11361 | -5257 |
RPL24 | -4591 | 12995 |
RPL26 | -8797 | 12658 |
RPL26L1 | -9387 | 12770 |
RPL27 | 6735 | 11625 |
RPL27A | -7818 | 13051 |
RPL28 | -5809 | 12962 |
RPL29 | -4515 | 12915 |
RPL3 | -6827 | -4536 |
RPL30 | -3907 | 11096 |
RPL31 | -8781 | 13131 |
RPL32 | -5028 | 12983 |
RPL34 | -9357 | 12996 |
RPL35 | -8027 | 13097 |
RPL35A | -1449 | 12789 |
RPL36 | -8818 | 12868 |
RPL36A | -4480 | 13010 |
RPL36AL | -8216 | 12702 |
RPL37 | -4624 | 13134 |
RPL37A | -9347 | 12675 |
RPL38 | 1558 | 13140 |
RPL39 | -6168 | 11962 |
RPL39L | -6608 | -6269 |
RPL3L | -510 | 7904 |
RPL4 | 11351 | 12558 |
RPL41 | -4616 | -6075 |
RPL5 | 4679 | 12075 |
RPL6 | -6903 | 12730 |
RPL7 | -3327 | -8789 |
RPL7A | -6163 | 11708 |
RPL8 | -7572 | 10323 |
RPL9 | -9659 | 12806 |
RPLP0 | -1504 | -7331 |
RPLP1 | 9026 | 12731 |
RPLP2 | -8225 | 12999 |
RPS10 | -8384 | 10665 |
RPS11 | -7725 | 12935 |
RPS12 | -7872 | 11600 |
RPS13 | -9450 | 12652 |
RPS14 | -1180 | 12428 |
RPS15 | -7430 | 12908 |
RPS15A | -8754 | 12989 |
RPS16 | -3844 | 12941 |
RPS17 | -10534 | 11631 |
RPS18 | -9122 | 12984 |
RPS19 | -7633 | 12888 |
RPS2 | -10222 | 8916 |
RPS20 | -4961 | 13095 |
RPS21 | -3001 | 13022 |
RPS23 | 6940 | 11907 |
RPS24 | 2369 | 13034 |
RPS25 | -9371 | 12690 |
RPS26 | -2615 | 13114 |
RPS27 | 651 | 11270 |
RPS27A | 5357 | 6464 |
RPS27L | 7330 | 12750 |
RPS28 | 2716 | 12485 |
RPS29 | -652 | 9078 |
RPS3 | -7756 | 12135 |
RPS3A | -9170 | 5257 |
RPS4X | -8542 | 12239 |
RPS5 | -6283 | -7965 |
RPS6 | -9225 | 12405 |
RPS7 | 5142 | 12976 |
RPS8 | -5812 | 12745 |
RPS9 | -8815 | 10189 |
RPSA | 292 | 11576 |
TRIB3 | -3221 | -5552 |
UBA52 | -6807 | 11639 |
Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC)
metric | value |
---|---|
setSize | 93 |
pMANOVA | 6.86e-38 |
p.adjustMANOVA | 4.02e-36 |
s.dist | 0.749 |
s.KO | -0.424 |
s.drug | 0.617 |
p.KO | 1.55e-12 |
p.drug | 6.83e-25 |
Gene | KO | drug |
---|---|---|
RPL22L1 | -10448 | 12221 |
RPL9 | -9659 | 12806 |
RPS17 | -10534 | 11631 |
RPL34 | -9357 | 12996 |
RPL12 | -9329 | 12992 |
RPL26L1 | -9387 | 12770 |
RPS13 | -9450 | 12652 |
RPS25 | -9371 | 12690 |
RPL37A | -9347 | 12675 |
RPS18 | -9122 | 12984 |
RPL17 | -8989 | 12909 |
RPL31 | -8781 | 13131 |
RPS6 | -9225 | 12405 |
RPS15A | -8754 | 12989 |
RPL36 | -8818 | 12868 |
FAU | -8610 | 13102 |
RPL26 | -8797 | 12658 |
RPLP2 | -8225 | 12999 |
RPL11 | -8529 | 12382 |
RPL35 | -8027 | 13097 |
KO | drug | |
---|---|---|
EIF4G1 | 9159 | -10287 |
ETF1 | -5515 | -9496 |
FAU | -8610 | 13102 |
GSPT1 | -11018 | -10261 |
GSPT2 | -5509 | -6727 |
NCBP1 | -7784 | -5234 |
NCBP2 | -6378 | -6281 |
PABPC1 | -7033 | -10406 |
RPL10 | -3821 | 1598 |
RPL10A | -9707 | -8212 |
RPL11 | -8529 | 12382 |
RPL12 | -9329 | 12992 |
RPL13 | -3469 | 12598 |
RPL13A | -6854 | 6955 |
RPL14 | -6386 | 13137 |
RPL15 | -786 | 12153 |
RPL17 | -8989 | 12909 |
RPL18 | -6672 | 12800 |
RPL18A | -6976 | 11926 |
RPL19 | 3924 | 12911 |
RPL21 | -6322 | 5141 |
RPL22 | -5554 | 9520 |
RPL22L1 | -10448 | 12221 |
RPL23 | 5769 | 12922 |
RPL23A | 11361 | -5257 |
RPL24 | -4591 | 12995 |
RPL26 | -8797 | 12658 |
RPL26L1 | -9387 | 12770 |
RPL27 | 6735 | 11625 |
RPL27A | -7818 | 13051 |
RPL28 | -5809 | 12962 |
RPL29 | -4515 | 12915 |
RPL3 | -6827 | -4536 |
RPL30 | -3907 | 11096 |
RPL31 | -8781 | 13131 |
RPL32 | -5028 | 12983 |
RPL34 | -9357 | 12996 |
RPL35 | -8027 | 13097 |
RPL35A | -1449 | 12789 |
RPL36 | -8818 | 12868 |
RPL36A | -4480 | 13010 |
RPL36AL | -8216 | 12702 |
RPL37 | -4624 | 13134 |
RPL37A | -9347 | 12675 |
RPL38 | 1558 | 13140 |
RPL39 | -6168 | 11962 |
RPL39L | -6608 | -6269 |
RPL3L | -510 | 7904 |
RPL4 | 11351 | 12558 |
RPL41 | -4616 | -6075 |
RPL5 | 4679 | 12075 |
RPL6 | -6903 | 12730 |
RPL7 | -3327 | -8789 |
RPL7A | -6163 | 11708 |
RPL8 | -7572 | 10323 |
RPL9 | -9659 | 12806 |
RPLP0 | -1504 | -7331 |
RPLP1 | 9026 | 12731 |
RPLP2 | -8225 | 12999 |
RPS10 | -8384 | 10665 |
RPS11 | -7725 | 12935 |
RPS12 | -7872 | 11600 |
RPS13 | -9450 | 12652 |
RPS14 | -1180 | 12428 |
RPS15 | -7430 | 12908 |
RPS15A | -8754 | 12989 |
RPS16 | -3844 | 12941 |
RPS17 | -10534 | 11631 |
RPS18 | -9122 | 12984 |
RPS19 | -7633 | 12888 |
RPS2 | -10222 | 8916 |
RPS20 | -4961 | 13095 |
RPS21 | -3001 | 13022 |
RPS23 | 6940 | 11907 |
RPS24 | 2369 | 13034 |
RPS25 | -9371 | 12690 |
RPS26 | -2615 | 13114 |
RPS27 | 651 | 11270 |
RPS27A | 5357 | 6464 |
RPS27L | 7330 | 12750 |
RPS28 | 2716 | 12485 |
RPS29 | -652 | 9078 |
RPS3 | -7756 | 12135 |
RPS3A | -9170 | 5257 |
RPS4X | -8542 | 12239 |
RPS5 | -6283 | -7965 |
RPS6 | -9225 | 12405 |
RPS7 | 5142 | 12976 |
RPS8 | -5812 | 12745 |
RPS9 | -8815 | 10189 |
RPSA | 292 | 11576 |
UBA52 | -6807 | 11639 |
UPF1 | -10419 | -10092 |
Selenocysteine synthesis
metric | value |
---|---|
setSize | 91 |
pMANOVA | 1.38e-38 |
p.adjustMANOVA | 8.77e-37 |
s.dist | 0.768 |
s.KO | -0.355 |
s.drug | 0.681 |
p.KO | 4.6e-09 |
p.drug | 2.66e-29 |
Gene | KO | drug |
---|---|---|
RPL22L1 | -10448 | 12221 |
RPL9 | -9659 | 12806 |
RPS17 | -10534 | 11631 |
RPL34 | -9357 | 12996 |
RPL12 | -9329 | 12992 |
RPL26L1 | -9387 | 12770 |
RPS13 | -9450 | 12652 |
RPS25 | -9371 | 12690 |
RPL37A | -9347 | 12675 |
RPS18 | -9122 | 12984 |
RPL17 | -8989 | 12909 |
RPL31 | -8781 | 13131 |
RPS6 | -9225 | 12405 |
RPS15A | -8754 | 12989 |
RPL36 | -8818 | 12868 |
FAU | -8610 | 13102 |
RPL26 | -8797 | 12658 |
RPLP2 | -8225 | 12999 |
RPL11 | -8529 | 12382 |
RPL35 | -8027 | 13097 |
KO | drug | |
---|---|---|
EEFSEC | 11184 | -3492 |
FAU | -8610 | 13102 |
PSTK | 5756 | 9314 |
RPL10 | -3821 | 1598 |
RPL10A | -9707 | -8212 |
RPL11 | -8529 | 12382 |
RPL12 | -9329 | 12992 |
RPL13 | -3469 | 12598 |
RPL13A | -6854 | 6955 |
RPL14 | -6386 | 13137 |
RPL15 | -786 | 12153 |
RPL17 | -8989 | 12909 |
RPL18 | -6672 | 12800 |
RPL18A | -6976 | 11926 |
RPL19 | 3924 | 12911 |
RPL21 | -6322 | 5141 |
RPL22 | -5554 | 9520 |
RPL22L1 | -10448 | 12221 |
RPL23 | 5769 | 12922 |
RPL23A | 11361 | -5257 |
RPL24 | -4591 | 12995 |
RPL26 | -8797 | 12658 |
RPL26L1 | -9387 | 12770 |
RPL27 | 6735 | 11625 |
RPL27A | -7818 | 13051 |
RPL28 | -5809 | 12962 |
RPL29 | -4515 | 12915 |
RPL3 | -6827 | -4536 |
RPL30 | -3907 | 11096 |
RPL31 | -8781 | 13131 |
RPL32 | -5028 | 12983 |
RPL34 | -9357 | 12996 |
RPL35 | -8027 | 13097 |
RPL35A | -1449 | 12789 |
RPL36 | -8818 | 12868 |
RPL36A | -4480 | 13010 |
RPL36AL | -8216 | 12702 |
RPL37 | -4624 | 13134 |
RPL37A | -9347 | 12675 |
RPL38 | 1558 | 13140 |
RPL39 | -6168 | 11962 |
RPL39L | -6608 | -6269 |
RPL3L | -510 | 7904 |
RPL4 | 11351 | 12558 |
RPL41 | -4616 | -6075 |
RPL5 | 4679 | 12075 |
RPL6 | -6903 | 12730 |
RPL7 | -3327 | -8789 |
RPL7A | -6163 | 11708 |
RPL8 | -7572 | 10323 |
RPL9 | -9659 | 12806 |
RPLP0 | -1504 | -7331 |
RPLP1 | 9026 | 12731 |
RPLP2 | -8225 | 12999 |
RPS10 | -8384 | 10665 |
RPS11 | -7725 | 12935 |
RPS12 | -7872 | 11600 |
RPS13 | -9450 | 12652 |
RPS14 | -1180 | 12428 |
RPS15 | -7430 | 12908 |
RPS15A | -8754 | 12989 |
RPS16 | -3844 | 12941 |
RPS17 | -10534 | 11631 |
RPS18 | -9122 | 12984 |
RPS19 | -7633 | 12888 |
RPS2 | -10222 | 8916 |
RPS20 | -4961 | 13095 |
RPS21 | -3001 | 13022 |
RPS23 | 6940 | 11907 |
RPS24 | 2369 | 13034 |
RPS25 | -9371 | 12690 |
RPS26 | -2615 | 13114 |
RPS27 | 651 | 11270 |
RPS27A | 5357 | 6464 |
RPS27L | 7330 | 12750 |
RPS28 | 2716 | 12485 |
RPS29 | -652 | 9078 |
RPS3 | -7756 | 12135 |
RPS3A | -9170 | 5257 |
RPS4X | -8542 | 12239 |
RPS5 | -6283 | -7965 |
RPS6 | -9225 | 12405 |
RPS7 | 5142 | 12976 |
RPS8 | -5812 | 12745 |
RPS9 | -8815 | 10189 |
RPSA | 292 | 11576 |
SARS1 | 10748 | -9421 |
SECISBP2 | 11207 | -6517 |
SEPHS2 | 8103 | -351 |
SEPSECS | -6443 | -5096 |
UBA52 | -6807 | 11639 |
Formation of the ternary complex, and subsequently, the 43S complex
metric | value |
---|---|
setSize | 50 |
pMANOVA | 7.28e-20 |
p.adjustMANOVA | 1.67e-18 |
s.dist | 0.731 |
s.KO | -0.501 |
s.drug | 0.532 |
p.KO | 8.83e-10 |
p.drug | 7.23e-11 |
Gene | KO | drug |
---|---|---|
RPS17 | -10534 | 11631 |
RPS13 | -9450 | 12652 |
RPS25 | -9371 | 12690 |
RPS18 | -9122 | 12984 |
RPS6 | -9225 | 12405 |
RPS15A | -8754 | 12989 |
FAU | -8610 | 13102 |
RPS4X | -8542 | 12239 |
RPS11 | -7725 | 12935 |
EIF3C | -8843 | 11244 |
RPS19 | -7633 | 12888 |
EIF3M | -10718 | 9044 |
EIF3I | -7897 | 12235 |
RPS15 | -7430 | 12908 |
EIF3E | -9070 | 10545 |
RPS3 | -7756 | 12135 |
RPS12 | -7872 | 11600 |
RPS2 | -10222 | 8916 |
RPS9 | -8815 | 10189 |
RPS10 | -8384 | 10665 |
KO | drug | |
---|---|---|
EIF1AX | -5479 | 11112 |
EIF2S1 | -8950 | -8774 |
EIF2S2 | -10653 | -6089 |
EIF2S3 | -10174 | -5022 |
EIF3A | -5233 | -9195 |
EIF3B | -4779 | -8277 |
EIF3C | -8843 | 11244 |
EIF3D | -10400 | -7621 |
EIF3E | -9070 | 10545 |
EIF3F | -1343 | -5879 |
EIF3G | -7655 | 4326 |
EIF3H | -8110 | -1879 |
EIF3I | -7897 | 12235 |
EIF3J | -4825 | -4367 |
EIF3K | -2668 | 9951 |
EIF3L | -9160 | -8016 |
EIF3M | -10718 | 9044 |
FAU | -8610 | 13102 |
RPS10 | -8384 | 10665 |
RPS11 | -7725 | 12935 |
RPS12 | -7872 | 11600 |
RPS13 | -9450 | 12652 |
RPS14 | -1180 | 12428 |
RPS15 | -7430 | 12908 |
RPS15A | -8754 | 12989 |
RPS16 | -3844 | 12941 |
RPS17 | -10534 | 11631 |
RPS18 | -9122 | 12984 |
RPS19 | -7633 | 12888 |
RPS2 | -10222 | 8916 |
RPS20 | -4961 | 13095 |
RPS21 | -3001 | 13022 |
RPS23 | 6940 | 11907 |
RPS24 | 2369 | 13034 |
RPS25 | -9371 | 12690 |
RPS26 | -2615 | 13114 |
RPS27 | 651 | 11270 |
RPS27A | 5357 | 6464 |
RPS27L | 7330 | 12750 |
RPS28 | 2716 | 12485 |
RPS29 | -652 | 9078 |
RPS3 | -7756 | 12135 |
RPS3A | -9170 | 5257 |
RPS4X | -8542 | 12239 |
RPS5 | -6283 | -7965 |
RPS6 | -9225 | 12405 |
RPS7 | 5142 | 12976 |
RPS8 | -5812 | 12745 |
RPS9 | -8815 | 10189 |
RPSA | 292 | 11576 |
Syndecan interactions
metric | value |
---|---|
setSize | 19 |
pMANOVA | 5.07e-10 |
p.adjustMANOVA | 4.45e-09 |
s.dist | 0.844 |
s.KO | 0.216 |
s.drug | -0.816 |
p.KO | 0.104 |
p.drug | 7.21e-10 |
Gene | KO | drug |
---|---|---|
ITGB3 | 12688 | -11286 |
SDC4 | 12322 | -10633 |
PRKCA | 12366 | -10396 |
ITGB5 | 12503 | -10104 |
ITGB4 | 12465 | -8452 |
THBS1 | 12626 | -7518 |
ITGA2 | 8062 | -11213 |
ACTN1 | 8122 | -10816 |
SDC1 | 12230 | -7104 |
SDC3 | 12401 | -6760 |
ITGAV | 144 | -11011 |
KO | drug | |
---|---|---|
ACTN1 | 8122 | -10816 |
CASK | -5732 | -8641 |
FGF2 | -5091 | -5204 |
ITGA2 | 8062 | -11213 |
ITGA6 | -7384 | -11184 |
ITGAV | 144 | -11011 |
ITGB1 | -3655 | -11215 |
ITGB3 | 12688 | -11286 |
ITGB4 | 12465 | -8452 |
ITGB5 | 12503 | -10104 |
PRKCA | 12366 | -10396 |
SDC1 | 12230 | -7104 |
SDC2 | -6754 | -5737 |
SDC3 | 12401 | -6760 |
SDC4 | 12322 | -10633 |
TGFB1 | -3526 | -8816 |
THBS1 | 12626 | -7518 |
TNC | -10537 | -10838 |
TRAPPC4 | -10355 | -4660 |
Mucopolysaccharidoses
metric | value |
---|---|
setSize | 11 |
pMANOVA | 1.36e-05 |
p.adjustMANOVA | 4.58e-05 |
s.dist | 0.799 |
s.KO | 0.756 |
s.drug | -0.258 |
p.KO | 1.41e-05 |
p.drug | 0.138 |
Gene | KO | drug |
---|---|---|
GNS | 11099 | -11125 |
GLB1 | 10162 | -9240 |
ARSB | 12086 | -7494 |
IDS | 8178 | -10132 |
GALNS | 11751 | -6370 |
NAGLU | 12163 | -5299 |
HGSNAT | 6442 | -3959 |
KO | drug | |
---|---|---|
ARSB | 12086 | -7494 |
GALNS | 11751 | -6370 |
GLB1 | 10162 | -9240 |
GNS | 11099 | -11125 |
GUSB | 9430 | 8910 |
HGSNAT | 6442 | -3959 |
HYAL1 | 4794 | 556 |
IDS | 8178 | -10132 |
IDUA | 11538 | 11620 |
NAGLU | 12163 | -5299 |
SGSH | 11466 | 8231 |
Defective B4GALT7 causes EDS, progeroid type
metric | value |
---|---|
setSize | 18 |
pMANOVA | 1.1e-07 |
p.adjustMANOVA | 5.83e-07 |
s.dist | 0.739 |
s.KO | 0.371 |
s.drug | -0.639 |
p.KO | 0.00644 |
p.drug | 2.71e-06 |
Gene | KO | drug |
---|---|---|
CSPG4 | 12459 | -11273 |
AGRN | 12518 | -11205 |
SDC4 | 12322 | -10633 |
GPC4 | 11190 | -8942 |
SDC1 | 12230 | -7104 |
SDC3 | 12401 | -6760 |
B4GALT7 | 10562 | -4980 |
BCAN | 12079 | -4013 |
GPC5 | 7673 | -3135 |
BGN | 11953 | -1313 |
GPC1 | 1951 | -7922 |
NCAN | 3533 | -1773 |
CSPG5 | 545 | -3163 |
KO | drug | |
---|---|---|
AGRN | 12518 | -11205 |
B4GALT7 | 10562 | -4980 |
BCAN | 12079 | -4013 |
BGN | 11953 | -1313 |
CSPG4 | 12459 | -11273 |
CSPG5 | 545 | -3163 |
GPC1 | 1951 | -7922 |
GPC2 | -3913 | -3279 |
GPC4 | 11190 | -8942 |
GPC5 | 7673 | -3135 |
GPC6 | -6095 | -11229 |
HSPG2 | -9046 | -9768 |
NCAN | 3533 | -1773 |
SDC1 | 12230 | -7104 |
SDC2 | -6754 | -5737 |
SDC3 | 12401 | -6760 |
SDC4 | 12322 | -10633 |
VCAN | -1861 | -11263 |
L13a-mediated translational silencing of Ceruloplasmin expression
metric | value |
---|---|
setSize | 109 |
pMANOVA | 3.24e-39 |
p.adjustMANOVA | 2.26e-37 |
s.dist | 0.702 |
s.KO | -0.466 |
s.drug | 0.525 |
p.KO | 3.94e-17 |
p.drug | 2.32e-21 |
Gene | KO | drug |
---|---|---|
RPL22L1 | -10448 | 12221 |
RPL9 | -9659 | 12806 |
RPS17 | -10534 | 11631 |
RPL34 | -9357 | 12996 |
RPL12 | -9329 | 12992 |
RPL26L1 | -9387 | 12770 |
RPS13 | -9450 | 12652 |
RPS25 | -9371 | 12690 |
RPL37A | -9347 | 12675 |
RPS18 | -9122 | 12984 |
RPL17 | -8989 | 12909 |
RPL31 | -8781 | 13131 |
RPS6 | -9225 | 12405 |
RPS15A | -8754 | 12989 |
RPL36 | -8818 | 12868 |
FAU | -8610 | 13102 |
RPL26 | -8797 | 12658 |
RPLP2 | -8225 | 12999 |
RPL11 | -8529 | 12382 |
RPL35 | -8027 | 13097 |
KO | drug | |
---|---|---|
EIF1AX | -5479 | 11112 |
EIF2S1 | -8950 | -8774 |
EIF2S2 | -10653 | -6089 |
EIF2S3 | -10174 | -5022 |
EIF3A | -5233 | -9195 |
EIF3B | -4779 | -8277 |
EIF3C | -8843 | 11244 |
EIF3D | -10400 | -7621 |
EIF3E | -9070 | 10545 |
EIF3F | -1343 | -5879 |
EIF3G | -7655 | 4326 |
EIF3H | -8110 | -1879 |
EIF3I | -7897 | 12235 |
EIF3J | -4825 | -4367 |
EIF3K | -2668 | 9951 |
EIF3L | -9160 | -8016 |
EIF3M | -10718 | 9044 |
EIF4A1 | -8156 | -2754 |
EIF4A2 | -9799 | -8479 |
EIF4B | -9005 | -10529 |
EIF4E | -10282 | -8119 |
EIF4G1 | 9159 | -10287 |
EIF4H | -10967 | -8512 |
FAU | -8610 | 13102 |
PABPC1 | -7033 | -10406 |
RPL10 | -3821 | 1598 |
RPL10A | -9707 | -8212 |
RPL11 | -8529 | 12382 |
RPL12 | -9329 | 12992 |
RPL13 | -3469 | 12598 |
RPL13A | -6854 | 6955 |
RPL14 | -6386 | 13137 |
RPL15 | -786 | 12153 |
RPL17 | -8989 | 12909 |
RPL18 | -6672 | 12800 |
RPL18A | -6976 | 11926 |
RPL19 | 3924 | 12911 |
RPL21 | -6322 | 5141 |
RPL22 | -5554 | 9520 |
RPL22L1 | -10448 | 12221 |
RPL23 | 5769 | 12922 |
RPL23A | 11361 | -5257 |
RPL24 | -4591 | 12995 |
RPL26 | -8797 | 12658 |
RPL26L1 | -9387 | 12770 |
RPL27 | 6735 | 11625 |
RPL27A | -7818 | 13051 |
RPL28 | -5809 | 12962 |
RPL29 | -4515 | 12915 |
RPL3 | -6827 | -4536 |
RPL30 | -3907 | 11096 |
RPL31 | -8781 | 13131 |
RPL32 | -5028 | 12983 |
RPL34 | -9357 | 12996 |
RPL35 | -8027 | 13097 |
RPL35A | -1449 | 12789 |
RPL36 | -8818 | 12868 |
RPL36A | -4480 | 13010 |
RPL36AL | -8216 | 12702 |
RPL37 | -4624 | 13134 |
RPL37A | -9347 | 12675 |
RPL38 | 1558 | 13140 |
RPL39 | -6168 | 11962 |
RPL39L | -6608 | -6269 |
RPL3L | -510 | 7904 |
RPL4 | 11351 | 12558 |
RPL41 | -4616 | -6075 |
RPL5 | 4679 | 12075 |
RPL6 | -6903 | 12730 |
RPL7 | -3327 | -8789 |
RPL7A | -6163 | 11708 |
RPL8 | -7572 | 10323 |
RPL9 | -9659 | 12806 |
RPLP0 | -1504 | -7331 |
RPLP1 | 9026 | 12731 |
RPLP2 | -8225 | 12999 |
RPS10 | -8384 | 10665 |
RPS11 | -7725 | 12935 |
RPS12 | -7872 | 11600 |
RPS13 | -9450 | 12652 |
RPS14 | -1180 | 12428 |
RPS15 | -7430 | 12908 |
RPS15A | -8754 | 12989 |
RPS16 | -3844 | 12941 |
RPS17 | -10534 | 11631 |
RPS18 | -9122 | 12984 |
RPS19 | -7633 | 12888 |
RPS2 | -10222 | 8916 |
RPS20 | -4961 | 13095 |
RPS21 | -3001 | 13022 |
RPS23 | 6940 | 11907 |
RPS24 | 2369 | 13034 |
RPS25 | -9371 | 12690 |
RPS26 | -2615 | 13114 |
RPS27 | 651 | 11270 |
RPS27A | 5357 | 6464 |
RPS27L | 7330 | 12750 |
RPS28 | 2716 | 12485 |
RPS29 | -652 | 9078 |
RPS3 | -7756 | 12135 |
RPS3A | -9170 | 5257 |
RPS4X | -8542 | 12239 |
RPS5 | -6283 | -7965 |
RPS6 | -9225 | 12405 |
RPS7 | 5142 | 12976 |
RPS8 | -5812 | 12745 |
RPS9 | -8815 | 10189 |
RPSA | 292 | 11576 |
UBA52 | -6807 | 11639 |
GTP hydrolysis and joining of the 60S ribosomal subunit
metric | value |
---|---|
setSize | 110 |
pMANOVA | 3.32e-38 |
p.adjustMANOVA | 2.03e-36 |
s.dist | 0.69 |
s.KO | -0.442 |
s.drug | 0.53 |
p.KO | 1.11e-15 |
p.drug | 6.6e-22 |
Gene | KO | drug |
---|---|---|
RPL22L1 | -10448 | 12221 |
RPL9 | -9659 | 12806 |
RPS17 | -10534 | 11631 |
RPL34 | -9357 | 12996 |
RPL12 | -9329 | 12992 |
RPL26L1 | -9387 | 12770 |
RPS13 | -9450 | 12652 |
RPS25 | -9371 | 12690 |
RPL37A | -9347 | 12675 |
RPS18 | -9122 | 12984 |
RPL17 | -8989 | 12909 |
RPL31 | -8781 | 13131 |
RPS6 | -9225 | 12405 |
RPS15A | -8754 | 12989 |
RPL36 | -8818 | 12868 |
FAU | -8610 | 13102 |
RPL26 | -8797 | 12658 |
RPLP2 | -8225 | 12999 |
RPL11 | -8529 | 12382 |
RPL35 | -8027 | 13097 |
KO | drug | |
---|---|---|
EIF1AX | -5479 | 11112 |
EIF2S1 | -8950 | -8774 |
EIF2S2 | -10653 | -6089 |
EIF2S3 | -10174 | -5022 |
EIF3A | -5233 | -9195 |
EIF3B | -4779 | -8277 |
EIF3C | -8843 | 11244 |
EIF3D | -10400 | -7621 |
EIF3E | -9070 | 10545 |
EIF3F | -1343 | -5879 |
EIF3G | -7655 | 4326 |
EIF3H | -8110 | -1879 |
EIF3I | -7897 | 12235 |
EIF3J | -4825 | -4367 |
EIF3K | -2668 | 9951 |
EIF3L | -9160 | -8016 |
EIF3M | -10718 | 9044 |
EIF4A1 | -8156 | -2754 |
EIF4A2 | -9799 | -8479 |
EIF4B | -9005 | -10529 |
EIF4E | -10282 | -8119 |
EIF4G1 | 9159 | -10287 |
EIF4H | -10967 | -8512 |
EIF5 | 10203 | -9440 |
EIF5B | 10163 | 12775 |
FAU | -8610 | 13102 |
RPL10 | -3821 | 1598 |
RPL10A | -9707 | -8212 |
RPL11 | -8529 | 12382 |
RPL12 | -9329 | 12992 |
RPL13 | -3469 | 12598 |
RPL13A | -6854 | 6955 |
RPL14 | -6386 | 13137 |
RPL15 | -786 | 12153 |
RPL17 | -8989 | 12909 |
RPL18 | -6672 | 12800 |
RPL18A | -6976 | 11926 |
RPL19 | 3924 | 12911 |
RPL21 | -6322 | 5141 |
RPL22 | -5554 | 9520 |
RPL22L1 | -10448 | 12221 |
RPL23 | 5769 | 12922 |
RPL23A | 11361 | -5257 |
RPL24 | -4591 | 12995 |
RPL26 | -8797 | 12658 |
RPL26L1 | -9387 | 12770 |
RPL27 | 6735 | 11625 |
RPL27A | -7818 | 13051 |
RPL28 | -5809 | 12962 |
RPL29 | -4515 | 12915 |
RPL3 | -6827 | -4536 |
RPL30 | -3907 | 11096 |
RPL31 | -8781 | 13131 |
RPL32 | -5028 | 12983 |
RPL34 | -9357 | 12996 |
RPL35 | -8027 | 13097 |
RPL35A | -1449 | 12789 |
RPL36 | -8818 | 12868 |
RPL36A | -4480 | 13010 |
RPL36AL | -8216 | 12702 |
RPL37 | -4624 | 13134 |
RPL37A | -9347 | 12675 |
RPL38 | 1558 | 13140 |
RPL39 | -6168 | 11962 |
RPL39L | -6608 | -6269 |
RPL3L | -510 | 7904 |
RPL4 | 11351 | 12558 |
RPL41 | -4616 | -6075 |
RPL5 | 4679 | 12075 |
RPL6 | -6903 | 12730 |
RPL7 | -3327 | -8789 |
RPL7A | -6163 | 11708 |
RPL8 | -7572 | 10323 |
RPL9 | -9659 | 12806 |
RPLP0 | -1504 | -7331 |
RPLP1 | 9026 | 12731 |
RPLP2 | -8225 | 12999 |
RPS10 | -8384 | 10665 |
RPS11 | -7725 | 12935 |
RPS12 | -7872 | 11600 |
RPS13 | -9450 | 12652 |
RPS14 | -1180 | 12428 |
RPS15 | -7430 | 12908 |
RPS15A | -8754 | 12989 |
RPS16 | -3844 | 12941 |
RPS17 | -10534 | 11631 |
RPS18 | -9122 | 12984 |
RPS19 | -7633 | 12888 |
RPS2 | -10222 | 8916 |
RPS20 | -4961 | 13095 |
RPS21 | -3001 | 13022 |
RPS23 | 6940 | 11907 |
RPS24 | 2369 | 13034 |
RPS25 | -9371 | 12690 |
RPS26 | -2615 | 13114 |
RPS27 | 651 | 11270 |
RPS27A | 5357 | 6464 |
RPS27L | 7330 | 12750 |
RPS28 | 2716 | 12485 |
RPS29 | -652 | 9078 |
RPS3 | -7756 | 12135 |
RPS3A | -9170 | 5257 |
RPS4X | -8542 | 12239 |
RPS5 | -6283 | -7965 |
RPS6 | -9225 | 12405 |
RPS7 | 5142 | 12976 |
RPS8 | -5812 | 12745 |
RPS9 | -8815 | 10189 |
RPSA | 292 | 11576 |
UBA52 | -6807 | 11639 |
Defective B3GAT3 causes JDSSDHD
metric | value |
---|---|
setSize | 18 |
pMANOVA | 9.01e-07 |
p.adjustMANOVA | 3.96e-06 |
s.dist | 0.687 |
s.KO | 0.376 |
s.drug | -0.575 |
p.KO | 0.00569 |
p.drug | 2.43e-05 |
Gene | KO | drug |
---|---|---|
CSPG4 | 12459 | -11273 |
AGRN | 12518 | -11205 |
SDC4 | 12322 | -10633 |
GPC4 | 11190 | -8942 |
SDC1 | 12230 | -7104 |
SDC3 | 12401 | -6760 |
BCAN | 12079 | -4013 |
GPC5 | 7673 | -3135 |
BGN | 11953 | -1313 |
GPC1 | 1951 | -7922 |
NCAN | 3533 | -1773 |
CSPG5 | 545 | -3163 |
KO | drug | |
---|---|---|
AGRN | 12518 | -11205 |
B3GAT3 | 11784 | 9103 |
BCAN | 12079 | -4013 |
BGN | 11953 | -1313 |
CSPG4 | 12459 | -11273 |
CSPG5 | 545 | -3163 |
GPC1 | 1951 | -7922 |
GPC2 | -3913 | -3279 |
GPC4 | 11190 | -8942 |
GPC5 | 7673 | -3135 |
GPC6 | -6095 | -11229 |
HSPG2 | -9046 | -9768 |
NCAN | 3533 | -1773 |
SDC1 | 12230 | -7104 |
SDC2 | -6754 | -5737 |
SDC3 | 12401 | -6760 |
SDC4 | 12322 | -10633 |
VCAN | -1861 | -11263 |
Other semaphorin interactions
metric | value |
---|---|
setSize | 15 |
pMANOVA | 8.68e-06 |
p.adjustMANOVA | 3.06e-05 |
s.dist | 0.689 |
s.KO | 0.359 |
s.drug | -0.588 |
p.KO | 0.0159 |
p.drug | 7.98e-05 |
Gene | KO | drug |
---|---|---|
PLXNA1 | 12834 | -10985 |
ITGA1 | 12258 | -10552 |
PLXNA4 | 11726 | -9845 |
SEMA7A | 9143 | -11223 |
SEMA6A | 12824 | -7654 |
PLXNB3 | 11348 | -6567 |
PLXND1 | 11557 | -4291 |
PLXNC1 | 7782 | -4731 |
KO | drug | |
---|---|---|
CD72 | -627 | 3306 |
ITGA1 | 12258 | -10552 |
ITGB1 | -3655 | -11215 |
PLXNA1 | 12834 | -10985 |
PLXNA2 | -1563 | -6909 |
PLXNA4 | 11726 | -9845 |
PLXNB3 | 11348 | -6567 |
PLXNC1 | 7782 | -4731 |
PLXND1 | 11557 | -4291 |
SEMA4A | -31 | 5409 |
SEMA4D | 9903 | 32 |
SEMA5A | -11537 | -10912 |
SEMA6A | 12824 | -7654 |
SEMA6D | -5924 | -7539 |
SEMA7A | 9143 | -11223 |
Defective B3GALT6 causes EDSP2 and SEMDJL1
metric | value |
---|---|
setSize | 18 |
pMANOVA | 1.31e-06 |
p.adjustMANOVA | 5.63e-06 |
s.dist | 0.677 |
s.KO | 0.375 |
s.drug | -0.564 |
p.KO | 0.00592 |
p.drug | 3.38e-05 |
Gene | KO | drug |
---|---|---|
CSPG4 | 12459 | -11273 |
AGRN | 12518 | -11205 |
SDC4 | 12322 | -10633 |
GPC4 | 11190 | -8942 |
SDC1 | 12230 | -7104 |
SDC3 | 12401 | -6760 |
BCAN | 12079 | -4013 |
GPC5 | 7673 | -3135 |
BGN | 11953 | -1313 |
GPC1 | 1951 | -7922 |
NCAN | 3533 | -1773 |
CSPG5 | 545 | -3163 |
KO | drug | |
---|---|---|
AGRN | 12518 | -11205 |
B3GALT6 | 11393 | 11355 |
BCAN | 12079 | -4013 |
BGN | 11953 | -1313 |
CSPG4 | 12459 | -11273 |
CSPG5 | 545 | -3163 |
GPC1 | 1951 | -7922 |
GPC2 | -3913 | -3279 |
GPC4 | 11190 | -8942 |
GPC5 | 7673 | -3135 |
GPC6 | -6095 | -11229 |
HSPG2 | -9046 | -9768 |
NCAN | 3533 | -1773 |
SDC1 | 12230 | -7104 |
SDC2 | -6754 | -5737 |
SDC3 | 12401 | -6760 |
SDC4 | 12322 | -10633 |
VCAN | -1861 | -11263 |
Cap-dependent Translation Initiation
metric | value |
---|---|
setSize | 117 |
pMANOVA | 2.43e-37 |
p.adjustMANOVA | 1.32e-35 |
s.dist | 0.662 |
s.KO | -0.423 |
s.drug | 0.509 |
p.KO | 2.56e-15 |
p.drug | 1.77e-21 |
Gene | KO | drug |
---|---|---|
EIF4EBP1 | -11425 | 12142 |
RPL22L1 | -10448 | 12221 |
RPL9 | -9659 | 12806 |
RPS17 | -10534 | 11631 |
RPL34 | -9357 | 12996 |
RPL12 | -9329 | 12992 |
RPL26L1 | -9387 | 12770 |
RPS13 | -9450 | 12652 |
RPS25 | -9371 | 12690 |
RPL37A | -9347 | 12675 |
RPS18 | -9122 | 12984 |
RPL17 | -8989 | 12909 |
RPL31 | -8781 | 13131 |
RPS6 | -9225 | 12405 |
RPS15A | -8754 | 12989 |
RPL36 | -8818 | 12868 |
FAU | -8610 | 13102 |
RPL26 | -8797 | 12658 |
RPLP2 | -8225 | 12999 |
RPL11 | -8529 | 12382 |
KO | drug | |
---|---|---|
EIF1AX | -5479 | 11112 |
EIF2B1 | 11179 | 11041 |
EIF2B2 | -2856 | -6814 |
EIF2B3 | 3812 | 8509 |
EIF2B4 | -8202 | 8563 |
EIF2B5 | 8652 | -2008 |
EIF2S1 | -8950 | -8774 |
EIF2S2 | -10653 | -6089 |
EIF2S3 | -10174 | -5022 |
EIF3A | -5233 | -9195 |
EIF3B | -4779 | -8277 |
EIF3C | -8843 | 11244 |
EIF3D | -10400 | -7621 |
EIF3E | -9070 | 10545 |
EIF3F | -1343 | -5879 |
EIF3G | -7655 | 4326 |
EIF3H | -8110 | -1879 |
EIF3I | -7897 | 12235 |
EIF3J | -4825 | -4367 |
EIF3K | -2668 | 9951 |
EIF3L | -9160 | -8016 |
EIF3M | -10718 | 9044 |
EIF4A1 | -8156 | -2754 |
EIF4A2 | -9799 | -8479 |
EIF4B | -9005 | -10529 |
EIF4E | -10282 | -8119 |
EIF4EBP1 | -11425 | 12142 |
EIF4G1 | 9159 | -10287 |
EIF4H | -10967 | -8512 |
EIF5 | 10203 | -9440 |
EIF5B | 10163 | 12775 |
FAU | -8610 | 13102 |
PABPC1 | -7033 | -10406 |
RPL10 | -3821 | 1598 |
RPL10A | -9707 | -8212 |
RPL11 | -8529 | 12382 |
RPL12 | -9329 | 12992 |
RPL13 | -3469 | 12598 |
RPL13A | -6854 | 6955 |
RPL14 | -6386 | 13137 |
RPL15 | -786 | 12153 |
RPL17 | -8989 | 12909 |
RPL18 | -6672 | 12800 |
RPL18A | -6976 | 11926 |
RPL19 | 3924 | 12911 |
RPL21 | -6322 | 5141 |
RPL22 | -5554 | 9520 |
RPL22L1 | -10448 | 12221 |
RPL23 | 5769 | 12922 |
RPL23A | 11361 | -5257 |
RPL24 | -4591 | 12995 |
RPL26 | -8797 | 12658 |
RPL26L1 | -9387 | 12770 |
RPL27 | 6735 | 11625 |
RPL27A | -7818 | 13051 |
RPL28 | -5809 | 12962 |
RPL29 | -4515 | 12915 |
RPL3 | -6827 | -4536 |
RPL30 | -3907 | 11096 |
RPL31 | -8781 | 13131 |
RPL32 | -5028 | 12983 |
RPL34 | -9357 | 12996 |
RPL35 | -8027 | 13097 |
RPL35A | -1449 | 12789 |
RPL36 | -8818 | 12868 |
RPL36A | -4480 | 13010 |
RPL36AL | -8216 | 12702 |
RPL37 | -4624 | 13134 |
RPL37A | -9347 | 12675 |
RPL38 | 1558 | 13140 |
RPL39 | -6168 | 11962 |
RPL39L | -6608 | -6269 |
RPL3L | -510 | 7904 |
RPL4 | 11351 | 12558 |
RPL41 | -4616 | -6075 |
RPL5 | 4679 | 12075 |
RPL6 | -6903 | 12730 |
RPL7 | -3327 | -8789 |
RPL7A | -6163 | 11708 |
RPL8 | -7572 | 10323 |
RPL9 | -9659 | 12806 |
RPLP0 | -1504 | -7331 |
RPLP1 | 9026 | 12731 |
RPLP2 | -8225 | 12999 |
RPS10 | -8384 | 10665 |
RPS11 | -7725 | 12935 |
RPS12 | -7872 | 11600 |
RPS13 | -9450 | 12652 |
RPS14 | -1180 | 12428 |
RPS15 | -7430 | 12908 |
RPS15A | -8754 | 12989 |
RPS16 | -3844 | 12941 |
RPS17 | -10534 | 11631 |
RPS18 | -9122 | 12984 |
RPS19 | -7633 | 12888 |
RPS2 | -10222 | 8916 |
RPS20 | -4961 | 13095 |
RPS21 | -3001 | 13022 |
RPS23 | 6940 | 11907 |
RPS24 | 2369 | 13034 |
RPS25 | -9371 | 12690 |
RPS26 | -2615 | 13114 |
RPS27 | 651 | 11270 |
RPS27A | 5357 | 6464 |
RPS27L | 7330 | 12750 |
RPS28 | 2716 | 12485 |
RPS29 | -652 | 9078 |
RPS3 | -7756 | 12135 |
RPS3A | -9170 | 5257 |
RPS4X | -8542 | 12239 |
RPS5 | -6283 | -7965 |
RPS6 | -9225 | 12405 |
RPS7 | 5142 | 12976 |
RPS8 | -5812 | 12745 |
RPS9 | -8815 | 10189 |
RPSA | 292 | 11576 |
UBA52 | -6807 | 11639 |
Eukaryotic Translation Initiation
metric | value |
---|---|
setSize | 117 |
pMANOVA | 2.43e-37 |
p.adjustMANOVA | 1.32e-35 |
s.dist | 0.662 |
s.KO | -0.423 |
s.drug | 0.509 |
p.KO | 2.56e-15 |
p.drug | 1.77e-21 |
Gene | KO | drug |
---|---|---|
EIF4EBP1 | -11425 | 12142 |
RPL22L1 | -10448 | 12221 |
RPL9 | -9659 | 12806 |
RPS17 | -10534 | 11631 |
RPL34 | -9357 | 12996 |
RPL12 | -9329 | 12992 |
RPL26L1 | -9387 | 12770 |
RPS13 | -9450 | 12652 |
RPS25 | -9371 | 12690 |
RPL37A | -9347 | 12675 |
RPS18 | -9122 | 12984 |
RPL17 | -8989 | 12909 |
RPL31 | -8781 | 13131 |
RPS6 | -9225 | 12405 |
RPS15A | -8754 | 12989 |
RPL36 | -8818 | 12868 |
FAU | -8610 | 13102 |
RPL26 | -8797 | 12658 |
RPLP2 | -8225 | 12999 |
RPL11 | -8529 | 12382 |
KO | drug | |
---|---|---|
EIF1AX | -5479 | 11112 |
EIF2B1 | 11179 | 11041 |
EIF2B2 | -2856 | -6814 |
EIF2B3 | 3812 | 8509 |
EIF2B4 | -8202 | 8563 |
EIF2B5 | 8652 | -2008 |
EIF2S1 | -8950 | -8774 |
EIF2S2 | -10653 | -6089 |
EIF2S3 | -10174 | -5022 |
EIF3A | -5233 | -9195 |
EIF3B | -4779 | -8277 |
EIF3C | -8843 | 11244 |
EIF3D | -10400 | -7621 |
EIF3E | -9070 | 10545 |
EIF3F | -1343 | -5879 |
EIF3G | -7655 | 4326 |
EIF3H | -8110 | -1879 |
EIF3I | -7897 | 12235 |
EIF3J | -4825 | -4367 |
EIF3K | -2668 | 9951 |
EIF3L | -9160 | -8016 |
EIF3M | -10718 | 9044 |
EIF4A1 | -8156 | -2754 |
EIF4A2 | -9799 | -8479 |
EIF4B | -9005 | -10529 |
EIF4E | -10282 | -8119 |
EIF4EBP1 | -11425 | 12142 |
EIF4G1 | 9159 | -10287 |
EIF4H | -10967 | -8512 |
EIF5 | 10203 | -9440 |
EIF5B | 10163 | 12775 |
FAU | -8610 | 13102 |
PABPC1 | -7033 | -10406 |
RPL10 | -3821 | 1598 |
RPL10A | -9707 | -8212 |
RPL11 | -8529 | 12382 |
RPL12 | -9329 | 12992 |
RPL13 | -3469 | 12598 |
RPL13A | -6854 | 6955 |
RPL14 | -6386 | 13137 |
RPL15 | -786 | 12153 |
RPL17 | -8989 | 12909 |
RPL18 | -6672 | 12800 |
RPL18A | -6976 | 11926 |
RPL19 | 3924 | 12911 |
RPL21 | -6322 | 5141 |
RPL22 | -5554 | 9520 |
RPL22L1 | -10448 | 12221 |
RPL23 | 5769 | 12922 |
RPL23A | 11361 | -5257 |
RPL24 | -4591 | 12995 |
RPL26 | -8797 | 12658 |
RPL26L1 | -9387 | 12770 |
RPL27 | 6735 | 11625 |
RPL27A | -7818 | 13051 |
RPL28 | -5809 | 12962 |
RPL29 | -4515 | 12915 |
RPL3 | -6827 | -4536 |
RPL30 | -3907 | 11096 |
RPL31 | -8781 | 13131 |
RPL32 | -5028 | 12983 |
RPL34 | -9357 | 12996 |
RPL35 | -8027 | 13097 |
RPL35A | -1449 | 12789 |
RPL36 | -8818 | 12868 |
RPL36A | -4480 | 13010 |
RPL36AL | -8216 | 12702 |
RPL37 | -4624 | 13134 |
RPL37A | -9347 | 12675 |
RPL38 | 1558 | 13140 |
RPL39 | -6168 | 11962 |
RPL39L | -6608 | -6269 |
RPL3L | -510 | 7904 |
RPL4 | 11351 | 12558 |
RPL41 | -4616 | -6075 |
RPL5 | 4679 | 12075 |
RPL6 | -6903 | 12730 |
RPL7 | -3327 | -8789 |
RPL7A | -6163 | 11708 |
RPL8 | -7572 | 10323 |
RPL9 | -9659 | 12806 |
RPLP0 | -1504 | -7331 |
RPLP1 | 9026 | 12731 |
RPLP2 | -8225 | 12999 |
RPS10 | -8384 | 10665 |
RPS11 | -7725 | 12935 |
RPS12 | -7872 | 11600 |
RPS13 | -9450 | 12652 |
RPS14 | -1180 | 12428 |
RPS15 | -7430 | 12908 |
RPS15A | -8754 | 12989 |
RPS16 | -3844 | 12941 |
RPS17 | -10534 | 11631 |
RPS18 | -9122 | 12984 |
RPS19 | -7633 | 12888 |
RPS2 | -10222 | 8916 |
RPS20 | -4961 | 13095 |
RPS21 | -3001 | 13022 |
RPS23 | 6940 | 11907 |
RPS24 | 2369 | 13034 |
RPS25 | -9371 | 12690 |
RPS26 | -2615 | 13114 |
RPS27 | 651 | 11270 |
RPS27A | 5357 | 6464 |
RPS27L | 7330 | 12750 |
RPS28 | 2716 | 12485 |
RPS29 | -652 | 9078 |
RPS3 | -7756 | 12135 |
RPS3A | -9170 | 5257 |
RPS4X | -8542 | 12239 |
RPS5 | -6283 | -7965 |
RPS6 | -9225 | 12405 |
RPS7 | 5142 | 12976 |
RPS8 | -5812 | 12745 |
RPS9 | -8815 | 10189 |
RPSA | 292 | 11576 |
UBA52 | -6807 | 11639 |
SRP-dependent cotranslational protein targeting to membrane
metric | value |
---|---|
setSize | 110 |
pMANOVA | 3.9e-35 |
p.adjustMANOVA | 1.97e-33 |
s.dist | 0.662 |
s.KO | -0.393 |
s.drug | 0.533 |
p.KO | 9.93e-13 |
p.drug | 4.19e-22 |
Gene | KO | drug |
---|---|---|
RPL22L1 | -10448 | 12221 |
RPL9 | -9659 | 12806 |
RPS17 | -10534 | 11631 |
RPL34 | -9357 | 12996 |
RPL12 | -9329 | 12992 |
RPL26L1 | -9387 | 12770 |
RPS13 | -9450 | 12652 |
RPS25 | -9371 | 12690 |
RPL37A | -9347 | 12675 |
RPS18 | -9122 | 12984 |
RPL17 | -8989 | 12909 |
RPL31 | -8781 | 13131 |
RPS6 | -9225 | 12405 |
RPS15A | -8754 | 12989 |
RPL36 | -8818 | 12868 |
FAU | -8610 | 13102 |
RPL26 | -8797 | 12658 |
RPLP2 | -8225 | 12999 |
RPL11 | -8529 | 12382 |
RPL35 | -8027 | 13097 |
KO | drug | |
---|---|---|
DDOST | 9438 | -6642 |
FAU | -8610 | 13102 |
RPL10 | -3821 | 1598 |
RPL10A | -9707 | -8212 |
RPL11 | -8529 | 12382 |
RPL12 | -9329 | 12992 |
RPL13 | -3469 | 12598 |
RPL13A | -6854 | 6955 |
RPL14 | -6386 | 13137 |
RPL15 | -786 | 12153 |
RPL17 | -8989 | 12909 |
RPL18 | -6672 | 12800 |
RPL18A | -6976 | 11926 |
RPL19 | 3924 | 12911 |
RPL21 | -6322 | 5141 |
RPL22 | -5554 | 9520 |
RPL22L1 | -10448 | 12221 |
RPL23 | 5769 | 12922 |
RPL23A | 11361 | -5257 |
RPL24 | -4591 | 12995 |
RPL26 | -8797 | 12658 |
RPL26L1 | -9387 | 12770 |
RPL27 | 6735 | 11625 |
RPL27A | -7818 | 13051 |
RPL28 | -5809 | 12962 |
RPL29 | -4515 | 12915 |
RPL3 | -6827 | -4536 |
RPL30 | -3907 | 11096 |
RPL31 | -8781 | 13131 |
RPL32 | -5028 | 12983 |
RPL34 | -9357 | 12996 |
RPL35 | -8027 | 13097 |
RPL35A | -1449 | 12789 |
RPL36 | -8818 | 12868 |
RPL36A | -4480 | 13010 |
RPL36AL | -8216 | 12702 |
RPL37 | -4624 | 13134 |
RPL37A | -9347 | 12675 |
RPL38 | 1558 | 13140 |
RPL39 | -6168 | 11962 |
RPL39L | -6608 | -6269 |
RPL3L | -510 | 7904 |
RPL4 | 11351 | 12558 |
RPL41 | -4616 | -6075 |
RPL5 | 4679 | 12075 |
RPL6 | -6903 | 12730 |
RPL7 | -3327 | -8789 |
RPL7A | -6163 | 11708 |
RPL8 | -7572 | 10323 |
RPL9 | -9659 | 12806 |
RPLP0 | -1504 | -7331 |
RPLP1 | 9026 | 12731 |
RPLP2 | -8225 | 12999 |
RPN1 | -4194 | 1205 |
RPN2 | 11923 | -9366 |
RPS10 | -8384 | 10665 |
RPS11 | -7725 | 12935 |
RPS12 | -7872 | 11600 |
RPS13 | -9450 | 12652 |
RPS14 | -1180 | 12428 |
RPS15 | -7430 | 12908 |
RPS15A | -8754 | 12989 |
RPS16 | -3844 | 12941 |
RPS17 | -10534 | 11631 |
RPS18 | -9122 | 12984 |
RPS19 | -7633 | 12888 |
RPS2 | -10222 | 8916 |
RPS20 | -4961 | 13095 |
RPS21 | -3001 | 13022 |
RPS23 | 6940 | 11907 |
RPS24 | 2369 | 13034 |
RPS25 | -9371 | 12690 |
RPS26 | -2615 | 13114 |
RPS27 | 651 | 11270 |
RPS27A | 5357 | 6464 |
RPS27L | 7330 | 12750 |
RPS28 | 2716 | 12485 |
RPS29 | -652 | 9078 |
RPS3 | -7756 | 12135 |
RPS3A | -9170 | 5257 |
RPS4X | -8542 | 12239 |
RPS5 | -6283 | -7965 |
RPS6 | -9225 | 12405 |
RPS7 | 5142 | 12976 |
RPS8 | -5812 | 12745 |
RPS9 | -8815 | 10189 |
RPSA | 292 | 11576 |
SEC11A | 7466 | 10882 |
SEC11C | -9228 | 9516 |
SEC61A1 | -5502 | -10602 |
SEC61A2 | -122 | -3639 |
SEC61B | -8269 | 12482 |
SEC61G | -7012 | -6414 |
SPCS1 | 1876 | 9024 |
SPCS2 | -9826 | 1441 |
SPCS3 | -4819 | -8123 |
SRP14 | 11867 | 12615 |
SRP19 | -7488 | 10214 |
SRP54 | -10408 | -9159 |
SRP68 | -8580 | -10245 |
SRP72 | -11292 | -11041 |
SRP9 | -5683 | -6445 |
SRPRA | -11264 | -9507 |
SRPRB | -4441 | 7574 |
SSR1 | -6980 | -9998 |
SSR2 | -4823 | -3645 |
SSR3 | 2021 | -10353 |
SSR4 | 4605 | 12772 |
TRAM1 | -8764 | -11121 |
UBA52 | -6807 | 11639 |
Reduction of cytosolic Ca++ levels
metric | value |
---|---|
setSize | 12 |
pMANOVA | 0.000199 |
p.adjustMANOVA | 0.000513 |
s.dist | 0.656 |
s.KO | 0.423 |
s.drug | -0.502 |
p.KO | 0.0112 |
p.drug | 0.00259 |
Gene | KO | drug |
---|---|---|
ATP2A3 | 12011 | -9206 |
ATP2B4 | 7929 | -11266 |
SLC8A2 | 11131 | -7612 |
ATP2A2 | 7536 | -11089 |
SLC8A3 | 12029 | -6726 |
CALM1 | 11329 | -6948 |
ATP2B1 | 6952 | -10931 |
SLC8A1 | 10101 | -6530 |
ATP2B2 | 1355 | -2448 |
KO | drug | |
---|---|---|
ATP2A1 | -7073 | 10801 |
ATP2A2 | 7536 | -11089 |
ATP2A3 | 12011 | -9206 |
ATP2B1 | 6952 | -10931 |
ATP2B2 | 1355 | -2448 |
ATP2B3 | 5288 | 7244 |
ATP2B4 | 7929 | -11266 |
CALM1 | 11329 | -6948 |
SLC8A1 | 10101 | -6530 |
SLC8A2 | 11131 | -7612 |
SLC8A3 | 12029 | -6726 |
SRI | -8466 | -7625 |
Non-integrin membrane-ECM interactions
metric | value |
---|---|
setSize | 41 |
pMANOVA | 1.27e-16 |
p.adjustMANOVA | 2.25e-15 |
s.dist | 0.751 |
s.KO | 0.2 |
s.drug | -0.724 |
p.KO | 0.0268 |
p.drug | 1e-15 |
Gene | KO | drug |
---|---|---|
LAMC1 | 12854 | -11227 |
ITGB3 | 12688 | -11286 |
PDGFB | 12741 | -11178 |
AGRN | 12518 | -11205 |
LAMB2 | 12607 | -10832 |
LAMA5 | 12583 | -10447 |
SDC4 | 12322 | -10633 |
LAMA1 | 12802 | -10091 |
PRKCA | 12366 | -10396 |
ITGB5 | 12503 | -10104 |
ITGB4 | 12465 | -8452 |
DDR1 | 12660 | -8206 |
THBS1 | 12626 | -7518 |
PDGFA | 12623 | -7408 |
ITGA2 | 8062 | -11213 |
ACTN1 | 8122 | -10816 |
SDC1 | 12230 | -7104 |
SDC3 | 12401 | -6760 |
LAMB3 | 7018 | -11255 |
LAMC2 | 10786 | -6533 |
KO | drug | |
---|---|---|
ACTN1 | 8122 | -10816 |
AGRN | 12518 | -11205 |
CASK | -5732 | -8641 |
DAG1 | 6148 | -8573 |
DDR1 | 12660 | -8206 |
DDR2 | -9960 | -7915 |
DMD | -237 | 910 |
FGF2 | -5091 | -5204 |
HSPG2 | -9046 | -9768 |
ITGA2 | 8062 | -11213 |
ITGA6 | -7384 | -11184 |
ITGAV | 144 | -11011 |
ITGB1 | -3655 | -11215 |
ITGB3 | 12688 | -11286 |
ITGB4 | 12465 | -8452 |
ITGB5 | 12503 | -10104 |
LAMA1 | 12802 | -10091 |
LAMA2 | -8729 | -4164 |
LAMA3 | -11238 | 4464 |
LAMA4 | -7403 | -10348 |
LAMA5 | 12583 | -10447 |
LAMB1 | -9087 | -10329 |
LAMB2 | 12607 | -10832 |
LAMB3 | 7018 | -11255 |
LAMC1 | 12854 | -11227 |
LAMC2 | 10786 | -6533 |
LAMC3 | 11660 | -2369 |
NRXN1 | -7510 | 141 |
NTN4 | -8804 | -7703 |
PDGFA | 12623 | -7408 |
PDGFB | 12741 | -11178 |
PRKCA | 12366 | -10396 |
SDC1 | 12230 | -7104 |
SDC2 | -6754 | -5737 |
SDC3 | 12401 | -6760 |
SDC4 | 12322 | -10633 |
TGFB1 | -3526 | -8816 |
THBS1 | 12626 | -7518 |
TNC | -10537 | -10838 |
TRAPPC4 | -10355 | -4660 |
TTR | -212 | 1928 |
MET activates PTK2 signaling
metric | value |
---|---|
setSize | 18 |
pMANOVA | 6.8e-08 |
p.adjustMANOVA | 3.72e-07 |
s.dist | 0.765 |
s.KO | 0.155 |
s.drug | -0.749 |
p.KO | 0.256 |
p.drug | 3.71e-08 |
Gene | KO | drug |
---|---|---|
LAMC1 | 12854 | -11227 |
LAMB2 | 12607 | -10832 |
LAMA5 | 12583 | -10447 |
LAMA1 | 12802 | -10091 |
ITGA3 | 12831 | -9596 |
MET | 10796 | -11047 |
ITGA2 | 8062 | -11213 |
LAMB3 | 7018 | -11255 |
LAMC2 | 10786 | -6533 |
LAMC3 | 11660 | -2369 |
KO | drug | |
---|---|---|
HGF | -5157 | -4177 |
ITGA2 | 8062 | -11213 |
ITGA3 | 12831 | -9596 |
ITGB1 | -3655 | -11215 |
LAMA1 | 12802 | -10091 |
LAMA2 | -8729 | -4164 |
LAMA3 | -11238 | 4464 |
LAMA4 | -7403 | -10348 |
LAMA5 | 12583 | -10447 |
LAMB1 | -9087 | -10329 |
LAMB2 | 12607 | -10832 |
LAMB3 | 7018 | -11255 |
LAMC1 | 12854 | -11227 |
LAMC2 | 10786 | -6533 |
LAMC3 | 11660 | -2369 |
MET | 10796 | -11047 |
PTK2 | -9167 | -10148 |
SRC | -11388 | -7284 |
Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S
metric | value |
---|---|
setSize | 58 |
pMANOVA | 5.49e-18 |
p.adjustMANOVA | 1.13e-16 |
s.dist | 0.646 |
s.KO | -0.521 |
s.drug | 0.382 |
p.KO | 6.74e-12 |
p.drug | 4.78e-07 |
Gene | KO | drug |
---|---|---|
EIF4EBP1 | -11425 | 12142 |
RPS17 | -10534 | 11631 |
RPS13 | -9450 | 12652 |
RPS25 | -9371 | 12690 |
RPS18 | -9122 | 12984 |
RPS6 | -9225 | 12405 |
RPS15A | -8754 | 12989 |
FAU | -8610 | 13102 |
RPS4X | -8542 | 12239 |
RPS11 | -7725 | 12935 |
EIF3C | -8843 | 11244 |
RPS19 | -7633 | 12888 |
EIF3M | -10718 | 9044 |
EIF3I | -7897 | 12235 |
RPS15 | -7430 | 12908 |
EIF3E | -9070 | 10545 |
RPS3 | -7756 | 12135 |
RPS12 | -7872 | 11600 |
RPS2 | -10222 | 8916 |
RPS9 | -8815 | 10189 |
KO | drug | |
---|---|---|
EIF1AX | -5479 | 11112 |
EIF2S1 | -8950 | -8774 |
EIF2S2 | -10653 | -6089 |
EIF2S3 | -10174 | -5022 |
EIF3A | -5233 | -9195 |
EIF3B | -4779 | -8277 |
EIF3C | -8843 | 11244 |
EIF3D | -10400 | -7621 |
EIF3E | -9070 | 10545 |
EIF3F | -1343 | -5879 |
EIF3G | -7655 | 4326 |
EIF3H | -8110 | -1879 |
EIF3I | -7897 | 12235 |
EIF3J | -4825 | -4367 |
EIF3K | -2668 | 9951 |
EIF3L | -9160 | -8016 |
EIF3M | -10718 | 9044 |
EIF4A1 | -8156 | -2754 |
EIF4A2 | -9799 | -8479 |
EIF4B | -9005 | -10529 |
EIF4E | -10282 | -8119 |
EIF4EBP1 | -11425 | 12142 |
EIF4G1 | 9159 | -10287 |
EIF4H | -10967 | -8512 |
FAU | -8610 | 13102 |
PABPC1 | -7033 | -10406 |
RPS10 | -8384 | 10665 |
RPS11 | -7725 | 12935 |
RPS12 | -7872 | 11600 |
RPS13 | -9450 | 12652 |
RPS14 | -1180 | 12428 |
RPS15 | -7430 | 12908 |
RPS15A | -8754 | 12989 |
RPS16 | -3844 | 12941 |
RPS17 | -10534 | 11631 |
RPS18 | -9122 | 12984 |
RPS19 | -7633 | 12888 |
RPS2 | -10222 | 8916 |
RPS20 | -4961 | 13095 |
RPS21 | -3001 | 13022 |
RPS23 | 6940 | 11907 |
RPS24 | 2369 | 13034 |
RPS25 | -9371 | 12690 |
RPS26 | -2615 | 13114 |
RPS27 | 651 | 11270 |
RPS27A | 5357 | 6464 |
RPS27L | 7330 | 12750 |
RPS28 | 2716 | 12485 |
RPS29 | -652 | 9078 |
RPS3 | -7756 | 12135 |
RPS3A | -9170 | 5257 |
RPS4X | -8542 | 12239 |
RPS5 | -6283 | -7965 |
RPS6 | -9225 | 12405 |
RPS7 | 5142 | 12976 |
RPS8 | -5812 | 12745 |
RPS9 | -8815 | 10189 |
RPSA | 292 | 11576 |
Mitochondrial iron-sulfur cluster biogenesis
metric | value |
---|---|
setSize | 13 |
pMANOVA | 0.000173 |
p.adjustMANOVA | 0.00045 |
s.dist | 0.635 |
s.KO | -0.437 |
s.drug | 0.462 |
p.KO | 0.00639 |
p.drug | 0.00396 |
Gene | KO | drug |
---|---|---|
SLC25A37 | -9868 | 12952 |
GLRX5 | -9519 | 11726 |
HSCB | -10466 | 7562 |
FDX1 | -8625 | 8318 |
ISCU | -6298 | 10132 |
FDX2 | -5678 | 10706 |
LYRM4 | -3448 | 10228 |
SLC25A28 | -2674 | 12676 |
KO | drug | |
---|---|---|
FDX1 | -8625 | 8318 |
FDX2 | -5678 | 10706 |
FDXR | 6797 | -10 |
FXN | 3001 | 6244 |
GLRX5 | -9519 | 11726 |
HSCB | -10466 | 7562 |
ISCA1 | -7587 | -4971 |
ISCA2 | 2253 | 4958 |
ISCU | -6298 | 10132 |
LYRM4 | -3448 | 10228 |
NFS1 | -8587 | -4816 |
SLC25A28 | -2674 | 12676 |
SLC25A37 | -9868 | 12952 |
Translation initiation complex formation
metric | value |
---|---|
setSize | 57 |
pMANOVA | 4.76e-17 |
p.adjustMANOVA | 8.61e-16 |
s.dist | 0.634 |
s.KO | -0.512 |
s.drug | 0.373 |
p.KO | 2.15e-11 |
p.drug | 1.12e-06 |
Gene | KO | drug |
---|---|---|
RPS17 | -10534 | 11631 |
RPS13 | -9450 | 12652 |
RPS25 | -9371 | 12690 |
RPS18 | -9122 | 12984 |
RPS6 | -9225 | 12405 |
RPS15A | -8754 | 12989 |
FAU | -8610 | 13102 |
RPS4X | -8542 | 12239 |
RPS11 | -7725 | 12935 |
EIF3C | -8843 | 11244 |
RPS19 | -7633 | 12888 |
EIF3M | -10718 | 9044 |
EIF3I | -7897 | 12235 |
RPS15 | -7430 | 12908 |
EIF3E | -9070 | 10545 |
RPS3 | -7756 | 12135 |
RPS12 | -7872 | 11600 |
RPS2 | -10222 | 8916 |
RPS9 | -8815 | 10189 |
RPS10 | -8384 | 10665 |
KO | drug | |
---|---|---|
EIF1AX | -5479 | 11112 |
EIF2S1 | -8950 | -8774 |
EIF2S2 | -10653 | -6089 |
EIF2S3 | -10174 | -5022 |
EIF3A | -5233 | -9195 |
EIF3B | -4779 | -8277 |
EIF3C | -8843 | 11244 |
EIF3D | -10400 | -7621 |
EIF3E | -9070 | 10545 |
EIF3F | -1343 | -5879 |
EIF3G | -7655 | 4326 |
EIF3H | -8110 | -1879 |
EIF3I | -7897 | 12235 |
EIF3J | -4825 | -4367 |
EIF3K | -2668 | 9951 |
EIF3L | -9160 | -8016 |
EIF3M | -10718 | 9044 |
EIF4A1 | -8156 | -2754 |
EIF4A2 | -9799 | -8479 |
EIF4B | -9005 | -10529 |
EIF4E | -10282 | -8119 |
EIF4G1 | 9159 | -10287 |
EIF4H | -10967 | -8512 |
FAU | -8610 | 13102 |
PABPC1 | -7033 | -10406 |
RPS10 | -8384 | 10665 |
RPS11 | -7725 | 12935 |
RPS12 | -7872 | 11600 |
RPS13 | -9450 | 12652 |
RPS14 | -1180 | 12428 |
RPS15 | -7430 | 12908 |
RPS15A | -8754 | 12989 |
RPS16 | -3844 | 12941 |
RPS17 | -10534 | 11631 |
RPS18 | -9122 | 12984 |
RPS19 | -7633 | 12888 |
RPS2 | -10222 | 8916 |
RPS20 | -4961 | 13095 |
RPS21 | -3001 | 13022 |
RPS23 | 6940 | 11907 |
RPS24 | 2369 | 13034 |
RPS25 | -9371 | 12690 |
RPS26 | -2615 | 13114 |
RPS27 | 651 | 11270 |
RPS27A | 5357 | 6464 |
RPS27L | 7330 | 12750 |
RPS28 | 2716 | 12485 |
RPS29 | -652 | 9078 |
RPS3 | -7756 | 12135 |
RPS3A | -9170 | 5257 |
RPS4X | -8542 | 12239 |
RPS5 | -6283 | -7965 |
RPS6 | -9225 | 12405 |
RPS7 | 5142 | 12976 |
RPS8 | -5812 | 12745 |
RPS9 | -8815 | 10189 |
RPSA | 292 | 11576 |
The activation of arylsulfatases
metric | value |
---|---|
setSize | 10 |
pMANOVA | 0.00191 |
p.adjustMANOVA | 0.00391 |
s.dist | 0.616 |
s.KO | 0.417 |
s.drug | -0.454 |
p.KO | 0.0225 |
p.drug | 0.0129 |
Gene | KO | drug |
---|---|---|
SUMF2 | 11753 | -9338 |
ARSB | 12086 | -7494 |
ARSD | 9745 | -6384 |
SUMF1 | 11852 | -4769 |
ARSG | 12508 | -4208 |
STS | 6761 | -3002 |
KO | drug | |
---|---|---|
ARSA | 11743 | 9589 |
ARSB | 12086 | -7494 |
ARSD | 9745 | -6384 |
ARSG | 12508 | -4208 |
ARSI | -7529 | -4701 |
ARSJ | -8413 | -8593 |
ARSK | -2824 | -7149 |
STS | 6761 | -3002 |
SUMF1 | 11852 | -4769 |
SUMF2 | 11753 | -9338 |
HS-GAG degradation
metric | value |
---|---|
setSize | 19 |
pMANOVA | 7.84e-06 |
p.adjustMANOVA | 2.77e-05 |
s.dist | 0.612 |
s.KO | 0.424 |
s.drug | -0.441 |
p.KO | 0.00136 |
p.drug | 0.000862 |
Gene | KO | drug |
---|---|---|
AGRN | 12518 | -11205 |
SDC4 | 12322 | -10633 |
GPC4 | 11190 | -8942 |
GLB1 | 10162 | -9240 |
SDC1 | 12230 | -7104 |
SDC3 | 12401 | -6760 |
IDS | 8178 | -10132 |
NAGLU | 12163 | -5299 |
GPC5 | 7673 | -3135 |
GPC1 | 1951 | -7922 |
KO | drug | |
---|---|---|
AGRN | 12518 | -11205 |
GLB1 | 10162 | -9240 |
GLB1L | 10787 | 1974 |
GPC1 | 1951 | -7922 |
GPC2 | -3913 | -3279 |
GPC4 | 11190 | -8942 |
GPC5 | 7673 | -3135 |
GPC6 | -6095 | -11229 |
GUSB | 9430 | 8910 |
HPSE | -6814 | -4898 |
HSPG2 | -9046 | -9768 |
IDS | 8178 | -10132 |
IDUA | 11538 | 11620 |
NAGLU | 12163 | -5299 |
SDC1 | 12230 | -7104 |
SDC2 | -6754 | -5737 |
SDC3 | 12401 | -6760 |
SDC4 | 12322 | -10633 |
SGSH | 11466 | 8231 |
Ribosomal scanning and start codon recognition
metric | value |
---|---|
setSize | 57 |
pMANOVA | 4.22e-16 |
p.adjustMANOVA | 7.19e-15 |
s.dist | 0.615 |
s.KO | -0.488 |
s.drug | 0.374 |
p.KO | 1.87e-10 |
p.drug | 1.03e-06 |
Gene | KO | drug |
---|---|---|
RPS17 | -10534 | 11631 |
RPS13 | -9450 | 12652 |
RPS25 | -9371 | 12690 |
RPS18 | -9122 | 12984 |
RPS6 | -9225 | 12405 |
RPS15A | -8754 | 12989 |
FAU | -8610 | 13102 |
RPS4X | -8542 | 12239 |
RPS11 | -7725 | 12935 |
EIF3C | -8843 | 11244 |
RPS19 | -7633 | 12888 |
EIF3M | -10718 | 9044 |
EIF3I | -7897 | 12235 |
RPS15 | -7430 | 12908 |
EIF3E | -9070 | 10545 |
RPS3 | -7756 | 12135 |
RPS12 | -7872 | 11600 |
RPS2 | -10222 | 8916 |
RPS9 | -8815 | 10189 |
RPS10 | -8384 | 10665 |
KO | drug | |
---|---|---|
EIF1AX | -5479 | 11112 |
EIF2S1 | -8950 | -8774 |
EIF2S2 | -10653 | -6089 |
EIF2S3 | -10174 | -5022 |
EIF3A | -5233 | -9195 |
EIF3B | -4779 | -8277 |
EIF3C | -8843 | 11244 |
EIF3D | -10400 | -7621 |
EIF3E | -9070 | 10545 |
EIF3F | -1343 | -5879 |
EIF3G | -7655 | 4326 |
EIF3H | -8110 | -1879 |
EIF3I | -7897 | 12235 |
EIF3J | -4825 | -4367 |
EIF3K | -2668 | 9951 |
EIF3L | -9160 | -8016 |
EIF3M | -10718 | 9044 |
EIF4A1 | -8156 | -2754 |
EIF4A2 | -9799 | -8479 |
EIF4B | -9005 | -10529 |
EIF4E | -10282 | -8119 |
EIF4G1 | 9159 | -10287 |
EIF4H | -10967 | -8512 |
EIF5 | 10203 | -9440 |
FAU | -8610 | 13102 |
RPS10 | -8384 | 10665 |
RPS11 | -7725 | 12935 |
RPS12 | -7872 | 11600 |
RPS13 | -9450 | 12652 |
RPS14 | -1180 | 12428 |
RPS15 | -7430 | 12908 |
RPS15A | -8754 | 12989 |
RPS16 | -3844 | 12941 |
RPS17 | -10534 | 11631 |
RPS18 | -9122 | 12984 |
RPS19 | -7633 | 12888 |
RPS2 | -10222 | 8916 |
RPS20 | -4961 | 13095 |
RPS21 | -3001 | 13022 |
RPS23 | 6940 | 11907 |
RPS24 | 2369 | 13034 |
RPS25 | -9371 | 12690 |
RPS26 | -2615 | 13114 |
RPS27 | 651 | 11270 |
RPS27A | 5357 | 6464 |
RPS27L | 7330 | 12750 |
RPS28 | 2716 | 12485 |
RPS29 | -652 | 9078 |
RPS3 | -7756 | 12135 |
RPS3A | -9170 | 5257 |
RPS4X | -8542 | 12239 |
RPS5 | -6283 | -7965 |
RPS6 | -9225 | 12405 |
RPS7 | 5142 | 12976 |
RPS8 | -5812 | 12745 |
RPS9 | -8815 | 10189 |
RPSA | 292 | 11576 |
Major pathway of rRNA processing in the nucleolus and cytosol
metric | value |
---|---|
setSize | 180 |
pMANOVA | 4.38e-48 |
p.adjustMANOVA | 7.14e-46 |
s.dist | 0.607 |
s.KO | -0.442 |
s.drug | 0.415 |
p.KO | 1.15e-24 |
p.drug | 6.33e-22 |
Gene | KO | drug |
---|---|---|
SNU13 | -10311 | 12575 |
RPP21 | -10144 | 12682 |
RPL22L1 | -10448 | 12221 |
RRP1 | -10564 | 11767 |
RPL9 | -9659 | 12806 |
RPS17 | -10534 | 11631 |
RPL34 | -9357 | 12996 |
RPL12 | -9329 | 12992 |
UTP11 | -10533 | 11453 |
RPL26L1 | -9387 | 12770 |
RPS13 | -9450 | 12652 |
NOP58 | -9719 | 12285 |
RPS25 | -9371 | 12690 |
PELP1 | -10416 | 11398 |
RPL37A | -9347 | 12675 |
RPS18 | -9122 | 12984 |
RPL17 | -8989 | 12909 |
RPL31 | -8781 | 13131 |
RPS6 | -9225 | 12405 |
RPS15A | -8754 | 12989 |
KO | drug | |
---|---|---|
BMS1 | 2178 | -7536 |
BOP1 | -7790 | 11804 |
BYSL | -9303 | -4305 |
C1D | 4815 | -6610 |
CSNK1D | 10532 | -5548 |
CSNK1E | -10445 | -9281 |
DCAF13 | -10197 | 3606 |
DDX21 | -9821 | -11141 |
DDX47 | -3040 | -3704 |
DDX49 | -6948 | 11408 |
DDX52 | -4956 | -6639 |
DHX37 | -6857 | -5150 |
DIS3 | -7066 | -10210 |
EBNA1BP2 | -5730 | 8621 |
EMG1 | -8533 | 12199 |
ERI1 | -6981 | -7986 |
EXOSC1 | 5616 | 12257 |
EXOSC10 | 11323 | 10109 |
EXOSC2 | -6345 | 11400 |
EXOSC3 | -9626 | 11413 |
EXOSC4 | -5748 | 12031 |
EXOSC5 | -8463 | 12469 |
EXOSC6 | -4792 | 6631 |
EXOSC7 | -9145 | 12400 |
EXOSC8 | -5608 | 12846 |
EXOSC9 | 2510 | 12417 |
FAU | -8610 | 13102 |
FBL | -9012 | 11058 |
FCF1 | 709 | -9413 |
FTSJ3 | 6717 | -6330 |
GNL3 | -10056 | -3684 |
HEATR1 | -2296 | -10015 |
IMP3 | 8515 | 12268 |
IMP4 | -11049 | 7633 |
ISG20L2 | 9239 | -8076 |
KRR1 | -1464 | -4631 |
LAS1L | 7432 | 11693 |
LTV1 | -7819 | 11102 |
MPHOSPH10 | -6190 | 11406 |
MPHOSPH6 | -2428 | 9099 |
MTREX | -8233 | -5923 |
NCL | -9791 | -342 |
NIP7 | -7922 | 9186 |
NOB1 | -9953 | -8397 |
NOC4L | -6715 | 11954 |
NOL11 | -3226 | -8080 |
NOL12 | 5520 | 12622 |
NOL6 | -9823 | 2445 |
NOL9 | -6385 | -511 |
NOP14 | -10166 | -3847 |
NOP56 | -7158 | 12073 |
NOP58 | -9719 | 12285 |
PDCD11 | -8464 | -9477 |
PELP1 | -10416 | 11398 |
PES1 | -9830 | -6872 |
PNO1 | -3440 | -3672 |
PWP2 | -2846 | -152 |
RBM28 | -10901 | 3636 |
RCL1 | -11359 | 8957 |
RIOK1 | -10244 | -3480 |
RIOK2 | -6415 | 4119 |
RIOK3 | -9445 | -11119 |
RPL10 | -3821 | 1598 |
RPL10A | -9707 | -8212 |
RPL11 | -8529 | 12382 |
RPL12 | -9329 | 12992 |
RPL13 | -3469 | 12598 |
RPL13A | -6854 | 6955 |
RPL14 | -6386 | 13137 |
RPL15 | -786 | 12153 |
RPL17 | -8989 | 12909 |
RPL18 | -6672 | 12800 |
RPL18A | -6976 | 11926 |
RPL19 | 3924 | 12911 |
RPL21 | -6322 | 5141 |
RPL22 | -5554 | 9520 |
RPL22L1 | -10448 | 12221 |
RPL23 | 5769 | 12922 |
RPL23A | 11361 | -5257 |
RPL24 | -4591 | 12995 |
RPL26 | -8797 | 12658 |
RPL26L1 | -9387 | 12770 |
RPL27 | 6735 | 11625 |
RPL27A | -7818 | 13051 |
RPL28 | -5809 | 12962 |
RPL29 | -4515 | 12915 |
RPL3 | -6827 | -4536 |
RPL30 | -3907 | 11096 |
RPL31 | -8781 | 13131 |
RPL32 | -5028 | 12983 |
RPL34 | -9357 | 12996 |
RPL35 | -8027 | 13097 |
RPL35A | -1449 | 12789 |
RPL36 | -8818 | 12868 |
RPL36A | -4480 | 13010 |
RPL36AL | -8216 | 12702 |
RPL37 | -4624 | 13134 |
RPL37A | -9347 | 12675 |
RPL38 | 1558 | 13140 |
RPL39 | -6168 | 11962 |
RPL39L | -6608 | -6269 |
RPL3L | -510 | 7904 |
RPL4 | 11351 | 12558 |
RPL41 | -4616 | -6075 |
RPL5 | 4679 | 12075 |
RPL6 | -6903 | 12730 |
RPL7 | -3327 | -8789 |
RPL7A | -6163 | 11708 |
RPL8 | -7572 | 10323 |
RPL9 | -9659 | 12806 |
RPLP0 | -1504 | -7331 |
RPLP1 | 9026 | 12731 |
RPLP2 | -8225 | 12999 |
RPP14 | -7031 | -2565 |
RPP21 | -10144 | 12682 |
RPP25 | 12002 | 11609 |
RPP30 | 4656 | 11993 |
RPP38 | -6789 | 3778 |
RPP40 | -7844 | 9292 |
RPS10 | -8384 | 10665 |
RPS11 | -7725 | 12935 |
RPS12 | -7872 | 11600 |
RPS13 | -9450 | 12652 |
RPS14 | -1180 | 12428 |
RPS15 | -7430 | 12908 |
RPS15A | -8754 | 12989 |
RPS16 | -3844 | 12941 |
RPS17 | -10534 | 11631 |
RPS18 | -9122 | 12984 |
RPS19 | -7633 | 12888 |
RPS2 | -10222 | 8916 |
RPS20 | -4961 | 13095 |
RPS21 | -3001 | 13022 |
RPS23 | 6940 | 11907 |
RPS24 | 2369 | 13034 |
RPS25 | -9371 | 12690 |
RPS26 | -2615 | 13114 |
RPS27 | 651 | 11270 |
RPS27A | 5357 | 6464 |
RPS27L | 7330 | 12750 |
RPS28 | 2716 | 12485 |
RPS29 | -652 | 9078 |
RPS3 | -7756 | 12135 |
RPS3A | -9170 | 5257 |
RPS4X | -8542 | 12239 |
RPS5 | -6283 | -7965 |
RPS6 | -9225 | 12405 |
RPS7 | 5142 | 12976 |
RPS8 | -5812 | 12745 |
RPS9 | -8815 | 10189 |
RPSA | 292 | 11576 |
RRP1 | -10564 | 11767 |
RRP36 | -6050 | -2045 |
RRP7A | -2282 | 10997 |
RRP9 | -7176 | 12125 |
SENP3 | -6212 | -9010 |
SNORD3A | -5504 | 7763 |
SNU13 | -10311 | 12575 |
TBL3 | -9717 | 9564 |
TEX10 | -10686 | -7186 |
TSR1 | -11196 | -7332 |
UBA52 | -6807 | 11639 |
UTP11 | -10533 | 11453 |
UTP14A | 6133 | 11385 |
UTP14C | 4183 | 769 |
UTP15 | -2850 | -3508 |
UTP18 | -9890 | -9637 |
UTP20 | 7490 | -8121 |
UTP25 | -2108 | -9255 |
UTP3 | -4017 | 10489 |
UTP4 | -6489 | 3608 |
UTP6 | -9002 | -4625 |
WDR12 | -10594 | 3479 |
WDR18 | -808 | 11293 |
WDR3 | -7914 | -8658 |
WDR36 | 2115 | -8307 |
WDR43 | -8618 | -5190 |
WDR46 | -9852 | 176 |
WDR75 | -11340 | 9185 |
XRN2 | -8638 | -11123 |
rRNA processing in the nucleus and cytosol
metric | value |
---|---|
setSize | 190 |
pMANOVA | 1.23e-50 |
p.adjustMANOVA | 2.57e-48 |
s.dist | 0.606 |
s.KO | -0.452 |
s.drug | 0.404 |
p.KO | 4.72e-27 |
p.drug | 6.93e-22 |
Gene | KO | drug |
---|---|---|
NOP2 | -10527 | 12781 |
SNU13 | -10311 | 12575 |
RPP21 | -10144 | 12682 |
RPL22L1 | -10448 | 12221 |
RRP1 | -10564 | 11767 |
RPL9 | -9659 | 12806 |
RPS17 | -10534 | 11631 |
RPL34 | -9357 | 12996 |
RPL12 | -9329 | 12992 |
UTP11 | -10533 | 11453 |
RPL26L1 | -9387 | 12770 |
RPS13 | -9450 | 12652 |
NOP58 | -9719 | 12285 |
RPS25 | -9371 | 12690 |
PELP1 | -10416 | 11398 |
RPL37A | -9347 | 12675 |
RPS18 | -9122 | 12984 |
RPL17 | -8989 | 12909 |
RPL31 | -8781 | 13131 |
RPS6 | -9225 | 12405 |
KO | drug | |
---|---|---|
BMS1 | 2178 | -7536 |
BOP1 | -7790 | 11804 |
BYSL | -9303 | -4305 |
C1D | 4815 | -6610 |
CSNK1D | 10532 | -5548 |
CSNK1E | -10445 | -9281 |
DCAF13 | -10197 | 3606 |
DDX21 | -9821 | -11141 |
DDX47 | -3040 | -3704 |
DDX49 | -6948 | 11408 |
DDX52 | -4956 | -6639 |
DHX37 | -6857 | -5150 |
DIMT1 | -9289 | -6845 |
DIS3 | -7066 | -10210 |
DKC1 | -9026 | -6327 |
EBNA1BP2 | -5730 | 8621 |
EMG1 | -8533 | 12199 |
ERI1 | -6981 | -7986 |
EXOSC1 | 5616 | 12257 |
EXOSC10 | 11323 | 10109 |
EXOSC2 | -6345 | 11400 |
EXOSC3 | -9626 | 11413 |
EXOSC4 | -5748 | 12031 |
EXOSC5 | -8463 | 12469 |
EXOSC6 | -4792 | 6631 |
EXOSC7 | -9145 | 12400 |
EXOSC8 | -5608 | 12846 |
EXOSC9 | 2510 | 12417 |
FAU | -8610 | 13102 |
FBL | -9012 | 11058 |
FCF1 | 709 | -9413 |
FTSJ3 | 6717 | -6330 |
GAR1 | -8958 | 8023 |
GNL3 | -10056 | -3684 |
HEATR1 | -2296 | -10015 |
IMP3 | 8515 | 12268 |
IMP4 | -11049 | 7633 |
ISG20L2 | 9239 | -8076 |
KRR1 | -1464 | -4631 |
LAS1L | 7432 | 11693 |
LTV1 | -7819 | 11102 |
MPHOSPH10 | -6190 | 11406 |
MPHOSPH6 | -2428 | 9099 |
MTREX | -8233 | -5923 |
NAT10 | -9415 | 792 |
NCL | -9791 | -342 |
NHP2 | -218 | 11370 |
NIP7 | -7922 | 9186 |
NOB1 | -9953 | -8397 |
NOC4L | -6715 | 11954 |
NOL11 | -3226 | -8080 |
NOL12 | 5520 | 12622 |
NOL6 | -9823 | 2445 |
NOL9 | -6385 | -511 |
NOP10 | 2766 | 11209 |
NOP14 | -10166 | -3847 |
NOP2 | -10527 | 12781 |
NOP56 | -7158 | 12073 |
NOP58 | -9719 | 12285 |
PDCD11 | -8464 | -9477 |
PELP1 | -10416 | 11398 |
PES1 | -9830 | -6872 |
PNO1 | -3440 | -3672 |
PWP2 | -2846 | -152 |
RBM28 | -10901 | 3636 |
RCL1 | -11359 | 8957 |
RIOK1 | -10244 | -3480 |
RIOK2 | -6415 | 4119 |
RIOK3 | -9445 | -11119 |
RPL10 | -3821 | 1598 |
RPL10A | -9707 | -8212 |
RPL11 | -8529 | 12382 |
RPL12 | -9329 | 12992 |
RPL13 | -3469 | 12598 |
RPL13A | -6854 | 6955 |
RPL14 | -6386 | 13137 |
RPL15 | -786 | 12153 |
RPL17 | -8989 | 12909 |
RPL18 | -6672 | 12800 |
RPL18A | -6976 | 11926 |
RPL19 | 3924 | 12911 |
RPL21 | -6322 | 5141 |
RPL22 | -5554 | 9520 |
RPL22L1 | -10448 | 12221 |
RPL23 | 5769 | 12922 |
RPL23A | 11361 | -5257 |
RPL24 | -4591 | 12995 |
RPL26 | -8797 | 12658 |
RPL26L1 | -9387 | 12770 |
RPL27 | 6735 | 11625 |
RPL27A | -7818 | 13051 |
RPL28 | -5809 | 12962 |
RPL29 | -4515 | 12915 |
RPL3 | -6827 | -4536 |
RPL30 | -3907 | 11096 |
RPL31 | -8781 | 13131 |
RPL32 | -5028 | 12983 |
RPL34 | -9357 | 12996 |
RPL35 | -8027 | 13097 |
RPL35A | -1449 | 12789 |
RPL36 | -8818 | 12868 |
RPL36A | -4480 | 13010 |
RPL36AL | -8216 | 12702 |
RPL37 | -4624 | 13134 |
RPL37A | -9347 | 12675 |
RPL38 | 1558 | 13140 |
RPL39 | -6168 | 11962 |
RPL39L | -6608 | -6269 |
RPL3L | -510 | 7904 |
RPL4 | 11351 | 12558 |
RPL41 | -4616 | -6075 |
RPL5 | 4679 | 12075 |
RPL6 | -6903 | 12730 |
RPL7 | -3327 | -8789 |
RPL7A | -6163 | 11708 |
RPL8 | -7572 | 10323 |
RPL9 | -9659 | 12806 |
RPLP0 | -1504 | -7331 |
RPLP1 | 9026 | 12731 |
RPLP2 | -8225 | 12999 |
RPP14 | -7031 | -2565 |
RPP21 | -10144 | 12682 |
RPP25 | 12002 | 11609 |
RPP30 | 4656 | 11993 |
RPP38 | -6789 | 3778 |
RPP40 | -7844 | 9292 |
RPS10 | -8384 | 10665 |
RPS11 | -7725 | 12935 |
RPS12 | -7872 | 11600 |
RPS13 | -9450 | 12652 |
RPS14 | -1180 | 12428 |
RPS15 | -7430 | 12908 |
RPS15A | -8754 | 12989 |
RPS16 | -3844 | 12941 |
RPS17 | -10534 | 11631 |
RPS18 | -9122 | 12984 |
RPS19 | -7633 | 12888 |
RPS2 | -10222 | 8916 |
RPS20 | -4961 | 13095 |
RPS21 | -3001 | 13022 |
RPS23 | 6940 | 11907 |
RPS24 | 2369 | 13034 |
RPS25 | -9371 | 12690 |
RPS26 | -2615 | 13114 |
RPS27 | 651 | 11270 |
RPS27A | 5357 | 6464 |
RPS27L | 7330 | 12750 |
RPS28 | 2716 | 12485 |
RPS29 | -652 | 9078 |
RPS3 | -7756 | 12135 |
RPS3A | -9170 | 5257 |
RPS4X | -8542 | 12239 |
RPS5 | -6283 | -7965 |
RPS6 | -9225 | 12405 |
RPS7 | 5142 | 12976 |
RPS8 | -5812 | 12745 |
RPS9 | -8815 | 10189 |
RPSA | 292 | 11576 |
RRP1 | -10564 | 11767 |
RRP36 | -6050 | -2045 |
RRP7A | -2282 | 10997 |
RRP9 | -7176 | 12125 |
SENP3 | -6212 | -9010 |
SNORD3A | -5504 | 7763 |
SNU13 | -10311 | 12575 |
TBL3 | -9717 | 9564 |
TEX10 | -10686 | -7186 |
THUMPD1 | -10328 | -6819 |
TRMT112 | -5741 | 13057 |
TSR1 | -11196 | -7332 |
TSR3 | -8931 | -3980 |
UBA52 | -6807 | 11639 |
UTP11 | -10533 | 11453 |
UTP14A | 6133 | 11385 |
UTP14C | 4183 | 769 |
UTP15 | -2850 | -3508 |
UTP18 | -9890 | -9637 |
UTP20 | 7490 | -8121 |
UTP25 | -2108 | -9255 |
UTP3 | -4017 | 10489 |
UTP4 | -6489 | 3608 |
UTP6 | -9002 | -4625 |
WDR12 | -10594 | 3479 |
WDR18 | -808 | 11293 |
WDR3 | -7914 | -8658 |
WDR36 | 2115 | -8307 |
WDR43 | -8618 | -5190 |
WDR46 | -9852 | 176 |
WDR75 | -11340 | 9185 |
XRN2 | -8638 | -11123 |
Selenoamino acid metabolism
metric | value |
---|---|
setSize | 115 |
pMANOVA | 5.95e-32 |
p.adjustMANOVA | 2.64e-30 |
s.dist | 0.618 |
s.KO | -0.336 |
s.drug | 0.519 |
p.KO | 4.63e-10 |
p.drug | 6.31e-22 |
Gene | KO | drug |
---|---|---|
RPL22L1 | -10448 | 12221 |
RPL9 | -9659 | 12806 |
RPS17 | -10534 | 11631 |
RPL34 | -9357 | 12996 |
RPL12 | -9329 | 12992 |
RPL26L1 | -9387 | 12770 |
RPS13 | -9450 | 12652 |
RPS25 | -9371 | 12690 |
RPL37A | -9347 | 12675 |
RPS18 | -9122 | 12984 |
RPL17 | -8989 | 12909 |
RPL31 | -8781 | 13131 |
RPS6 | -9225 | 12405 |
RPS15A | -8754 | 12989 |
RPL36 | -8818 | 12868 |
FAU | -8610 | 13102 |
RPL26 | -8797 | 12658 |
RPLP2 | -8225 | 12999 |
RPL11 | -8529 | 12382 |
RPL35 | -8027 | 13097 |
KO | drug | |
---|---|---|
AHCY | 1345 | 629 |
AIMP1 | -9006 | 1838 |
AIMP2 | 1872 | -2032 |
CBS | 10907 | 11159 |
CTH | -3063 | -3718 |
DARS1 | -10008 | 4484 |
EEF1E1 | -10204 | 1085 |
EEFSEC | 11184 | -3492 |
EPRS1 | 1368 | -10895 |
FAU | -8610 | 13102 |
GNMT | -1375 | 5139 |
GSR | -11433 | -4996 |
HNMT | -1649 | 3699 |
IARS1 | -2182 | -9570 |
INMT | 9444 | -4952 |
KARS1 | -10243 | 9778 |
LARS1 | -7999 | -5859 |
MARS1 | -1476 | 10979 |
MAT1A | -6091 | 2828 |
NNMT | 12760 | 12864 |
PAPSS1 | -10307 | -3927 |
PAPSS2 | 6847 | -10771 |
PSTK | 5756 | 9314 |
QARS1 | 10134 | -6688 |
RARS1 | -9720 | -7252 |
RPL10 | -3821 | 1598 |
RPL10A | -9707 | -8212 |
RPL11 | -8529 | 12382 |
RPL12 | -9329 | 12992 |
RPL13 | -3469 | 12598 |
RPL13A | -6854 | 6955 |
RPL14 | -6386 | 13137 |
RPL15 | -786 | 12153 |
RPL17 | -8989 | 12909 |
RPL18 | -6672 | 12800 |
RPL18A | -6976 | 11926 |
RPL19 | 3924 | 12911 |
RPL21 | -6322 | 5141 |
RPL22 | -5554 | 9520 |
RPL22L1 | -10448 | 12221 |
RPL23 | 5769 | 12922 |
RPL23A | 11361 | -5257 |
RPL24 | -4591 | 12995 |
RPL26 | -8797 | 12658 |
RPL26L1 | -9387 | 12770 |
RPL27 | 6735 | 11625 |
RPL27A | -7818 | 13051 |
RPL28 | -5809 | 12962 |
RPL29 | -4515 | 12915 |
RPL3 | -6827 | -4536 |
RPL30 | -3907 | 11096 |
RPL31 | -8781 | 13131 |
RPL32 | -5028 | 12983 |
RPL34 | -9357 | 12996 |
RPL35 | -8027 | 13097 |
RPL35A | -1449 | 12789 |
RPL36 | -8818 | 12868 |
RPL36A | -4480 | 13010 |
RPL36AL | -8216 | 12702 |
RPL37 | -4624 | 13134 |
RPL37A | -9347 | 12675 |
RPL38 | 1558 | 13140 |
RPL39 | -6168 | 11962 |
RPL39L | -6608 | -6269 |
RPL3L | -510 | 7904 |
RPL4 | 11351 | 12558 |
RPL41 | -4616 | -6075 |
RPL5 | 4679 | 12075 |
RPL6 | -6903 | 12730 |
RPL7 | -3327 | -8789 |
RPL7A | -6163 | 11708 |
RPL8 | -7572 | 10323 |
RPL9 | -9659 | 12806 |
RPLP0 | -1504 | -7331 |
RPLP1 | 9026 | 12731 |
RPLP2 | -8225 | 12999 |
RPS10 | -8384 | 10665 |
RPS11 | -7725 | 12935 |
RPS12 | -7872 | 11600 |
RPS13 | -9450 | 12652 |
RPS14 | -1180 | 12428 |
RPS15 | -7430 | 12908 |
RPS15A | -8754 | 12989 |
RPS16 | -3844 | 12941 |
RPS17 | -10534 | 11631 |
RPS18 | -9122 | 12984 |
RPS19 | -7633 | 12888 |
RPS2 | -10222 | 8916 |
RPS20 | -4961 | 13095 |
RPS21 | -3001 | 13022 |
RPS23 | 6940 | 11907 |
RPS24 | 2369 | 13034 |
RPS25 | -9371 | 12690 |
RPS26 | -2615 | 13114 |
RPS27 | 651 | 11270 |
RPS27A | 5357 | 6464 |
RPS27L | 7330 | 12750 |
RPS28 | 2716 | 12485 |
RPS29 | -652 | 9078 |
RPS3 | -7756 | 12135 |
RPS3A | -9170 | 5257 |
RPS4X | -8542 | 12239 |
RPS5 | -6283 | -7965 |
RPS6 | -9225 | 12405 |
RPS7 | 5142 | 12976 |
RPS8 | -5812 | 12745 |
RPS9 | -8815 | 10189 |
RPSA | 292 | 11576 |
SARS1 | 10748 | -9421 |
SCLY | -9481 | 10671 |
SECISBP2 | 11207 | -6517 |
SEPHS2 | 8103 | -351 |
SEPSECS | -6443 | -5096 |
TXNRD1 | -10964 | -9955 |
UBA52 | -6807 | 11639 |
Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC)
metric | value |
---|---|
setSize | 113 |
pMANOVA | 2.07e-30 |
p.adjustMANOVA | 8.41e-29 |
s.dist | 0.606 |
s.KO | -0.392 |
s.drug | 0.462 |
p.KO | 5.64e-13 |
p.drug | 1.93e-17 |
Gene | KO | drug |
---|---|---|
RPL22L1 | -10448 | 12221 |
RPL9 | -9659 | 12806 |
RPS17 | -10534 | 11631 |
RPL34 | -9357 | 12996 |
RPL12 | -9329 | 12992 |
RPL26L1 | -9387 | 12770 |
RPS13 | -9450 | 12652 |
RPS25 | -9371 | 12690 |
RPL37A | -9347 | 12675 |
RPS18 | -9122 | 12984 |
RPL17 | -8989 | 12909 |
RPL31 | -8781 | 13131 |
RPS6 | -9225 | 12405 |
RPS15A | -8754 | 12989 |
RPL36 | -8818 | 12868 |
FAU | -8610 | 13102 |
RPL26 | -8797 | 12658 |
RPLP2 | -8225 | 12999 |
RPL11 | -8529 | 12382 |
RPL35 | -8027 | 13097 |
KO | drug | |
---|---|---|
CASC3 | 3621 | -10268 |
DCP1A | -8837 | -10280 |
EIF4A3 | -628 | -6343 |
EIF4G1 | 9159 | -10287 |
ETF1 | -5515 | -9496 |
FAU | -8610 | 13102 |
GSPT1 | -11018 | -10261 |
GSPT2 | -5509 | -6727 |
MAGOH | -5607 | 12947 |
MAGOHB | -7769 | 12200 |
NCBP1 | -7784 | -5234 |
NCBP2 | -6378 | -6281 |
PABPC1 | -7033 | -10406 |
PNRC2 | 2116 | 6441 |
PPP2CA | -3124 | -7225 |
PPP2R1A | -9193 | -4828 |
PPP2R2A | -11248 | -10666 |
RBM8A | 8447 | 9246 |
RNPS1 | -10981 | -5614 |
RPL10 | -3821 | 1598 |
RPL10A | -9707 | -8212 |
RPL11 | -8529 | 12382 |
RPL12 | -9329 | 12992 |
RPL13 | -3469 | 12598 |
RPL13A | -6854 | 6955 |
RPL14 | -6386 | 13137 |
RPL15 | -786 | 12153 |
RPL17 | -8989 | 12909 |
RPL18 | -6672 | 12800 |
RPL18A | -6976 | 11926 |
RPL19 | 3924 | 12911 |
RPL21 | -6322 | 5141 |
RPL22 | -5554 | 9520 |
RPL22L1 | -10448 | 12221 |
RPL23 | 5769 | 12922 |
RPL23A | 11361 | -5257 |
RPL24 | -4591 | 12995 |
RPL26 | -8797 | 12658 |
RPL26L1 | -9387 | 12770 |
RPL27 | 6735 | 11625 |
RPL27A | -7818 | 13051 |
RPL28 | -5809 | 12962 |
RPL29 | -4515 | 12915 |
RPL3 | -6827 | -4536 |
RPL30 | -3907 | 11096 |
RPL31 | -8781 | 13131 |
RPL32 | -5028 | 12983 |
RPL34 | -9357 | 12996 |
RPL35 | -8027 | 13097 |
RPL35A | -1449 | 12789 |
RPL36 | -8818 | 12868 |
RPL36A | -4480 | 13010 |
RPL36AL | -8216 | 12702 |
RPL37 | -4624 | 13134 |
RPL37A | -9347 | 12675 |
RPL38 | 1558 | 13140 |
RPL39 | -6168 | 11962 |
RPL39L | -6608 | -6269 |
RPL3L | -510 | 7904 |
RPL4 | 11351 | 12558 |
RPL41 | -4616 | -6075 |
RPL5 | 4679 | 12075 |
RPL6 | -6903 | 12730 |
RPL7 | -3327 | -8789 |
RPL7A | -6163 | 11708 |
RPL8 | -7572 | 10323 |
RPL9 | -9659 | 12806 |
RPLP0 | -1504 | -7331 |
RPLP1 | 9026 | 12731 |
RPLP2 | -8225 | 12999 |
RPS10 | -8384 | 10665 |
RPS11 | -7725 | 12935 |
RPS12 | -7872 | 11600 |
RPS13 | -9450 | 12652 |
RPS14 | -1180 | 12428 |
RPS15 | -7430 | 12908 |
RPS15A | -8754 | 12989 |
RPS16 | -3844 | 12941 |
RPS17 | -10534 | 11631 |
RPS18 | -9122 | 12984 |
RPS19 | -7633 | 12888 |
RPS2 | -10222 | 8916 |
RPS20 | -4961 | 13095 |
RPS21 | -3001 | 13022 |
RPS23 | 6940 | 11907 |
RPS24 | 2369 | 13034 |
RPS25 | -9371 | 12690 |
RPS26 | -2615 | 13114 |
RPS27 | 651 | 11270 |
RPS27A | 5357 | 6464 |
RPS27L | 7330 | 12750 |
RPS28 | 2716 | 12485 |
RPS29 | -652 | 9078 |
RPS3 | -7756 | 12135 |
RPS3A | -9170 | 5257 |
RPS4X | -8542 | 12239 |
RPS5 | -6283 | -7965 |
RPS6 | -9225 | 12405 |
RPS7 | 5142 | 12976 |
RPS8 | -5812 | 12745 |
RPS9 | -8815 | 10189 |
RPSA | 292 | 11576 |
SMG1 | -8987 | -10553 |
SMG5 | 10836 | -9825 |
SMG6 | -7165 | -6549 |
SMG7 | 9137 | -8660 |
SMG8 | 9515 | -8783 |
SMG9 | -11415 | -3130 |
UBA52 | -6807 | 11639 |
UPF1 | -10419 | -10092 |
UPF2 | 6857 | -7169 |
UPF3A | -8410 | 11718 |
UPF3B | -3041 | 12685 |
Nonsense-Mediated Decay (NMD)
metric | value |
---|---|
setSize | 113 |
pMANOVA | 2.07e-30 |
p.adjustMANOVA | 8.41e-29 |
s.dist | 0.606 |
s.KO | -0.392 |
s.drug | 0.462 |
p.KO | 5.64e-13 |
p.drug | 1.93e-17 |
Gene | KO | drug |
---|---|---|
RPL22L1 | -10448 | 12221 |
RPL9 | -9659 | 12806 |
RPS17 | -10534 | 11631 |
RPL34 | -9357 | 12996 |
RPL12 | -9329 | 12992 |
RPL26L1 | -9387 | 12770 |
RPS13 | -9450 | 12652 |
RPS25 | -9371 | 12690 |
RPL37A | -9347 | 12675 |
RPS18 | -9122 | 12984 |
RPL17 | -8989 | 12909 |
RPL31 | -8781 | 13131 |
RPS6 | -9225 | 12405 |
RPS15A | -8754 | 12989 |
RPL36 | -8818 | 12868 |
FAU | -8610 | 13102 |
RPL26 | -8797 | 12658 |
RPLP2 | -8225 | 12999 |
RPL11 | -8529 | 12382 |
RPL35 | -8027 | 13097 |
KO | drug | |
---|---|---|
CASC3 | 3621 | -10268 |
DCP1A | -8837 | -10280 |
EIF4A3 | -628 | -6343 |
EIF4G1 | 9159 | -10287 |
ETF1 | -5515 | -9496 |
FAU | -8610 | 13102 |
GSPT1 | -11018 | -10261 |
GSPT2 | -5509 | -6727 |
MAGOH | -5607 | 12947 |
MAGOHB | -7769 | 12200 |
NCBP1 | -7784 | -5234 |
NCBP2 | -6378 | -6281 |
PABPC1 | -7033 | -10406 |
PNRC2 | 2116 | 6441 |
PPP2CA | -3124 | -7225 |
PPP2R1A | -9193 | -4828 |
PPP2R2A | -11248 | -10666 |
RBM8A | 8447 | 9246 |
RNPS1 | -10981 | -5614 |
RPL10 | -3821 | 1598 |
RPL10A | -9707 | -8212 |
RPL11 | -8529 | 12382 |
RPL12 | -9329 | 12992 |
RPL13 | -3469 | 12598 |
RPL13A | -6854 | 6955 |
RPL14 | -6386 | 13137 |
RPL15 | -786 | 12153 |
RPL17 | -8989 | 12909 |
RPL18 | -6672 | 12800 |
RPL18A | -6976 | 11926 |
RPL19 | 3924 | 12911 |
RPL21 | -6322 | 5141 |
RPL22 | -5554 | 9520 |
RPL22L1 | -10448 | 12221 |
RPL23 | 5769 | 12922 |
RPL23A | 11361 | -5257 |
RPL24 | -4591 | 12995 |
RPL26 | -8797 | 12658 |
RPL26L1 | -9387 | 12770 |
RPL27 | 6735 | 11625 |
RPL27A | -7818 | 13051 |
RPL28 | -5809 | 12962 |
RPL29 | -4515 | 12915 |
RPL3 | -6827 | -4536 |
RPL30 | -3907 | 11096 |
RPL31 | -8781 | 13131 |
RPL32 | -5028 | 12983 |
RPL34 | -9357 | 12996 |
RPL35 | -8027 | 13097 |
RPL35A | -1449 | 12789 |
RPL36 | -8818 | 12868 |
RPL36A | -4480 | 13010 |
RPL36AL | -8216 | 12702 |
RPL37 | -4624 | 13134 |
RPL37A | -9347 | 12675 |
RPL38 | 1558 | 13140 |
RPL39 | -6168 | 11962 |
RPL39L | -6608 | -6269 |
RPL3L | -510 | 7904 |
RPL4 | 11351 | 12558 |
RPL41 | -4616 | -6075 |
RPL5 | 4679 | 12075 |
RPL6 | -6903 | 12730 |
RPL7 | -3327 | -8789 |
RPL7A | -6163 | 11708 |
RPL8 | -7572 | 10323 |
RPL9 | -9659 | 12806 |
RPLP0 | -1504 | -7331 |
RPLP1 | 9026 | 12731 |
RPLP2 | -8225 | 12999 |
RPS10 | -8384 | 10665 |
RPS11 | -7725 | 12935 |
RPS12 | -7872 | 11600 |
RPS13 | -9450 | 12652 |
RPS14 | -1180 | 12428 |
RPS15 | -7430 | 12908 |
RPS15A | -8754 | 12989 |
RPS16 | -3844 | 12941 |
RPS17 | -10534 | 11631 |
RPS18 | -9122 | 12984 |
RPS19 | -7633 | 12888 |
RPS2 | -10222 | 8916 |
RPS20 | -4961 | 13095 |
RPS21 | -3001 | 13022 |
RPS23 | 6940 | 11907 |
RPS24 | 2369 | 13034 |
RPS25 | -9371 | 12690 |
RPS26 | -2615 | 13114 |
RPS27 | 651 | 11270 |
RPS27A | 5357 | 6464 |
RPS27L | 7330 | 12750 |
RPS28 | 2716 | 12485 |
RPS29 | -652 | 9078 |
RPS3 | -7756 | 12135 |
RPS3A | -9170 | 5257 |
RPS4X | -8542 | 12239 |
RPS5 | -6283 | -7965 |
RPS6 | -9225 | 12405 |
RPS7 | 5142 | 12976 |
RPS8 | -5812 | 12745 |
RPS9 | -8815 | 10189 |
RPSA | 292 | 11576 |
SMG1 | -8987 | -10553 |
SMG5 | 10836 | -9825 |
SMG6 | -7165 | -6549 |
SMG7 | 9137 | -8660 |
SMG8 | 9515 | -8783 |
SMG9 | -11415 | -3130 |
UBA52 | -6807 | 11639 |
UPF1 | -10419 | -10092 |
UPF2 | 6857 | -7169 |
UPF3A | -8410 | 11718 |
UPF3B | -3041 | 12685 |
Complex I biogenesis
metric | value |
---|---|
setSize | 57 |
pMANOVA | 8.21e-22 |
p.adjustMANOVA | 2.23e-20 |
s.dist | 0.74 |
s.KO | -0.123 |
s.drug | 0.729 |
p.KO | 0.109 |
p.drug | 1.49e-21 |
Gene | KO | drug |
---|---|---|
NDUFA6 | -10640 | 12901 |
NDUFB10 | -9687 | 12582 |
NDUFA8 | -8774 | 12900 |
NDUFS3 | -8653 | 12725 |
NDUFB9 | -8544 | 12805 |
NDUFS8 | -7989 | 12773 |
NDUFB6 | -8238 | 12165 |
NDUFAB1 | -10558 | 8746 |
NDUFV2 | -6865 | 13148 |
NDUFC1 | -7186 | 12437 |
NDUFAF4 | -8760 | 9608 |
NDUFS5 | -6394 | 13145 |
NDUFV3 | -6779 | 12304 |
NDUFB11 | -7090 | 11583 |
NDUFA1 | -6222 | 13127 |
TMEM126B | -8036 | 9815 |
NDUFS6 | -6327 | 12108 |
NDUFA5 | -6593 | 11094 |
NDUFAF2 | -5167 | 12574 |
ECSIT | -6333 | 10115 |
KO | drug | |
---|---|---|
ACAD9 | 12457 | 11377 |
COA1 | 11438 | 12298 |
ECSIT | -6333 | 10115 |
MT-ND1 | 5209 | 13177 |
MT-ND2 | -1457 | 13183 |
MT-ND3 | 6571 | 13181 |
MT-ND4 | 566 | 13174 |
MT-ND5 | 4289 | 13012 |
MT-ND6 | 4676 | 13045 |
NDUFA1 | -6222 | 13127 |
NDUFA10 | -7241 | -4286 |
NDUFA11 | 9807 | 12851 |
NDUFA12 | 6720 | 13049 |
NDUFA13 | -4424 | 12971 |
NDUFA2 | 5937 | 13125 |
NDUFA3 | -4508 | 13084 |
NDUFA5 | -6593 | 11094 |
NDUFA6 | -10640 | 12901 |
NDUFA7 | 8872 | 13143 |
NDUFA8 | -8774 | 12900 |
NDUFA9 | 2605 | 10360 |
NDUFAB1 | -10558 | 8746 |
NDUFAF1 | 2883 | 9463 |
NDUFAF2 | -5167 | 12574 |
NDUFAF3 | 10175 | 13112 |
NDUFAF4 | -8760 | 9608 |
NDUFAF5 | -3460 | 9719 |
NDUFAF6 | -5625 | 10508 |
NDUFAF7 | 6751 | 8883 |
NDUFB1 | 8092 | 13163 |
NDUFB10 | -9687 | 12582 |
NDUFB11 | -7090 | 11583 |
NDUFB2 | 11367 | 12511 |
NDUFB3 | 1661 | 12046 |
NDUFB4 | 8888 | 13008 |
NDUFB5 | -3244 | -5075 |
NDUFB6 | -8238 | 12165 |
NDUFB7 | -4205 | 12444 |
NDUFB8 | 8367 | 13039 |
NDUFB9 | -8544 | 12805 |
NDUFC1 | -7186 | 12437 |
NDUFC2 | -5184 | 11409 |
NDUFS1 | -9609 | -7041 |
NDUFS2 | 3967 | -10068 |
NDUFS3 | -8653 | 12725 |
NDUFS4 | 6388 | 3949 |
NDUFS5 | -6394 | 13145 |
NDUFS6 | -6327 | 12108 |
NDUFS7 | 5531 | 12411 |
NDUFS8 | -7989 | 12773 |
NDUFV1 | -5404 | 8980 |
NDUFV2 | -6865 | 13148 |
NDUFV3 | -6779 | 12304 |
NUBPL | 8039 | -8010 |
TIMMDC1 | 9211 | -3329 |
TMEM126B | -8036 | 9815 |
TMEM186 | -8187 | 5086 |
Biotin transport and metabolism
metric | value |
---|---|
setSize | 11 |
pMANOVA | 0.000811 |
p.adjustMANOVA | 0.00183 |
s.dist | 0.631 |
s.KO | 0.561 |
s.drug | -0.29 |
p.KO | 0.00128 |
p.drug | 0.0961 |
Gene | KO | drug |
---|---|---|
ACACA | 11587 | -9231 |
BTD | 11562 | -8185 |
PCCA | 11484 | -7458 |
MCCC1 | 12225 | -6790 |
PC | 10642 | -7758 |
PCCB | 2928 | -5796 |
HLCS | 1981 | -7850 |
MCCC2 | 8284 | -1797 |
KO | drug | |
---|---|---|
ACACA | 11587 | -9231 |
ACACB | 10941 | 6062 |
BTD | 11562 | -8185 |
HLCS | 1981 | -7850 |
MCCC1 | 12225 | -6790 |
MCCC2 | 8284 | -1797 |
PC | 10642 | -7758 |
PCCA | 11484 | -7458 |
PCCB | 2928 | -5796 |
PDZD11 | 10212 | 12640 |
SLC5A6 | -9022 | 7606 |
rRNA processing
metric | value |
---|---|
setSize | 214 |
pMANOVA | 9.34e-54 |
p.adjustMANOVA | 2.74e-51 |
s.dist | 0.589 |
s.KO | -0.397 |
s.drug | 0.435 |
p.KO | 1.09e-23 |
p.drug | 4.38e-28 |
Gene | KO | drug |
---|---|---|
NOP2 | -10527 | 12781 |
SNU13 | -10311 | 12575 |
RPP21 | -10144 | 12682 |
RPL22L1 | -10448 | 12221 |
RRP1 | -10564 | 11767 |
RPL9 | -9659 | 12806 |
RPS17 | -10534 | 11631 |
RPL34 | -9357 | 12996 |
RPL12 | -9329 | 12992 |
UTP11 | -10533 | 11453 |
RPL26L1 | -9387 | 12770 |
RPS13 | -9450 | 12652 |
NOP58 | -9719 | 12285 |
RPS25 | -9371 | 12690 |
PELP1 | -10416 | 11398 |
RPL37A | -9347 | 12675 |
RPS18 | -9122 | 12984 |
RPL17 | -8989 | 12909 |
RPL31 | -8781 | 13131 |
RPS6 | -9225 | 12405 |
KO | drug | |
---|---|---|
BMS1 | 2178 | -7536 |
BOP1 | -7790 | 11804 |
BYSL | -9303 | -4305 |
C1D | 4815 | -6610 |
CSNK1D | 10532 | -5548 |
CSNK1E | -10445 | -9281 |
DCAF13 | -10197 | 3606 |
DDX21 | -9821 | -11141 |
DDX47 | -3040 | -3704 |
DDX49 | -6948 | 11408 |
DDX52 | -4956 | -6639 |
DHX37 | -6857 | -5150 |
DIMT1 | -9289 | -6845 |
DIS3 | -7066 | -10210 |
DKC1 | -9026 | -6327 |
EBNA1BP2 | -5730 | 8621 |
ELAC2 | -9745 | -1209 |
EMG1 | -8533 | 12199 |
ERI1 | -6981 | -7986 |
EXOSC1 | 5616 | 12257 |
EXOSC10 | 11323 | 10109 |
EXOSC2 | -6345 | 11400 |
EXOSC3 | -9626 | 11413 |
EXOSC4 | -5748 | 12031 |
EXOSC5 | -8463 | 12469 |
EXOSC6 | -4792 | 6631 |
EXOSC7 | -9145 | 12400 |
EXOSC8 | -5608 | 12846 |
EXOSC9 | 2510 | 12417 |
FAU | -8610 | 13102 |
FBL | -9012 | 11058 |
FCF1 | 709 | -9413 |
FTSJ3 | 6717 | -6330 |
GAR1 | -8958 | 8023 |
GNL3 | -10056 | -3684 |
HEATR1 | -2296 | -10015 |
HSD17B10 | 2620 | 11931 |
IMP3 | 8515 | 12268 |
IMP4 | -11049 | 7633 |
ISG20L2 | 9239 | -8076 |
KRR1 | -1464 | -4631 |
LAS1L | 7432 | 11693 |
LTV1 | -7819 | 11102 |
MPHOSPH10 | -6190 | 11406 |
MPHOSPH6 | -2428 | 9099 |
MRM1 | 6997 | 6882 |
MRM2 | 9539 | 10866 |
MRM3 | -8705 | 6922 |
MT-ATP6 | 8420 | 13018 |
MT-ATP8 | 9404 | 12604 |
MT-CO1 | 9067 | 13178 |
MT-CO2 | 8603 | 13180 |
MT-CO3 | 8245 | 13176 |
MT-CYB | 5991 | 13184 |
MT-ND1 | 5209 | 13177 |
MT-ND2 | -1457 | 13183 |
MT-ND3 | 6571 | 13181 |
MT-ND4 | 566 | 13174 |
MT-ND4L | 2132 | 13172 |
MT-ND5 | 4289 | 13012 |
MT-RNR1 | -5225 | 13169 |
MT-RNR2 | -1383 | 13168 |
MTERF4 | -10210 | 9791 |
MTREX | -8233 | -5923 |
NAT10 | -9415 | 792 |
NCL | -9791 | -342 |
NHP2 | -218 | 11370 |
NIP7 | -7922 | 9186 |
NOB1 | -9953 | -8397 |
NOC4L | -6715 | 11954 |
NOL11 | -3226 | -8080 |
NOL12 | 5520 | 12622 |
NOL6 | -9823 | 2445 |
NOL9 | -6385 | -511 |
NOP10 | 2766 | 11209 |
NOP14 | -10166 | -3847 |
NOP2 | -10527 | 12781 |
NOP56 | -7158 | 12073 |
NOP58 | -9719 | 12285 |
NSUN4 | -8664 | -9020 |
PDCD11 | -8464 | -9477 |
PELP1 | -10416 | 11398 |
PES1 | -9830 | -6872 |
PNO1 | -3440 | -3672 |
PRORP | -2649 | -8367 |
PWP2 | -2846 | -152 |
RBM28 | -10901 | 3636 |
RCL1 | -11359 | 8957 |
RIOK1 | -10244 | -3480 |
RIOK2 | -6415 | 4119 |
RIOK3 | -9445 | -11119 |
RPL10 | -3821 | 1598 |
RPL10A | -9707 | -8212 |
RPL11 | -8529 | 12382 |
RPL12 | -9329 | 12992 |
RPL13 | -3469 | 12598 |
RPL13A | -6854 | 6955 |
RPL14 | -6386 | 13137 |
RPL15 | -786 | 12153 |
RPL17 | -8989 | 12909 |
RPL18 | -6672 | 12800 |
RPL18A | -6976 | 11926 |
RPL19 | 3924 | 12911 |
RPL21 | -6322 | 5141 |
RPL22 | -5554 | 9520 |
RPL22L1 | -10448 | 12221 |
RPL23 | 5769 | 12922 |
RPL23A | 11361 | -5257 |
RPL24 | -4591 | 12995 |
RPL26 | -8797 | 12658 |
RPL26L1 | -9387 | 12770 |
RPL27 | 6735 | 11625 |
RPL27A | -7818 | 13051 |
RPL28 | -5809 | 12962 |
RPL29 | -4515 | 12915 |
RPL3 | -6827 | -4536 |
RPL30 | -3907 | 11096 |
RPL31 | -8781 | 13131 |
RPL32 | -5028 | 12983 |
RPL34 | -9357 | 12996 |
RPL35 | -8027 | 13097 |
RPL35A | -1449 | 12789 |
RPL36 | -8818 | 12868 |
RPL36A | -4480 | 13010 |
RPL36AL | -8216 | 12702 |
RPL37 | -4624 | 13134 |
RPL37A | -9347 | 12675 |
RPL38 | 1558 | 13140 |
RPL39 | -6168 | 11962 |
RPL39L | -6608 | -6269 |
RPL3L | -510 | 7904 |
RPL4 | 11351 | 12558 |
RPL41 | -4616 | -6075 |
RPL5 | 4679 | 12075 |
RPL6 | -6903 | 12730 |
RPL7 | -3327 | -8789 |
RPL7A | -6163 | 11708 |
RPL8 | -7572 | 10323 |
RPL9 | -9659 | 12806 |
RPLP0 | -1504 | -7331 |
RPLP1 | 9026 | 12731 |
RPLP2 | -8225 | 12999 |
RPP14 | -7031 | -2565 |
RPP21 | -10144 | 12682 |
RPP25 | 12002 | 11609 |
RPP30 | 4656 | 11993 |
RPP38 | -6789 | 3778 |
RPP40 | -7844 | 9292 |
RPS10 | -8384 | 10665 |
RPS11 | -7725 | 12935 |
RPS12 | -7872 | 11600 |
RPS13 | -9450 | 12652 |
RPS14 | -1180 | 12428 |
RPS15 | -7430 | 12908 |
RPS15A | -8754 | 12989 |
RPS16 | -3844 | 12941 |
RPS17 | -10534 | 11631 |
RPS18 | -9122 | 12984 |
RPS19 | -7633 | 12888 |
RPS2 | -10222 | 8916 |
RPS20 | -4961 | 13095 |
RPS21 | -3001 | 13022 |
RPS23 | 6940 | 11907 |
RPS24 | 2369 | 13034 |
RPS25 | -9371 | 12690 |
RPS26 | -2615 | 13114 |
RPS27 | 651 | 11270 |
RPS27A | 5357 | 6464 |
RPS27L | 7330 | 12750 |
RPS28 | 2716 | 12485 |
RPS29 | -652 | 9078 |
RPS3 | -7756 | 12135 |
RPS3A | -9170 | 5257 |
RPS4X | -8542 | 12239 |
RPS5 | -6283 | -7965 |
RPS6 | -9225 | 12405 |
RPS7 | 5142 | 12976 |
RPS8 | -5812 | 12745 |
RPS9 | -8815 | 10189 |
RPSA | 292 | 11576 |
RRP1 | -10564 | 11767 |
RRP36 | -6050 | -2045 |
RRP7A | -2282 | 10997 |
RRP9 | -7176 | 12125 |
SENP3 | -6212 | -9010 |
SNORD3A | -5504 | 7763 |
SNU13 | -10311 | 12575 |
TBL3 | -9717 | 9564 |
TEX10 | -10686 | -7186 |
TFB1M | -11120 | 4823 |
THUMPD1 | -10328 | -6819 |
TRMT10C | -106 | 3998 |
TRMT112 | -5741 | 13057 |
TSR1 | -11196 | -7332 |
TSR3 | -8931 | -3980 |
UBA52 | -6807 | 11639 |
UTP11 | -10533 | 11453 |
UTP14A | 6133 | 11385 |
UTP14C | 4183 | 769 |
UTP15 | -2850 | -3508 |
UTP18 | -9890 | -9637 |
UTP20 | 7490 | -8121 |
UTP25 | -2108 | -9255 |
UTP3 | -4017 | 10489 |
UTP4 | -6489 | 3608 |
UTP6 | -9002 | -4625 |
WDR12 | -10594 | 3479 |
WDR18 | -808 | 11293 |
WDR3 | -7914 | -8658 |
WDR36 | 2115 | -8307 |
WDR43 | -8618 | -5190 |
WDR46 | -9852 | 176 |
WDR75 | -11340 | 9185 |
XRN2 | -8638 | -11123 |
ATF4 activates genes in response to endoplasmic reticulum stress
metric | value |
---|---|
setSize | 26 |
pMANOVA | 4.79e-07 |
p.adjustMANOVA | 2.26e-06 |
s.dist | 0.583 |
s.KO | -0.453 |
s.drug | 0.367 |
p.KO | 6.33e-05 |
p.drug | 0.0012 |
Gene | KO | drug |
---|---|---|
ASNS | -10878 | 12349 |
EXOSC7 | -9145 | 12400 |
EXOSC3 | -9626 | 11413 |
EXOSC5 | -8463 | 12469 |
DDIT3 | -9395 | 10987 |
CEBPB | -7116 | 12656 |
ATF4 | -6768 | 11948 |
KHSRP | -8858 | 8459 |
EXOSC2 | -6345 | 11400 |
EXOSC8 | -5608 | 12846 |
EXOSC4 | -5748 | 12031 |
CEBPG | -9940 | 6581 |
NFYB | -5919 | 7739 |
NFYC | -3340 | 12311 |
EXOSC6 | -4792 | 6631 |
KO | drug | |
---|---|---|
ASNS | -10878 | 12349 |
ATF3 | -4081 | -4353 |
ATF4 | -6768 | 11948 |
ATF6 | 8977 | -10990 |
CEBPB | -7116 | 12656 |
CEBPG | -9940 | 6581 |
CXCL8 | -4457 | -2346 |
DCP2 | -7297 | -9802 |
DDIT3 | -9395 | 10987 |
DIS3 | -7066 | -10210 |
EXOSC1 | 5616 | 12257 |
EXOSC2 | -6345 | 11400 |
EXOSC3 | -9626 | 11413 |
EXOSC4 | -5748 | 12031 |
EXOSC5 | -8463 | 12469 |
EXOSC6 | -4792 | 6631 |
EXOSC7 | -9145 | 12400 |
EXOSC8 | -5608 | 12846 |
EXOSC9 | 2510 | 12417 |
HERPUD1 | -261 | -7658 |
IGFBP1 | 12833 | 11045 |
KHSRP | -8858 | 8459 |
NFYA | -10786 | -9962 |
NFYB | -5919 | 7739 |
NFYC | -3340 | 12311 |
PARN | -10553 | -1376 |
SLBP Dependent Processing of Replication-Dependent Histone Pre-mRNAs
metric | value |
---|---|
setSize | 11 |
pMANOVA | 0.00138 |
p.adjustMANOVA | 0.00294 |
s.dist | 0.607 |
s.KO | -0.543 |
s.drug | 0.273 |
p.KO | 0.00183 |
p.drug | 0.118 |
Gene | KO | drug |
---|---|---|
SNRPD3 | -5633 | 11696 |
SNRPB | -4839 | 12483 |
SNRPF | -4377 | 13130 |
SNRPE | -4775 | 10726 |
SNRPG | -3856 | 13126 |
LSM10 | -2802 | 12334 |
SLBP | -10989 | 534 |
KO | drug | |
---|---|---|
LSM10 | -2802 | 12334 |
LSM11 | -6043 | -9210 |
NCBP1 | -7784 | -5234 |
NCBP2 | -6378 | -6281 |
SLBP | -10989 | 534 |
SNRPB | -4839 | 12483 |
SNRPD3 | -5633 | 11696 |
SNRPE | -4775 | 10726 |
SNRPF | -4377 | 13130 |
SNRPG | -3856 | 13126 |
ZNF473 | -8128 | -6210 |
SLBP independent Processing of Histone Pre-mRNAs
metric | value |
---|---|
setSize | 10 |
pMANOVA | 0.00365 |
p.adjustMANOVA | 0.00697 |
s.dist | 0.586 |
s.KO | -0.502 |
s.drug | 0.303 |
p.KO | 0.00602 |
p.drug | 0.0969 |
Gene | KO | drug |
---|---|---|
SNRPD3 | -5633 | 11696 |
SNRPB | -4839 | 12483 |
SNRPF | -4377 | 13130 |
SNRPE | -4775 | 10726 |
SNRPG | -3856 | 13126 |
LSM10 | -2802 | 12334 |
KO | drug | |
---|---|---|
LSM10 | -2802 | 12334 |
LSM11 | -6043 | -9210 |
NCBP1 | -7784 | -5234 |
NCBP2 | -6378 | -6281 |
SNRPB | -4839 | 12483 |
SNRPD3 | -5633 | 11696 |
SNRPE | -4775 | 10726 |
SNRPF | -4377 | 13130 |
SNRPG | -3856 | 13126 |
ZNF473 | -8128 | -6210 |
Regulation of expression of SLITs and ROBOs
metric | value |
---|---|
setSize | 166 |
pMANOVA | 3.5e-39 |
p.adjustMANOVA | 2.33e-37 |
s.dist | 0.57 |
s.KO | -0.356 |
s.drug | 0.445 |
p.KO | 2.19e-15 |
p.drug | 4.05e-23 |
Gene | KO | drug |
---|---|---|
SEM1 | -9978 | 13108 |
RPL22L1 | -10448 | 12221 |
ELOB | -9703 | 13020 |
RPL9 | -9659 | 12806 |
RPS17 | -10534 | 11631 |
RPL34 | -9357 | 12996 |
RPL12 | -9329 | 12992 |
RBX1 | -9316 | 12919 |
RPL26L1 | -9387 | 12770 |
RPS13 | -9450 | 12652 |
RPS25 | -9371 | 12690 |
RPL37A | -9347 | 12675 |
RPS18 | -9122 | 12984 |
RPL17 | -8989 | 12909 |
RPL31 | -8781 | 13131 |
RPS6 | -9225 | 12405 |
RPS15A | -8754 | 12989 |
RPL36 | -8818 | 12868 |
PSMA4 | -9907 | 11447 |
FAU | -8610 | 13102 |
KO | drug | |
---|---|---|
CASC3 | 3621 | -10268 |
COL4A5 | 12376 | 8368 |
CUL2 | -2032 | -10093 |
DAG1 | 6148 | -8573 |
EIF4A3 | -628 | -6343 |
EIF4G1 | 9159 | -10287 |
ELOB | -9703 | 13020 |
ELOC | -7394 | 12764 |
ETF1 | -5515 | -9496 |
FAU | -8610 | 13102 |
GSPT1 | -11018 | -10261 |
GSPT2 | -5509 | -6727 |
HOXA2 | 8898 | 12312 |
ISL1 | -4207 | 3822 |
LDB1 | 4147 | 748 |
LHX2 | 10308 | -302 |
LHX4 | 11564 | -5603 |
LHX9 | 9237 | -4741 |
MAGOH | -5607 | 12947 |
MAGOHB | -7769 | 12200 |
MSI1 | 9573 | 10261 |
NCBP1 | -7784 | -5234 |
NCBP2 | -6378 | -6281 |
PABPC1 | -7033 | -10406 |
PSMA1 | -9646 | 10578 |
PSMA2 | -4002 | -4430 |
PSMA3 | -5668 | 12561 |
PSMA4 | -9907 | 11447 |
PSMA5 | 5538 | 826 |
PSMA6 | -3328 | 8997 |
PSMA7 | -10164 | -7607 |
PSMB1 | -6139 | 12480 |
PSMB10 | 9537 | 11663 |
PSMB2 | -3364 | 8976 |
PSMB3 | 7905 | 13078 |
PSMB4 | -1370 | 12998 |
PSMB5 | -6937 | -2970 |
PSMB6 | -6537 | 10901 |
PSMB7 | -8656 | 12462 |
PSMB8 | -9783 | 11153 |
PSMB9 | -9810 | 10733 |
PSMC1 | -3547 | -3814 |
PSMC2 | -9185 | 11068 |
PSMC3 | -1273 | 12327 |
PSMC4 | -7156 | 12714 |
PSMC5 | 7024 | 12041 |
PSMC6 | -7069 | 697 |
PSMD1 | -9192 | -10441 |
PSMD10 | -6869 | 1286 |
PSMD11 | 7720 | -8518 |
PSMD12 | 813 | 8775 |
PSMD13 | -5300 | 12140 |
PSMD14 | -10615 | 8461 |
PSMD2 | -6801 | -10378 |
PSMD3 | -8058 | -4798 |
PSMD4 | 743 | 11756 |
PSMD5 | -9642 | -8039 |
PSMD6 | -7577 | 12228 |
PSMD7 | -6198 | -6043 |
PSMD8 | -9103 | -6526 |
PSMD9 | -7638 | -3346 |
PSME1 | -8654 | 11878 |
PSME2 | -4231 | 12869 |
PSME3 | 11811 | -7813 |
PSME4 | -10581 | -10843 |
PSMF1 | -7549 | -4369 |
RBM8A | 8447 | 9246 |
RBX1 | -9316 | 12919 |
RNPS1 | -10981 | -5614 |
ROBO1 | -4716 | -10678 |
ROBO2 | -6358 | 1760 |
ROBO3 | -7871 | 12150 |
RPL10 | -3821 | 1598 |
RPL10A | -9707 | -8212 |
RPL11 | -8529 | 12382 |
RPL12 | -9329 | 12992 |
RPL13 | -3469 | 12598 |
RPL13A | -6854 | 6955 |
RPL14 | -6386 | 13137 |
RPL15 | -786 | 12153 |
RPL17 | -8989 | 12909 |
RPL18 | -6672 | 12800 |
RPL18A | -6976 | 11926 |
RPL19 | 3924 | 12911 |
RPL21 | -6322 | 5141 |
RPL22 | -5554 | 9520 |
RPL22L1 | -10448 | 12221 |
RPL23 | 5769 | 12922 |
RPL23A | 11361 | -5257 |
RPL24 | -4591 | 12995 |
RPL26 | -8797 | 12658 |
RPL26L1 | -9387 | 12770 |
RPL27 | 6735 | 11625 |
RPL27A | -7818 | 13051 |
RPL28 | -5809 | 12962 |
RPL29 | -4515 | 12915 |
RPL3 | -6827 | -4536 |
RPL30 | -3907 | 11096 |
RPL31 | -8781 | 13131 |
RPL32 | -5028 | 12983 |
RPL34 | -9357 | 12996 |
RPL35 | -8027 | 13097 |
RPL35A | -1449 | 12789 |
RPL36 | -8818 | 12868 |
RPL36A | -4480 | 13010 |
RPL36AL | -8216 | 12702 |
RPL37 | -4624 | 13134 |
RPL37A | -9347 | 12675 |
RPL38 | 1558 | 13140 |
RPL39 | -6168 | 11962 |
RPL39L | -6608 | -6269 |
RPL3L | -510 | 7904 |
RPL4 | 11351 | 12558 |
RPL41 | -4616 | -6075 |
RPL5 | 4679 | 12075 |
RPL6 | -6903 | 12730 |
RPL7 | -3327 | -8789 |
RPL7A | -6163 | 11708 |
RPL8 | -7572 | 10323 |
RPL9 | -9659 | 12806 |
RPLP0 | -1504 | -7331 |
RPLP1 | 9026 | 12731 |
RPLP2 | -8225 | 12999 |
RPS10 | -8384 | 10665 |
RPS11 | -7725 | 12935 |
RPS12 | -7872 | 11600 |
RPS13 | -9450 | 12652 |
RPS14 | -1180 | 12428 |
RPS15 | -7430 | 12908 |
RPS15A | -8754 | 12989 |
RPS16 | -3844 | 12941 |
RPS17 | -10534 | 11631 |
RPS18 | -9122 | 12984 |
RPS19 | -7633 | 12888 |
RPS2 | -10222 | 8916 |
RPS20 | -4961 | 13095 |
RPS21 | -3001 | 13022 |
RPS23 | 6940 | 11907 |
RPS24 | 2369 | 13034 |
RPS25 | -9371 | 12690 |
RPS26 | -2615 | 13114 |
RPS27 | 651 | 11270 |
RPS27A | 5357 | 6464 |
RPS27L | 7330 | 12750 |
RPS28 | 2716 | 12485 |
RPS29 | -652 | 9078 |
RPS3 | -7756 | 12135 |
RPS3A | -9170 | 5257 |
RPS4X | -8542 | 12239 |
RPS5 | -6283 | -7965 |
RPS6 | -9225 | 12405 |
RPS7 | 5142 | 12976 |
RPS8 | -5812 | 12745 |
RPS9 | -8815 | 10189 |
RPSA | 292 | 11576 |
SEM1 | -9978 | 13108 |
SLIT1 | 12338 | -6263 |
SLIT2 | -11365 | -9218 |
UBA52 | -6807 | 11639 |
UBB | -5602 | 12024 |
UBC | -10397 | 7017 |
UPF2 | 6857 | -7169 |
UPF3A | -8410 | 11718 |
UPF3B | -3041 | 12685 |
USP33 | 1911 | -8690 |
ZSWIM8 | 10701 | -5986 |
CREB1 phosphorylation through the activation of Adenylate Cyclase
metric | value |
---|---|
setSize | 10 |
pMANOVA | 0.00171 |
p.adjustMANOVA | 0.00356 |
s.dist | 0.632 |
s.KO | 0.195 |
s.drug | -0.602 |
p.KO | 0.286 |
p.drug | 0.000985 |
Gene | KO | drug |
---|---|---|
ADCY1 | 11934 | -11008 |
PRKAR1A | 8600 | -10630 |
PRKACB | 8849 | -9614 |
CALM1 | 11329 | -6948 |
PRKAR1B | 8608 | -4934 |
KO | drug | |
---|---|---|
ADCY1 | 11934 | -11008 |
CALM1 | 11329 | -6948 |
CREB1 | -4739 | -8655 |
PRKACA | 8250 | 9679 |
PRKACB | 8849 | -9614 |
PRKAR1A | 8600 | -10630 |
PRKAR1B | 8608 | -4934 |
PRKAR2A | -5980 | -10943 |
PRKAR2B | -9276 | -5166 |
PRKX | -7017 | -5888 |
A tetrasaccharide linker sequence is required for GAG synthesis
metric | value |
---|---|
setSize | 24 |
pMANOVA | 3.1e-06 |
p.adjustMANOVA | 1.21e-05 |
s.dist | 0.567 |
s.KO | 0.325 |
s.drug | -0.465 |
p.KO | 0.00589 |
p.drug | 7.89e-05 |
Gene | KO | drug |
---|---|---|
CSPG4 | 12459 | -11273 |
AGRN | 12518 | -11205 |
SDC4 | 12322 | -10633 |
GPC4 | 11190 | -8942 |
SDC1 | 12230 | -7104 |
SDC3 | 12401 | -6760 |
XYLT2 | 10574 | -7316 |
B4GALT7 | 10562 | -4980 |
BCAN | 12079 | -4013 |
GPC5 | 7673 | -3135 |
BGN | 11953 | -1313 |
GPC1 | 1951 | -7922 |
NCAN | 3533 | -1773 |
CSPG5 | 545 | -3163 |
KO | drug | |
---|---|---|
AGRN | 12518 | -11205 |
B3GALT6 | 11393 | 11355 |
B3GAT1 | -914 | 2011 |
B3GAT2 | -4097 | 5251 |
B3GAT3 | 11784 | 9103 |
B4GALT7 | 10562 | -4980 |
BCAN | 12079 | -4013 |
BGN | 11953 | -1313 |
CSPG4 | 12459 | -11273 |
CSPG5 | 545 | -3163 |
GPC1 | 1951 | -7922 |
GPC2 | -3913 | -3279 |
GPC4 | 11190 | -8942 |
GPC5 | 7673 | -3135 |
GPC6 | -6095 | -11229 |
HSPG2 | -9046 | -9768 |
NCAN | 3533 | -1773 |
SDC1 | 12230 | -7104 |
SDC2 | -6754 | -5737 |
SDC3 | 12401 | -6760 |
SDC4 | 12322 | -10633 |
VCAN | -1861 | -11263 |
XYLT1 | -11081 | -10705 |
XYLT2 | 10574 | -7316 |
Influenza Viral RNA Transcription and Replication
metric | value |
---|---|
setSize | 134 |
pMANOVA | 3.21e-30 |
p.adjustMANOVA | 1.27e-28 |
s.dist | 0.555 |
s.KO | -0.386 |
s.drug | 0.398 |
p.KO | 1.09e-14 |
p.drug | 1.59e-15 |
Gene | KO | drug |
---|---|---|
RPL22L1 | -10448 | 12221 |
RPL9 | -9659 | 12806 |
RPS17 | -10534 | 11631 |
RPL34 | -9357 | 12996 |
RPL12 | -9329 | 12992 |
RPL26L1 | -9387 | 12770 |
RPS13 | -9450 | 12652 |
RPS25 | -9371 | 12690 |
RPL37A | -9347 | 12675 |
RPS18 | -9122 | 12984 |
RPL17 | -8989 | 12909 |
RPL31 | -8781 | 13131 |
RPS6 | -9225 | 12405 |
RPS15A | -8754 | 12989 |
RPL36 | -8818 | 12868 |
FAU | -8610 | 13102 |
POLR2F | -8900 | 12621 |
RPL26 | -8797 | 12658 |
RPLP2 | -8225 | 12999 |
RPL11 | -8529 | 12382 |
KO | drug | |
---|---|---|
AAAS | -4744 | 12385 |
DNAJC3 | -2895 | -7549 |
FAU | -8610 | 13102 |
GRSF1 | -11152 | -7843 |
GTF2F1 | -7239 | -7788 |
GTF2F2 | -7180 | 9519 |
HSP90AA1 | 11397 | -7534 |
IPO5 | -10440 | -10308 |
NDC1 | -5800 | -9199 |
NUP107 | 10317 | 11210 |
NUP133 | 6251 | -8590 |
NUP153 | -8447 | -10433 |
NUP155 | 1534 | -10720 |
NUP160 | -10172 | -9854 |
NUP188 | -11151 | -5029 |
NUP205 | 12369 | -7848 |
NUP210 | 12856 | -5260 |
NUP214 | -6331 | -6303 |
NUP35 | -10251 | 8114 |
NUP37 | 3092 | 10118 |
NUP42 | 8137 | 9137 |
NUP43 | -7490 | 9639 |
NUP50 | -10234 | -3947 |
NUP54 | -10563 | -8348 |
NUP58 | -7370 | -10307 |
NUP62 | -5900 | -6034 |
NUP85 | 7849 | 10502 |
NUP88 | -10968 | 2131 |
NUP93 | -6918 | -6255 |
NUP98 | -10847 | -10135 |
PARP1 | 11937 | -9418 |
POLR2A | -11346 | -10737 |
POLR2B | -9710 | -9575 |
POLR2C | -9451 | -4938 |
POLR2D | -9238 | 4530 |
POLR2E | -4690 | -3689 |
POLR2F | -8900 | 12621 |
POLR2G | -5631 | 9765 |
POLR2H | 7259 | 12667 |
POLR2I | -5731 | 12659 |
POLR2J | -6932 | 12928 |
POLR2K | 8115 | 12316 |
POLR2L | 12166 | 11532 |
POM121 | -8878 | -9749 |
POM121C | -9406 | -9089 |
RAE1 | -7356 | -5016 |
RANBP2 | -5941 | -10334 |
RPL10 | -3821 | 1598 |
RPL10A | -9707 | -8212 |
RPL11 | -8529 | 12382 |
RPL12 | -9329 | 12992 |
RPL13 | -3469 | 12598 |
RPL13A | -6854 | 6955 |
RPL14 | -6386 | 13137 |
RPL15 | -786 | 12153 |
RPL17 | -8989 | 12909 |
RPL18 | -6672 | 12800 |
RPL18A | -6976 | 11926 |
RPL19 | 3924 | 12911 |
RPL21 | -6322 | 5141 |
RPL22 | -5554 | 9520 |
RPL22L1 | -10448 | 12221 |
RPL23 | 5769 | 12922 |
RPL23A | 11361 | -5257 |
RPL24 | -4591 | 12995 |
RPL26 | -8797 | 12658 |
RPL26L1 | -9387 | 12770 |
RPL27 | 6735 | 11625 |
RPL27A | -7818 | 13051 |
RPL28 | -5809 | 12962 |
RPL29 | -4515 | 12915 |
RPL3 | -6827 | -4536 |
RPL30 | -3907 | 11096 |
RPL31 | -8781 | 13131 |
RPL32 | -5028 | 12983 |
RPL34 | -9357 | 12996 |
RPL35 | -8027 | 13097 |
RPL35A | -1449 | 12789 |
RPL36 | -8818 | 12868 |
RPL36A | -4480 | 13010 |
RPL36AL | -8216 | 12702 |
RPL37 | -4624 | 13134 |
RPL37A | -9347 | 12675 |
RPL38 | 1558 | 13140 |
RPL39 | -6168 | 11962 |
RPL39L | -6608 | -6269 |
RPL3L | -510 | 7904 |
RPL4 | 11351 | 12558 |
RPL41 | -4616 | -6075 |
RPL5 | 4679 | 12075 |
RPL6 | -6903 | 12730 |
RPL7 | -3327 | -8789 |
RPL7A | -6163 | 11708 |
RPL8 | -7572 | 10323 |
RPL9 | -9659 | 12806 |
RPLP0 | -1504 | -7331 |
RPLP1 | 9026 | 12731 |
RPLP2 | -8225 | 12999 |
RPS10 | -8384 | 10665 |
RPS11 | -7725 | 12935 |
RPS12 | -7872 | 11600 |
RPS13 | -9450 | 12652 |
RPS14 | -1180 | 12428 |
RPS15 | -7430 | 12908 |
RPS15A | -8754 | 12989 |
RPS16 | -3844 | 12941 |
RPS17 | -10534 | 11631 |
RPS18 | -9122 | 12984 |
RPS19 | -7633 | 12888 |
RPS2 | -10222 | 8916 |
RPS20 | -4961 | 13095 |
RPS21 | -3001 | 13022 |
RPS23 | 6940 | 11907 |
RPS24 | 2369 | 13034 |
RPS25 | -9371 | 12690 |
RPS26 | -2615 | 13114 |
RPS27 | 651 | 11270 |
RPS27A | 5357 | 6464 |
RPS27L | 7330 | 12750 |
RPS28 | 2716 | 12485 |
RPS29 | -652 | 9078 |
RPS3 | -7756 | 12135 |
RPS3A | -9170 | 5257 |
RPS4X | -8542 | 12239 |
RPS5 | -6283 | -7965 |
RPS6 | -9225 | 12405 |
RPS7 | 5142 | 12976 |
RPS8 | -5812 | 12745 |
RPS9 | -8815 | 10189 |
RPSA | 292 | 11576 |
SEC13 | -9702 | -8646 |
SEH1L | -9333 | -5653 |
TPR | 8761 | -5835 |
UBA52 | -6807 | 11639 |
Chondroitin sulfate biosynthesis
metric | value |
---|---|
setSize | 19 |
pMANOVA | 7e-05 |
p.adjustMANOVA | 0.000198 |
s.dist | 0.553 |
s.KO | 0.35 |
s.drug | -0.428 |
p.KO | 0.00818 |
p.drug | 0.00125 |
Gene | KO | drug |
---|---|---|
CHST15 | 12906 | -11169 |
CSPG4 | 12459 | -11273 |
CHST11 | 12103 | -10187 |
CHSY3 | 10102 | -9769 |
BCAN | 12079 | -4013 |
CHSY1 | 3107 | -10988 |
BGN | 11953 | -1313 |
CHST9 | 11110 | -1231 |
NCAN | 3533 | -1773 |
CSPG5 | 545 | -3163 |
KO | drug | |
---|---|---|
BCAN | 12079 | -4013 |
BGN | 11953 | -1313 |
CHPF | -11347 | -6066 |
CHPF2 | 12137 | 9414 |
CHST11 | 12103 | -10187 |
CHST12 | 11011 | 10555 |
CHST13 | 11177 | 9777 |
CHST15 | 12906 | -11169 |
CHST3 | -2862 | -10133 |
CHST7 | -2403 | -5448 |
CHST9 | 11110 | -1231 |
CHSY1 | 3107 | -10988 |
CHSY3 | 10102 | -9769 |
CSGALNACT1 | -750 | -2738 |
CSGALNACT2 | -10808 | -10564 |
CSPG4 | 12459 | -11273 |
CSPG5 | 545 | -3163 |
NCAN | 3533 | -1773 |
VCAN | -1861 | -11263 |
PKA activation
metric | value |
---|---|
setSize | 16 |
pMANOVA | 2.75e-05 |
p.adjustMANOVA | 8.39e-05 |
s.dist | 0.646 |
s.KO | 0.145 |
s.drug | -0.63 |
p.KO | 0.317 |
p.drug | 1.29e-05 |
Gene | KO | drug |
---|---|---|
ADCY6 | 12249 | -10841 |
ADCY1 | 11934 | -11008 |
NBEA | 10299 | -10694 |
PRKAR1A | 8600 | -10630 |
PRKACB | 8849 | -9614 |
CALM1 | 11329 | -6948 |
ADCY5 | 11160 | -6292 |
PRKAR1B | 8608 | -4934 |
ADCY4 | 2183 | -585 |
KO | drug | |
---|---|---|
ADCY1 | 11934 | -11008 |
ADCY2 | -11203 | -2904 |
ADCY3 | -9214 | -7503 |
ADCY4 | 2183 | -585 |
ADCY5 | 11160 | -6292 |
ADCY6 | 12249 | -10841 |
ADCY7 | -11317 | -10422 |
ADCY9 | -7412 | -9235 |
CALM1 | 11329 | -6948 |
NBEA | 10299 | -10694 |
PRKACA | 8250 | 9679 |
PRKACB | 8849 | -9614 |
PRKAR1A | 8600 | -10630 |
PRKAR1B | 8608 | -4934 |
PRKAR2A | -5980 | -10943 |
PRKAR2B | -9276 | -5166 |
Diseases associated with glycosaminoglycan metabolism
metric | value |
---|---|
setSize | 35 |
pMANOVA | 2.97e-08 |
p.adjustMANOVA | 1.79e-07 |
s.dist | 0.551 |
s.KO | 0.273 |
s.drug | -0.479 |
p.KO | 0.00521 |
p.drug | 9.35e-07 |
Gene | KO | drug |
---|---|---|
CSPG4 | 12459 | -11273 |
AGRN | 12518 | -11205 |
SDC4 | 12322 | -10633 |
EXT2 | 11023 | -9224 |
GPC4 | 11190 | -8942 |
SDC1 | 12230 | -7104 |
SDC3 | 12401 | -6760 |
PAPSS2 | 6847 | -10771 |
EXT1 | 10114 | -6275 |
B4GALT7 | 10562 | -4980 |
BCAN | 12079 | -4013 |
CHSY1 | 3107 | -10988 |
GPC5 | 7673 | -3135 |
BGN | 11953 | -1313 |
GPC1 | 1951 | -7922 |
NCAN | 3533 | -1773 |
HEXB | 1770 | -1985 |
CSPG5 | 545 | -3163 |
KO | drug | |
---|---|---|
ACAN | -11431 | -5454 |
AGRN | 12518 | -11205 |
B3GALT6 | 11393 | 11355 |
B3GAT3 | 11784 | 9103 |
B4GALT1 | -11375 | -10725 |
B4GALT7 | 10562 | -4980 |
BCAN | 12079 | -4013 |
BGN | 11953 | -1313 |
CHST14 | 12268 | 10719 |
CHST3 | -2862 | -10133 |
CHST6 | -4221 | -9474 |
CHSY1 | 3107 | -10988 |
CSPG4 | 12459 | -11273 |
CSPG5 | 545 | -3163 |
EXT1 | 10114 | -6275 |
EXT2 | 11023 | -9224 |
GPC1 | 1951 | -7922 |
GPC2 | -3913 | -3279 |
GPC4 | 11190 | -8942 |
GPC5 | 7673 | -3135 |
GPC6 | -6095 | -11229 |
HEXA | 12426 | 6143 |
HEXB | 1770 | -1985 |
HSPG2 | -9046 | -9768 |
NCAN | 3533 | -1773 |
OMD | 2559 | 1901 |
PAPSS2 | 6847 | -10771 |
PRELP | 4474 | 2215 |
SDC1 | 12230 | -7104 |
SDC2 | -6754 | -5737 |
SDC3 | 12401 | -6760 |
SDC4 | 12322 | -10633 |
SLC26A2 | -4295 | -10449 |
ST3GAL3 | -7104 | -4100 |
VCAN | -1861 | -11263 |
Respiratory electron transport
metric | value |
---|---|
setSize | 103 |
pMANOVA | 4.7e-27 |
p.adjustMANOVA | 1.64e-25 |
s.dist | 0.61 |
s.KO | -0.16 |
s.drug | 0.589 |
p.KO | 0.0049 |
p.drug | 4.56e-25 |
Gene | KO | drug |
---|---|---|
NDUFA6 | -10640 | 12901 |
NDUFB10 | -9687 | 12582 |
COX6B1 | -9124 | 13132 |
UQCR10 | -9028 | 12920 |
NDUFA8 | -8774 | 12900 |
NDUFS3 | -8653 | 12725 |
NDUFB9 | -8544 | 12805 |
UQCRH | -8039 | 12733 |
NDUFS8 | -7989 | 12773 |
COX20 | -9184 | 10961 |
NDUFB6 | -8238 | 12165 |
COX7B | -7400 | 13161 |
TRAP1 | -11197 | 8602 |
SCO2 | -9739 | 9526 |
NDUFAB1 | -10558 | 8746 |
COX8A | -7227 | 12756 |
NDUFV2 | -6865 | 13148 |
NDUFC1 | -7186 | 12437 |
COX5B | -6531 | 13149 |
NDUFAF4 | -8760 | 9608 |
KO | drug | |
---|---|---|
ACAD9 | 12457 | 11377 |
COA1 | 11438 | 12298 |
COQ10A | 2060 | 8793 |
COQ10B | -11071 | 1561 |
COX11 | 3872 | -3998 |
COX14 | -5296 | 7054 |
COX16 | -4741 | 10348 |
COX18 | -7574 | -2747 |
COX19 | 5255 | 5188 |
COX20 | -9184 | 10961 |
COX4I1 | -1716 | 13016 |
COX5A | 8620 | 10682 |
COX5B | -6531 | 13149 |
COX6A1 | -1616 | 13101 |
COX6B1 | -9124 | 13132 |
COX6C | 5468 | 12965 |
COX7A2L | -5446 | -8229 |
COX7B | -7400 | 13161 |
COX7C | 9483 | 12599 |
COX8A | -7227 | 12756 |
CYC1 | -8796 | 9550 |
CYCS | -2044 | 10884 |
ECSIT | -6333 | 10115 |
ETFA | -3727 | -7917 |
ETFB | -10912 | 576 |
ETFDH | 2376 | 356 |
LRPPRC | -7531 | -9087 |
MT-CO1 | 9067 | 13178 |
MT-CO2 | 8603 | 13180 |
MT-CO3 | 8245 | 13176 |
MT-CYB | 5991 | 13184 |
MT-ND1 | 5209 | 13177 |
MT-ND2 | -1457 | 13183 |
MT-ND3 | 6571 | 13181 |
MT-ND4 | 566 | 13174 |
MT-ND5 | 4289 | 13012 |
MT-ND6 | 4676 | 13045 |
NDUFA1 | -6222 | 13127 |
NDUFA10 | -7241 | -4286 |
NDUFA11 | 9807 | 12851 |
NDUFA12 | 6720 | 13049 |
NDUFA13 | -4424 | 12971 |
NDUFA2 | 5937 | 13125 |
NDUFA3 | -4508 | 13084 |
NDUFA4 | 9132 | 11345 |
NDUFA5 | -6593 | 11094 |
NDUFA6 | -10640 | 12901 |
NDUFA7 | 8872 | 13143 |
NDUFA8 | -8774 | 12900 |
NDUFA9 | 2605 | 10360 |
NDUFAB1 | -10558 | 8746 |
NDUFAF1 | 2883 | 9463 |
NDUFAF2 | -5167 | 12574 |
NDUFAF3 | 10175 | 13112 |
NDUFAF4 | -8760 | 9608 |
NDUFAF5 | -3460 | 9719 |
NDUFAF6 | -5625 | 10508 |
NDUFAF7 | 6751 | 8883 |
NDUFB1 | 8092 | 13163 |
NDUFB10 | -9687 | 12582 |
NDUFB11 | -7090 | 11583 |
NDUFB2 | 11367 | 12511 |
NDUFB3 | 1661 | 12046 |
NDUFB4 | 8888 | 13008 |
NDUFB5 | -3244 | -5075 |
NDUFB6 | -8238 | 12165 |
NDUFB7 | -4205 | 12444 |
NDUFB8 | 8367 | 13039 |
NDUFB9 | -8544 | 12805 |
NDUFC1 | -7186 | 12437 |
NDUFC2 | -5184 | 11409 |
NDUFS1 | -9609 | -7041 |
NDUFS2 | 3967 | -10068 |
NDUFS3 | -8653 | 12725 |
NDUFS4 | 6388 | 3949 |
NDUFS5 | -6394 | 13145 |
NDUFS6 | -6327 | 12108 |
NDUFS7 | 5531 | 12411 |
NDUFS8 | -7989 | 12773 |
NDUFV1 | -5404 | 8980 |
NDUFV2 | -6865 | 13148 |
NDUFV3 | -6779 | 12304 |
NUBPL | 8039 | -8010 |
SCO1 | -10631 | -6537 |
SCO2 | -9739 | 9526 |
SDHA | -10480 | -9986 |
SDHB | -299 | 5982 |
SDHC | 9345 | -5559 |
SDHD | -9641 | -2716 |
SURF1 | 8003 | 9112 |
TACO1 | 8239 | 8081 |
TIMMDC1 | 9211 | -3329 |
TMEM126B | -8036 | 9815 |
TMEM186 | -8187 | 5086 |
TRAP1 | -11197 | 8602 |
UQCR10 | -9028 | 12920 |
UQCR11 | -5675 | 11509 |
UQCRB | -979 | 12923 |
UQCRC1 | 8588 | -1762 |
UQCRC2 | -11089 | -6026 |
UQCRFS1 | -10915 | -8657 |
UQCRH | -8039 | 12733 |
UQCRQ | 10244 | 13147 |
Regulation of localization of FOXO transcription factors
metric | value |
---|---|
setSize | 12 |
pMANOVA | 0.00154 |
p.adjustMANOVA | 0.00324 |
s.dist | 0.58 |
s.KO | 0.206 |
s.drug | -0.542 |
p.KO | 0.216 |
p.drug | 0.00115 |
Gene | KO | drug |
---|---|---|
YWHAQ | 7979 | -10945 |
FOXO1 | 7945 | -10183 |
YWHAB | 11096 | -6543 |
AKT3 | 6626 | -10834 |
FOXO4 | 7396 | -7380 |
SFN | 5633 | -2792 |
KO | drug | |
---|---|---|
AKT1 | -1733 | -1215 |
AKT2 | 9732 | 3410 |
AKT3 | 6626 | -10834 |
FOXO1 | 7945 | -10183 |
FOXO3 | -9950 | -10606 |
FOXO4 | 7396 | -7380 |
FOXO6 | 7392 | 9947 |
SFN | 5633 | -2792 |
YWHAB | 11096 | -6543 |
YWHAG | -8344 | -10868 |
YWHAQ | 7979 | -10945 |
YWHAZ | -5429 | -10168 |
Here is the session info with all the versions of packages used.
sessionInfo()
## R version 4.2.1 (2022-06-23)
## Platform: x86_64-pc-linux-gnu (64-bit)
## Running under: Ubuntu 22.04.1 LTS
##
## Matrix products: default
## BLAS: /usr/lib/x86_64-linux-gnu/openblas-pthread/libblas.so.3
## LAPACK: /usr/lib/x86_64-linux-gnu/openblas-pthread/libopenblasp-r0.3.20.so
##
## locale:
## [1] LC_CTYPE=en_US.UTF-8 LC_NUMERIC=C
## [3] LC_TIME=en_US.UTF-8 LC_COLLATE=en_US.UTF-8
## [5] LC_MONETARY=en_US.UTF-8 LC_MESSAGES=en_US.UTF-8
## [7] LC_PAPER=en_US.UTF-8 LC_NAME=C
## [9] LC_ADDRESS=C LC_TELEPHONE=C
## [11] LC_MEASUREMENT=en_US.UTF-8 LC_IDENTIFICATION=C
##
## attached base packages:
## [1] stats4 stats graphics grDevices utils datasets methods
## [8] base
##
## other attached packages:
## [1] pkgload_1.3.0 GGally_2.1.2
## [3] gtools_3.9.2.2 echarts4r_0.4.4
## [5] beeswarm_0.4.0 vioplot_0.3.7
## [7] sm_2.2-5.7 kableExtra_1.3.4
## [9] topconfects_1.12.0 limma_3.52.1
## [11] eulerr_6.1.1 mitch_1.8.0
## [13] MASS_7.3-58 fgsea_1.22.0
## [15] gplots_3.1.3 DESeq2_1.36.0
## [17] SummarizedExperiment_1.26.1 Biobase_2.56.0
## [19] MatrixGenerics_1.8.0 matrixStats_0.62.0
## [21] GenomicRanges_1.48.0 GenomeInfoDb_1.32.2
## [23] IRanges_2.30.0 S4Vectors_0.34.0
## [25] BiocGenerics_0.42.0 reshape2_1.4.4
## [27] forcats_0.5.1 stringr_1.4.0
## [29] dplyr_1.0.9 purrr_0.3.4
## [31] readr_2.1.2 tidyr_1.2.0
## [33] tibble_3.1.7 ggplot2_3.3.6
## [35] tidyverse_1.3.1 zoo_1.8-10
##
## loaded via a namespace (and not attached):
## [1] readxl_1.4.0 backports_1.4.1 fastmatch_1.1-3
## [4] systemfonts_1.0.4 plyr_1.8.7 polylabelr_0.2.0
## [7] splines_4.2.1 BiocParallel_1.30.3 digest_0.6.29
## [10] htmltools_0.5.2 fansi_1.0.3 magrittr_2.0.3
## [13] memoise_2.0.1 tzdb_0.3.0 Biostrings_2.64.0
## [16] annotate_1.74.0 modelr_0.1.8 svglite_2.1.0
## [19] colorspace_2.0-3 blob_1.2.3 rvest_1.0.2
## [22] haven_2.5.0 xfun_0.31 crayon_1.5.1
## [25] RCurl_1.98-1.7 jsonlite_1.8.0 genefilter_1.78.0
## [28] survival_3.4-0 glue_1.6.2 polyclip_1.10-0
## [31] gtable_0.3.0 zlibbioc_1.42.0 XVector_0.36.0
## [34] webshot_0.5.3 DelayedArray_0.22.0 scales_1.2.0
## [37] DBI_1.1.3 Rcpp_1.0.8.3 viridisLite_0.4.0
## [40] xtable_1.8-4 bit_4.0.4 htmlwidgets_1.5.4
## [43] httr_1.4.3 RColorBrewer_1.1-3 ellipsis_0.3.2
## [46] farver_2.1.0 pkgconfig_2.0.3 reshape_0.8.9
## [49] XML_3.99-0.10 sass_0.4.1 dbplyr_2.2.1
## [52] locfit_1.5-9.5 utf8_1.2.2 labeling_0.4.2
## [55] tidyselect_1.1.2 rlang_1.0.3 later_1.3.0
## [58] AnnotationDbi_1.58.0 munsell_0.5.0 cellranger_1.1.0
## [61] tools_4.2.1 cachem_1.0.6 cli_3.3.0
## [64] generics_0.1.2 RSQLite_2.2.14 broom_0.8.0
## [67] evaluate_0.15 fastmap_1.1.0 yaml_2.3.5
## [70] knitr_1.39 bit64_4.0.5 fs_1.5.2
## [73] caTools_1.18.2 KEGGREST_1.36.2 mime_0.12
## [76] xml2_1.3.3 compiler_4.2.1 rstudioapi_0.13
## [79] png_0.1-7 reprex_2.0.1 geneplotter_1.74.0
## [82] bslib_0.3.1 stringi_1.7.6 highr_0.9
## [85] lattice_0.20-45 Matrix_1.4-1 vctrs_0.4.1
## [88] pillar_1.7.0 lifecycle_1.0.1 jquerylib_0.1.4
## [91] data.table_1.14.2 bitops_1.0-7 httpuv_1.6.5
## [94] R6_2.5.1 promises_1.2.0.1 KernSmooth_2.23-20
## [97] gridExtra_2.3 codetools_0.2-18 assertthat_0.2.1
## [100] withr_2.5.0 GenomeInfoDbData_1.2.8 parallel_4.2.1
## [103] hms_1.1.1 grid_4.2.1 rmarkdown_2.14
## [106] shiny_1.7.1 lubridate_1.8.0
END of report